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 Pharmaceuticals and their metabolites, collectively known as pharmaceutically 
active compounds (PhACs), have been detected in surface water, groundwater, and 
drinking water, in a number of countries, since the mid-1990s.  Pharmaceuticals can be 
used in human or veterinary medicine; human pharmaceuticals in the environment are the 
subject of this dissertation.  Human pharmaceuticals enter the environment via 
wastewater treatment plants, after being consumed and excreted by humans, and through 
improper disposal, to toilets and garbage, among other routes of entry.  Some PhACs 
have been found to have detrimental effects on aquatic organisms at low concentrations, 
such as the feminization of fish after exposure to low levels of 17α-ethinylestradiol, the 
active ingredient in the birth control pill.  Others are suspected of having effects on non-
target species, but the impacts of long-term exposure to mixtures of PhACs generally 
remain poorly understood.  Nevertheless, the precautionary principle suggests that 
management action to mitigate the environmental impacts of PhACs should be 
considered and possibly implemented. 
 The purpose of this dissertation is to provide an analysis of precautionary 
management strategies to mitigate the environment impacts of human PhACs.  Four 
underlying objectives are set.  The first is to review the extant scientific understanding of 
human PhACs in the environment, so that this knowledge can be applied to the analysis 
of management strategies.  The sources, transport, fate, and occurrence of PhACs are 
discussed, and several classes of PhACs of particular concern are highlighted.  The 
effects of PhACs on humans and aquatic organisms are explored, in addition to the gaps 
in scientific understanding of PhACs in aquatic environments.  Finally, a rough ranking 
of priority PhACs is conducted; the PhACs of greatest concern are found to be 
carbamazepine, clofibric acid, ifosfamid, 17a-ethinylestradiol, oxytetracycline, 
ciprofloxacin, and diclofenac. 
 The second objective is to investigate how planning and management principles 
and theories can be applied to the problem of PhACs in the environment.  The 
precautionary principle and the theory of adaptive planning are identified as essential 





to pharmaceuticals in the environment are discussed, and a management framework is 
developed.   
 The third objective is to determine how human PhACs in the environment can be 
managed at a local scale, using a case study in the Region of Waterloo.  Pharmaceuticals 
released from two wastewater treatment plans are found entering the local environment at 
concentrations similar to those in other cities internationally.  Social surveys indicate that 
residents desire management action to prevent environmental contamination by 
pharmaceuticals, but at a limited cost.  The surveys also indicate that many residents 
dispose of pharmaceuticals improperly; education to encourage proper drug disposal is 
therefore recommended as one of several management strategies.  The other two 
recommended management strategies target the wastewater treatment plants.  In Foxboro, 
where the wastewater treatment plant is functioning less than optimally, optimization 
without technological upgrades is suggested.  In Kitchener, where the plant is functioning 
within ministerial guidelines, ozonation is suggested as a means of improving 
pharmaceutical removal without exceeding residents’ willingness to pay. 
 The fourth and final objective is to assess how human pharmaceuticals can be 
managed at a broad scale, such as at the national scale.  Stakeholder interviews are 
conducted with the purpose of gaining a deeper understanding of possible management 
strategies.  A policy analysis is conducted to determine which combinations of 
management strategies are likely to optimally address the problem of PhACs in the 
environment, and some policy packages are recommended for implementation by 
governments – in particular, multiple levels of government in Canada. 
 This dissertation is among the first research efforts to investigate the management 
of pharmaceuticals in the environment.  Few efforts to date have combined natural 
scientific research, social scientific research, and an understanding of planning and 
management theories, to explore policy and management options for this issue.  It is 
hoped that this research will provide assistance to various governments grappling with 
pharmaceuticals in the environment.  Furthermore, the research provides insight into how 
environmental problems surrounded by high levels of scientific uncertainty can be 





provide guidance to planners, managers and policy makers faced with the problem of 
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Chapter 1: Introduction 
 
1.1.  Introduction 
 Awareness of the problem of pharmaceuticals in the environment is increasing 
among scientific researchers, governments, pharmaceutical companies, and the public.  
Since the mid-1990s, scientists have regularly detected pharmaceuticals and their 
metabolites, referred to collectively as PhACs (Pharmaceutically Active Compounds), in 
surface water (Kolpin et al., 2002; Metcalfe, Miao, Koenig, & Struger, 2003; Stumpf, 
Ternes, Wilken, Rodrigues, & Baumann, 1999; Ternes, 1998), groundwater (Barnes et 
al., 2004; Bund/Länderausschuss für Chemikaliensicherheit (BLAC), 2003; Eckel, Ross, 
& Isensee, 1993; Heberer et al., 2004), and occasionally in drinking water (Boyd, 
Reemtsma, Grimm, & Mitra, 2003; Mittelstaedt, 2003; Stan, Heberer, & Linkerhagner, 
1994).  These pharmaceuticals are mainly human pharmaceuticals, the subject of this 
thesis, although veterinary pharmaceuticals from agricultural sources have also been 
detected in environmental samples (Hirsch, Ternes, Haberer, & Kratz, 1999; Lissemore, 
Yang, Hao, & Solomon, 2005).  Human pharmaceuticals are frequently found in the 
waters of wealthy nations where citizens consume relatively large quantities of 
pharmaceuticals, especially in urban areas where dilution is minimal (Heberer et al., 
2004).  The presence of PhACs in natural waters represents a potential concern for both 
the health of ecosystems (Daughton & Ternes, 1999; Ferrari, Paxeus, Lo Giudice, Pollio, 
& Garric, 2003; Henschel, Wenzel, Diedrich, & Fliedner, 1997) and possibly for human 
health (Daughton & Ternes, 1999), although many scientists believe that human health 
impacts are unlikely (Christensen, 1998; Schulman et al., 2002; Webb, Ternes, Gibert, & 
Olejniczak, 2003).  While abundant studies indicate the presence of pharmaceuticals in 
natural waters, very little is known about the impacts of these pharmaceuticals on aquatic 
ecosystems.  Pharmaceuticals found in rivers and streams occur at extremely low 
concentrations and therefore are not expected to induce acute effects such as fish kills.  
Rather, any impacts of pharmaceuticals on aquatic species or ecosystems are expected to 
be subtle, long-term, and therefore difficult to detect (Daughton & Ternes, 1999; Seiler, 
2002).   Possibly the clearest example to date of the effects of pharmaceuticals on aquatic 





exposure to low levels of oral contraceptives (17α-ethinylestradiol), among other 
estrogenic substances that enter streams from wastewater treatment plant outfalls 
(Jobling, Nolan, Tyler, Brightly, & Sumpter, 1998; Larsson et al., 1999; Purdom et al., 
1994).  Examples of linkages between pharmaceutical contamination and effects on 
aquatic organisms in the field remain limited, however, and the scientific uncertainty 
regarding the environmental risk posed by pharmaceuticals in natural waters remains 
high. 
 While more scientific research into the problem of pharmaceuticals in the 
environment is clearly needed, our awareness of the problem also demands that 
management action be considered to mitigate any impacts of pharmaceuticals on the 
environment.  The precautionary principle states that when a substance poses a serious 
threat to the environment1, a lack of scientific certainty concerning the impacts should not 
be permitted to delay management action (CEPA, 1999; Commission of the European 
Communities, 2000; Quijano, 2003; United Nations General Assembly, 1992).  This does 
not suggest that pharmaceuticals be banned because of potential environmental impacts.  
Rather, it means that academics, scientists and members of the pharmaceutical industry 
should begin to develop and assess strategies to address the issue of PhACs in the 
environment now, instead of waiting several more decades until the degree of 
environmental damage1 caused by pharmaceuticals can be measured.  The theory of 
adaptive planning tells us that under conditions of uncertainty, flexible management 
strategies, which can be adjusted to newly acquired information, should be implemented 
(Briassoulis, 1989; Holling, 1978; Lessard, 1998).  Furthermore, management strategies 
must meet the needs of stakeholders as much as possible (Canadian Standards 
Association, 1997).   
 The overall purpose of this thesis is to analyze management strategies to mitigate 
the environmental impacts of human pharmaceuticals in natural waters.  Within this 
overarching goal are several objectives, based upon a number of research question (Fig. 
1.1): 1) To review the state of science with regard to pharmaceuticals in the environment, 
so that existing scientific knowledge can be used in developing management strategies.  
                                                 
1 What constitutes a ‘serious threat to the environment’ or ‘environmental damage’ is subjective and is up 





Specific research questions underlying this objective include:  What is known about the 
sources, transport, fate, occurrence and effects of pharmaceuticals released to the 
environment?  How much uncertainty (see Ch. 3 for discussion of uncertainty) is there in 
our collective understanding?  What are the gaps in scientific understanding and why do 
these gaps exist?  Which pharmaceuticals or classes of pharmaceuticals merit the greatest 
concern in terms of environmental impact?   
2) To explore planning and management theories and principles that can be of use in 
developing an appropriate risk management framework for pharmaceuticals in the 
environment.  Underlying research questions include:  What is risk management, what are 
its essential elements and which forms does it take?  What does uncertainty mean for the 
risk management process?  Which theories and principles address uncertainty within a 
planning and management context and how do they do so?  Can a risk management 
framework, inclusive of these theories and/or principles, be constructed and used in 
exploring the management pharmaceuticals in the environment, throughout this study? 
3)  To assess how human pharmaceuticals in the environment can be managed at a local 
scale, using a case study in the Region of Waterloo, Ontario, Canada.  Research 
questions include:  Are pharmaceuticals being released to the environment in the Region 
of Waterloo, and how do local concentrations compare to those in other areas?  Which 
pharmaceuticals are being released at particularly high concentrations?  What are the 
sources of these pharmaceuticals, and how might these sources be targeted in risk 
management?  Are there behaviours of residents which might contribute to the release of 
PhACs to the environment? Are local residents interested in seeing management action 
taken to reduce the release of PhACs to the environment?  Finally, which management 
strategies might be used to mitigate the release of PhACs  to the environment, locally?  
4)  To assess how human pharmaceuticals in the environment might be managed at a 
broad – mainly national --  scale.  Underlying research questions are: What are the views 
of stakeholders on the issue and the management of pharmaceuticals in the environment?  
Which management strategies meet the needs of stakeholders?  Which combinations of 
policies/management strategies are likely to optimally address the issue, and can some of 
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This thesis is organized to sequentially address these objectives and research questions. 
Chapter 2 provides an overview of scientific knowledge regarding pharmaceuticals in the 
environment.  Chapter 3 introduces risk management, the precautionary principle and  
adaptive planning; concepts which are especially relevant to the problem of 
pharmaceuticals in the environment.  The implications of the precautionary principle and 
the theory of adaptive planning for the development of management strategies for 
pharmaceuticals in the environment are discussed.  Chapter 4 is a case study examining 
the management of human pharmaceuticals in the mid-sized Region of Waterloo, 
Ontario.  Samples of influent and effluent from wastewater treatment plants in the Region 
were analyzed to determine how well pharmaceuticals were removed by the plants, and 
the concentrations at which PhACs were entering local surface water.  Furthermore, 
surveys of local residents were conducted to assess local habits of pharmaceutical use, 
disposal, and attitudes toward the environment.  Based on the results of the wastewater 
analyses and the surveys, recommendations are made to enhance the management of 
pharmaceuticals in the environment.  Chapter 5 describes a consultation of international 
stakeholders on pharmaceuticals in the environment.  Academics, government experts 
and representatives of the pharmaceutical industry were asked about their views 
regarding pharmaceuticals in the environment, including management strategies.  Finally, 
Chapter 6 involves an analysis of policy strategies to mitigate the environmental impacts 
of pharmaceuticals, with a particular focus on Canada.  It is hoped that the analyses 
conducted in this thesis will be of use to governments in two regards: first, in providing 
suggestions for management of the specific issue of pharmaceuticals in the environment; 
second, in providing guidance as to how the precautionary principle can be applied in the 
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Chapter 2: Scientific Understanding of PhACs in the Environment 
 
2.1.  Introduction 
 Pharmaceutically active compounds (PhACs) have been detected in surface water 
(Kolpin et al., 2002a; Metcalfe, Miao, Koenig, & Struger, 2003; Stumpf, Ternes, Wilken, 
Rodrigues, & Baumann, 1999; Wiegel et al., 2004), groundwater (Barnes et al., 2004; 
Heberer, Schmidt-Bäumier, & Stan, 1998; Holm, Rugger, Bjerg, & Christensen, 1995; 
Sacher, Lange, Brauch, & Blankenhorn, 2001), and drinking water (Boyd, Reemtsma, 
Grimm, & Mitra, 2003; Loraine & Pettigrove, 2006; Mittelstaedt, 2003; Stan, Heberer, & 
Linkerhagner, 1994) in a number of countries, especially developed countries, since the 
mid-1990s.  These products include medications for human and veterinary use, as well as 
their metabolites.  Field and laboratory evidence suggest that some PhACs may have 
subtle, chronic effects on the reproduction, development, and behavior of aquatic species, 
among other effects (Fong, 1998; Jobling, Nolan, Tyler, Brightly, & Sumpter, 1998).  
Effects of PhACs in drinking water on humans, while not seen as probable (Christensen, 
1998; Webb, Ternes, Gibert, & Olejniczak, 2003), cannot be ruled out.  Thus PhACs are 
environmental contaminants whose presence in the environment can be demonstrated, but 
whose effects remain poorly understood.  While scientific understanding of PhACs in the 
environment remains limited, it is important that management of the issue be based on 
credible scientific knowledge.  With the purpose of establishing a background for later 
discussions of management, therefore, this chapter presents a review of the state of 
scientific understanding of PhACs in the environment, with a particular focus on human 
pharmaceuticals.  Sources, transport, fate, and effects of PhACs are discussed, in addition 
to technologies to remove PhACs from water/wastewater.    
 
2.2.  History of PhACs in the environment 
 Interest in the environmental impacts of PhACs in natural waters has emerged in 
the past decade, particularly in developed countries, where large quantities of 
pharmaceuticals are consumed by humans and are used in agriculture.  Concerns about 
environmental contamination by pharmaceuticals were first raised in the 1970s (Tabak & 





concentrations in surface water and potable water were performed (Richardson & 
Bowron, 1985).   Only since the 1990s has technology became sufficiently advanced for 
researchers to quantify PhAC concentrations in aquatic samples at low µg/L and ng/L 
levels (Stan & Heberer, 1997; Stan et al., 1994).  There has been a gradual increase in the 
detection of PhACs in aquatic environments.  By 1996, 25 PhACs had been identified in 
aquatic environments, but this number increased to 68 by 1999 (Jorgensen & Halling-
Sorensen, 2000) and to more than 80 by 2002 (Heberer, 2002a).  While increased 
detection of PhACs in the environment was largely due to improvements in analytical 
methodology and technology for measuring low concentrations of PhACs in water, 
greater urban density and the increasing use of pharmaceuticals, may also have 
contributed to the trend (Heberer, 2002a). 
 
2.3.  Sources, transport, and fate of PhACs 
 PhACs enter aquatic environments via a number of routes (Figs. 2.1 & 2.2).  
Pathways through which PhACs reach natural waters differ depending on the use of the 
pharmaceutical, specifically whether the parent pharmaceutical is a human 
pharmaceutical or a veterinary pharmaceutical.   
 The most common pathway followed by human PhACs is consumption, followed 
by excretion to a sewage collection system (from a home, hospital, etc.), treatment at a 
wastewater treatment plant (WWTP) and release to surface water as wastewater effluent 
(Fig. 2.1).  The degree to which pharmaceuticals are metabolized in the body varies; 80-
90% of the antibiotic amoxicillin is released in the parent form, but only 3% of 
carbamazepine is excreted unchanged (Bound & Voulvoulis, 2004).  Fourty-five to sixty-
two percent of the drug ciprofloxacin is excreted in human urine, while another 15-25% 
is excreted in the feces (Golet, Xifra, Siegrist, Alder, & Giger, 2003).  When 
pharmaceuticals are metabolized to inactive conjugates in the digestive tract through 
glucuronidation, they serve as reservoirs of pharmaceutically active compounds.  The 
conjugates are frequently cleaved in wastewater treatment systems and sewers, causing 
the active parent pharmaceutical to be released (Baronti et al., 2000; Hirsch, Ternes, 





been detected in environmental water samples (Gross, Montgomery-Brown, Naumann, & 
Reinhard, 2004; Winkler, Lawrence, & Neu, 2001). 
 The loading of PhACs to the environment after consumption and excretion is 




Figure 2.1.  Some major routes of entry of human PhACs into the aquatic environment.  
The most common route of entry is via consumption. 
 
PhAC-contaminated sewage is treated.  Conventional, secondary sewage treatment 
involving coagulation/flocculation/sedimentation, successfully removes some PhACs, 
such as ibuprofen and salicylic acid (Kimura, Hara, & Watanabe, 2005; Lee, Sarafin, 
Peart, & Svoboda, 2004; Lindqvist, Tuhkanen, & Kronberg, 2005; Snyder, Westerhoff, 
Yoon, & Sedlak, 2003).  Other PhACs, however, such as the anticonvulsant 
carbamazepine, the lipid regulator gemfibrozil, the analgesic diclofenac and the drug 
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Erythromycin   0 Castiglioni et al., 2006 
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50 
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  24-44 Castiglioni et al., 2006 
1in surface water, 2in aerobic aquifer material,  3in soil, 4in sediment 
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& Meyer, 1997 
Iopromide 7.6-69.31 Kalsch, 1999 0 
0 
Carballa et al., 2004 
Hua et al., 2003 
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Norfloxacin   97 Lindberg et al., 2006 
Ofloxacin 10.61 Andreozzi et al., 2003 43-57 Castiglioni et al., 2006 
Oxazepam 541&4 Löffler et al., 2005   
Oxytetracycline 1514 Hektoen, Berge, 
Hormazabal, & Yndestad, 
1995 
  
Propranolol 16.81 Andreozzi et al., 2003 50 
95 
Sedlak & Pinkston, 2001 
Ternes, 2001 
Ranitidine   39-84 Castiglioni et al., 2006 
Salbutamol   0 Castiglioni et al., 2006 
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90 
Lee et al., 2004 
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Table 2.1 cont’d.  Half-lives and wastewater treatment plant (WWTP) removal rates for 
PhACs. 
 
 (Heberer, 2002b; Kimura et al., 2005; Lee et al., 2004; Lindqvist et al., 2005; Sedlak & 
Pinkston, 2001).  In a study of the effects of sewage treatment on 55 pharmaceutical 





60% for a German WWTP using clarification, aeration and addition of Fe(II) chloride.  
Removal rates are highly variable, however, depending on the specific operating 
parameters of individual wastewater treatment plants (Tauxe-Wuersch, De Alencastro, 
Grandjean, & Tarradellas, 2005).  The modification of operating parameters of 
conventional, sludge-activated wastewater treatment plants, particularly the solids or 
sludge retention time (SRT) can enhance the removal of some microbially-degraded 
pharmaceuticals such as bezafibrate, but attenuation of PhACs resistant to microbial 
degradation, such as carbamazepine, will not be enhanced by optimization of the SRT 
(Clara, Kreuzinger, Strenn, Gans, & Kroiss, 2005).  The use of membrane bioreactors can 
also increase removal of microbially degradable PhACs by allowing higher SRTs within 
a low-volume system (Clara et al., 2005; Kimura et al., 2005).  Nitrifying bacteria may 
help to remove some of the more polar PhACs (Eichhorn, Ferguson, Pérez, & Aga, 
2005).  Treatment methods relying on microbial degradation are extremely sensitive to 
seasonal variation, as decreasing temperature by 10o C halves the degradation rate (Clara 
et al., 2005).  Vieno, Tukhanen and Cronberg (2005) found that removal of PhACs in 
Finnish WWTPs decreased by 25% on average in the winter.  Performance of WWTPs in 
terms of plant parameters such as BOD, COD, and nitrogen removal is a good indicator 
of capacity to remove PhACs (Clara et al., 2005; Vieno et al., 2005)  
Specialized sewage treatment techniques such  as PhAC removal by activated 
carbon (Adams, Wang, Loftin, & Meyer, 2002),  oxidation by chlorination or ozonation 
(Boyd et al., 2003; Ternes et al., 2003; Zwiener & Frimmel, 2000) and membrane 
filtration (Boyd et al., 2003; Heberer, Feldmann, Reddersen, Altmann, & Zimmerman, 
2002; Sedlak & Pinkston, 2001; Yoon, Westerhoff, Snyder, & Wert, 2006) can increase 
PhAC removal rates to more than 95%.   However the most persistent PhACs may not be 
completely removed by some of these processes (Arslan-Alaton & Caglayan, 2006; 
Huber, Canonica, Park, & Von Gunten, 2003; Snyder et al., 2003; Zwiener & Frimmel, 
2000).   In particular, ozonation is more effective than chlorination (Westerhoff, Yoon, 
Snyder, & Wert, 2005); advanced oxidation methods (ex: O3/H2O2) are more effective 
than ozonation alone (Huber et al., 2003; Zwiener & Frimmel, 2000); and membrane 
filtration is most effective (Heberer et al., 2002).  Oxidation processes involving 





understood than those of the parent PhACs, (Daughton, 2001; Snyder et al., 2003; Ternes 
et al., 2003).  The products of naproxen chlorination have been found to be detrimental to 
biofilms, which has negative implications for both engineered and natural systems in 
which biofilms play important roles (Boyd, Zhang, & Grimm, 2005).  The chlorination of 
acetaminophen generates toxic byproducts (Bedner & MacCrehan, 2006).  Clearly, 
specialized wastewater treatment methods, while more effective than traditional 
wastewater treatment, are not without problems. 
Another concern with regard to wastewater treatment is the partitioning of 
hydrophobic PhACs to sludge.  Although this can effectively remove the more lipophilic 
PhACs such as 17α-ethinylestradiol from the wastewater (Taro & Kikuta, 2005), it 
creates the potential for groundwater or surface water contamination when sludge is 
spread on fields as an agricultural fertilizer (Dizer et al., 2002; Heberer, 2002a).  
Hydrophobic PhACs can be transported to surface water associated with organic 
particulate matter in runoff (Boxall, Blackwell, Cavallo, Kay, & Tolls, 2002).  
Furthermore repeated spreading of sludge may lead to the accumulation of PhACs in soil 
(Golet et al., 2003). 
 Other less studied, wastewater related sources of PhACs include septic systems 
and leaky sewage pipes.  Wolf, Held, Eiswirth, and Hötzl (2004) found water containing 
iodinated contrast media below leaky sewage pipes in Germany.  Septic systems are 
suspected of releasing PhACs which may contaminate groundwater; research on 
groundwater contamination by PhACs from septic systems is currently ongoing (pers. 
comm., Dr. Carol Ptacek, 2006). 
 Pharmaceuticals can also enter the soil and potentially contaminate groundwater, 
when reclaimed wastewater is used for irrigation.  As water resources are depleted, 
particularly in arid parts of the U.S., reclaimed wastewater is increasingly becoming an 
important source of irrigation water and may eventually be used to generate drinking 
water (Daughton, 2004a, 2004b; Kinney, Furlong, Werner, & Cahill, 2006; Loraine & 
Pettigrove, 2006; Toze, 2006).  In a study by Kinney et al. (2006), pharmaceuticals were 
found in soil irrigated by reclaimed wastewater.  Some PhACs, such as carbamazepine 





PhACs may accumulate in soils that receive year-round irrigation from reclaimed 
wastewater, and may eventually migrate to the water table.   
Improper disposal of unused pharmaceuticals contributes to the loading of PhACs 
to the environment (Fig. 2.1).  Estimates of the fraction of drugs which are disposed of 
rather than consumed range as high as 1/3 (Greiner & Rönnefahrt, 2003).  Improper 
disposal usually means flushing pharmaceuticals down the toilet, whereby they enter the 
sewage stream, or disposing drugs in the garbage, whereby they are stored in landfills.  
Contamination of groundwater by PhACs from landfill leachate has been documented by 
several researchers (Barnes et al., 2004; Eckel, Ross, & Isensee, 1993; Holm et al., 1995).  
Furthermore, when leachate is collected, it is often subsequently sent to a wastewater 
treatment plant (pers. comm.., D. Andrews, wastewater operations manager, Region of 
Waterloo, 2005). 
 Industrial spills of PhACs were once common, as the practice of dumping 
industrial residues was accepted. Such spills resulted in some of the major cleanup efforts 
sponsored by Superfund in the U.S. (Heberer, 2002a), and groundwater in some areas is 
still contaminated as a result of past spills (Heberer et al., 2004; Reddersen, Heberer, & 
Dünnbier, 2002).  More recent regulations governing the disposal of industrial waste in 
developed countries are much stronger than several decades ago, and spills are becoming 
rare.  Some PhACs are still released to the environment through manufacturing 
wastewater, including in water used to wash pharmaceutical manufacturing equipment 
(Balcýoðlu & Ötker, 2003; Guardabassi, Petersen, Olsen, & Dalsgaard, 1998) (Fig. 2.1).  
However pharmaceutical companies are devoting much effort to the development of 
advanced treatment plants to mitigate the entry of PhACs into wastewater from 
pharmaceutical manufacturing plants (AstraZeneca, 2003). 
 Dermally applied human pharmaceuticals can be washed into water by bathing, 
showering, swimming, and similar activities (Daughton & Ternes, 1999).  In the case of 
bathing in natural waters such as lakes, pharmaceuticals can directly enter the 
environment (Fig. 2.1).  Bathing and showering indoors causes pharmaceuticals washed 
from the body to enter the sewage collection system (Fig. 2.1). 
 Veterinary pharmaceuticals are used for agriculture, aquaculture, and for pets.  





aquifers or be carried to surface waters as runoff (Daughton, 2001) (Fig. 2.2).  PhACs for 
aquaculture – mainly antimicrobials – are applied directly to the water.  Consequently, 
75-80% of medication for fish is released directly to the environment, without ever being 
consumed (Hektoen et al., 1995).  PhACs used in agriculture can be excreted directly 
onto fields by farm animals, or manure containing PhACs may be applied to land.  As a 
result, some PhACs are bound to the soil (Schiffer, Daxenberger, Meyer, & Meyer, 2001) 
where they may also be degraded by microbes in the soil and/or manure (Carlson & 
Mabury, 2006).  Hydrophilic PhACs will easily be dissolved by rainwater and may 
infiltrate into underlying aquifers or may be carried to surface water as runoff.  However 
PhACs may degrade as they migrate through the soil and the unsaturated zone, and may 
never reach the water table (Boxall et al., 2002).  As with sewage sludge, hydrophobic 
PhACs from manure may be transported to surface or groundwater together with 
































Once PhACs have reached natural waters, they may degrade by a variety of 
mechanisms, depending on the compound.  Table 2.1 provides half-lives for some 
pharmaceuticals in aquatic environments.  Many pharmaceuticals, including the drug 
diclofenac, undergo photodegradation (Boreen, Arnold, & McNeill, 2003; Buser, Poiger, 
& Müller, 1999; Buser, Polger, & Müller, 1998; Packer et al., 2003).  Humic matter can 
increase or decrease the rate of photodegradation of some PhACs, depending on its 
concentration, and nitrate can also act as a photosensitizer for some drugs (Andreozzi et 
al., 2004; Doll & Frimmel, 2003).  Biodegradation is an important removal mechanism 
for the drug ibuprofen in surface water (Löffler et al., 2005; Winkler et al., 2001).  Both 
biodegradation and photodegradation are highly sensitive to varying climatic conditions; 
Vieno et al. (2005) found that concentrations of pharmaceuticals in surface water were 
much higher in winter than in summer, due in large to the inhibition of biodegradation by 
cold temperatures, and photodegradation by the presence of ice and snow on the river, 
and limited daylight.  Sorption to sediment is an important mechanism for the attenuation 
of hydrophobic PhACs such 17α-ethinylestradiol and diazepam in surface 
water/sediment (Löffler et al., 2005; Ying et al., 2003; Ying, Kookana, & Dillon, 2004), 
but is not a significant attenuation mechanism for some of the more polar PhACs such as 
diclofenac (T. Scheytt, Mersmann, Lindstädt, & Heberer, 2005), although ion exchange 
play a role in the attenuation of charged compounds (Lorphensri et al., 2006).  Finally, 
some pharmaceuticals are extremely persistent and are not easily attenuated at all, such as 
the anti-epileptic drug carbamazepine and clofibric acid, the metabolite of the cholesterol 
medication clofibrate (Löffler et al., 2005; T. Scheytt, Mersmann, Leidig, Pekdeger, & 
Heberer, 2004; T. J. Scheytt, Mersmann, & Heberer, 2006; Tixier et al., 2003). 
 
2.4.  Classes of PhACs of concern 
 Several classes of PhACs are of special concern with respect to environmental 
impacts.  Some are produced and consumed in large quantities; others are highly potent at 
low concentrations; and still others are extremely persistent in the environment.   
 





 Antimicrobials can disrupt wastewater treatment processes and have a high 
potential for ecosystem impacts because they are designed specifically to be toxic to 
bacteria (Jorgensen & Halling-Sorensen, 2000; Kümmerer, 2001).  They can be 
hydrophobic or hydrophilic, and some bioaccumulate (Wollenberger, Halling-Sorensen, 
& Kusk, 2000).  For instance, erythromycin has been found to have a bioaccumulation 
factor of 45.31 (Jones, Voulvoulis, & Lester, 2002).  Erythromycin also appears to 
accumulate in soils (Löffler et al., 2005).  It is possible that low concentrations of 
antimicrobials in natural waters may exert selective pressure leading to the development 
of antibiotic resistance in bacteria (Witte, 2000).  Evidence of the transference of 
resistance between bacteria in wastewater and the bacteria in sludge in sewage treatment 
plants has been recorded (Witte, 2000).  Sources of antimicrobials of special concern 
include a) agriculture:  agriculture accounts for 50% of antibiotic use in Europe, and 
manure used as fertilizer represents a potential source of antibiotic contamination of 
surface water and groundwater (Kümmerer, 2001);  b) hospitals: hospital effluent may 
contain sufficient quantities of antimicrobials to induce microbial resistance.  
Concentrations of antibiotics in the range of the MIC50 values of most pathogens have 
been found in hospital effluent, indicating the possible exertion of selective pressures on 
pathogenic bacteria (Al-Ahmad, Daschner, & Kümmerer, 1999; Kümmerer & Henninger, 
2003).  In particular, ciprofloxacin, a fluoroquinolone antimicrobial, is known to be 
highly toxic to bacteria (Hartmann, Alder, Koller, & Widmer, 1998), and is therefore of 
special concern with regard to ecosystem impacts (Bund/Länderausschuss für 
Chemikaliensicherheit (BLAC), 2003).   
  
2.4.2  Synthetic hormones 
 Synthetic hormones have the potential to affect the endocrine systems of humans 
and wildlife at low levels.  The main synthetic hormone found in environmental samples 
is 17α-ethinylestradiol (EE2), used in oral contraceptives for humans.  Other synthetic 
hormones exist, such as mestranol, which is also used as a human oral contraceptive but 
has only occasionally been found in environmental samples (Heberer, 2002b).  EE2 is 
excreted by humans as an inactive glucuronide but it is de-conjugated to the active parent 





removes EE2 somewhat successfully but not completely; removal rates vary between 75-
85% for secondary wastewater treatment (Baronti et al., 2000; 1999; Ying, Kookana, & 
Ru, 2002).   EE2 is primarily removed from sewage by passive sorption to sludge rather 
than by biodegradation, due to its log Kow of 3.9-4.1 (Johnson & Sumpter, 2001).  
Because EE2 partitions to sludge, it may be contained in biosolids spread on fields as 
agricultural fertilizer, potentially entering surface water in the form of runoff or entering 
groundwater by leaching.  Some studies indicate that EE2 in biosolids spread on 
agricultural fields may be degraded or diluted to concentrations below detection within 
days, and may therefore not reach the water table (Colucci & Topp, 2001; Lorenzen, 
Burnison, Servos, & Topp, 2003).  A study of aquifer storage recovery by Ying, Kookana 
& Dillon (2004), however, determined that EE2 did not degrade significantly in aquifer 
material over a period of 70 days. 
 EE2 is a concern because it is extremely potent at very low concentrations.  A 
concentration of 0.1 ng/L EE2 in surface water is sufficient to induce production of the 
female egg protein vitellogenin in male rainbow trout (Purdom et al., 1994).   In the U.K., 
concentrations of EE2 of up to 10 ng/L are commonly found in wastewater treatment 
plant effluents (Purdom et al., 1994). EE2 is suspected of being the cause of intersex fish 
in U.K. rivers and streams.  The synthetic hormone has been found to bioaccumulate, 
reaching concentrations in the bile of trout exposed to sewage effluent of 104-106 times 
the concentrations in the surrounding water (Larsson et al., 1999).   
 
2.4.3.  Lipid regulators 
 Lipid regulators are among the most ubiquitous PhACs in aquatic environments.  
Clofibric acid, a metabolite of the lipid regulator clofibrate, was the first PhAC to be 
detected in tap water, at concentrations of 10-165 ng/L in Berlin (Stan et al., 1994). 
Clofibric acid is extremely persistent.  It has a reported half-life of up to 21 years and 
continues to be found in environmental samples, including drinking water, even in 
locations where it has been removed from the market (Zuccato, Calamari, Natangelo, & 
Fanelli, 2000).  The metabolite is incompletely removed by standard ozonation procedure 





water supplies (Zwiener & Frimmel, 2000).  Clofibric acid is suspected of being harmful 
to aquatic organisms (Henschel, Wenzel, Diedrich, & Fliedner, 1997). 
 Gemfibrozil has been found in drinking water in Canada (Mittelstaedt, 2003) and 
bezafibrate and fenofibrate have been found in German drinking water (Ternes, 2001) at 
ng/L concentrations.  Gemfibrozil is not effectively removed by WWTPs; Lee et al. 
(2004) found a removal rate of 5% for Gemfibrozil in Canadian WWTPs.  Although the 
effects of lipid regulators such as clofibric acid, gemfibrozil, fenofibrate and bezafibrate 
on humans at low concentrations are unknown, their occurrence in drinking water is a 
concern, as is their ubiquity in surface waters.  Environmental levels of gemfibrozil have 
been found to reduce the production of sex hormones in male goldfish (Trudeau et al., 
2004). 
 Other types of lipid regulators that have been detected in aquatic environments 
include the statin class of lipid regulators.  Statin lipid regulators are recommended more 
frequently in Canada than any other lipid regulators; atorvastatin accounted for 52% of 
recommendations for lipid regulators in 2003 (IMS Health Canada, 2004).  Atorvastatin 
has been detected in the effluents of several Canadian WWTPs as well as in nearby 
surface water (Metcalfe, Miao et al., 2003). 
  
2.4.4.  Anti-inflammatories and analgesics 
 Anti-inflammatories and analgesics include some of the most widely used 
pharmaceuticals such as the over-the-counter pain killers acetaminophen, ibuprofen and 
acetylsalicylic acid (ASA).  They are ubiquitous in surface waters and are occasionally 
detected in groundwater.  Anti-inflammatories and analgesics have also been found in 
drinking water; Ternes (2001) detected 6 ng/L diclofenac, 3 ng/L ibuprofen, and 50 ng/L 
phenazone in German tap water, and Vieno et al. (2005) measured 8.5 ng/L ibuprofen and 
8 ng/L ketoprofen in Finnish drinking water.  Anti-inflammatories of special concern 
include ibuprofen, which is used in large quantities and is poorly removed from raw 
water by ozonation (Heberer, 2002a; Zwiener & Frimmel, 2000), and diclofenac, which 
is ubiquitous and is relatively poorly removed by secondary sewage treatment (Table 2.1) 
(Lee et al., 2004; Ternes, 2001).  Diclofenac has received increased attention recently as 





backed vulture population.  The drug, present in dead livestock, caused renal failure in 
the vultures (Oaks et al., 2004).  Although it is photodegradable (Buser et al., 1998), 
diclofenac has been found in groundwater samples (Heberer et al., 1998). 
  
2.4.5.  Antiepileptics 
 The anti-convulsant drug carbamazepine is frequently found in environmental 
samples.  It has been detected in surface water at up to 1.1 µg/L (Ternes, 1998) and in 
groundwater at 900 ng/L (Sacher et al., 2001), and has been found in Canadian drinking 
water (Mittelstaedt, 2003) as well as at 30 ng/L in German drinking water (Ternes, 2001).  
The removal rate of carbamazepine from wastewater by a secondary sewage treatment 
plants has been found to be quite low, between 7-40%  (Table 2.1), and its half-life has 
been found to be between 47-328 days (Andreozzi et al., 2003; Löffler et al., 2005).  The 
anti-epileptics carbamazepine and primidone were found to persist and were readily 
transported to groundwater during bank filtration experiments (Drewes, Heberer, Rauch, 
& Reddersen, 2003; Heberer et al., 2004); column experiments have found virtually no 
retardation for carbamazepine migrating through sand (T. Scheytt et al., 2004).  
Carbamazepine was found to persist in soil more than 6 months after irrigation by 
reclaimed wastewater in Colorado (Kinney et al., 2006). Carmabazepine is so persistent 
that some researchers have suggested it be used as a tracer to indicate water 
contamination by sewage effluent (Clara, Strenn, & Kreuzinger, 2004).  Ferrari et al. 
(2003) found a risk quotient of greater than one for carbamazepine in surface water, 
indicating that it could be harmful to aquatic organisms, particularly invertebrates.   
 
2.4.6.  Selective Serotonin Reuptake Inhibitors (SSRIs) 
 Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine are usually 
prescribed as anti-depressants.  They can exert a wide range of effects on aquatic 
organisms, especially on invertebrates (Brooks et al., 2003; Fong, 2001), inducing 
reactions such as the spawning of mussels (Fong, 1998).  Fluoxetine has been detected at 
up to 0.099 µg/L in Canadian WWTP effluents, and at lower levels in Canadian surface 






2.4.7.  Other PhACs  
 Beta blockers are ubiquitous and are not always removed by WWTPs.  For 
instance, one study found that less than 50% of propranolol was removed by secondary 
sewage treatment (Sedlak & Pinkston, 2001).  The beta blockers metoprolol was the 
PhAC with the highest concentrations in the Weschnitz river in a German study (2001), at 
> 1 µg/L.  Cytostatics and immunosuppressants have been detected in WWTPs effluent 
but not in natural waters (Ternes, 1998).  They are of concern due to their teratogenicity, 
mutagenicity, carcinogenicity, and genotoxicity (Sanderson, Johnson, Wilson, Brain, & 
Solomon, 2003). Iodinated contrast media, often used to perform X-ray exams in 
hospitals,  spread widely in the environment and have been detected in groundwater 
(Putschew, Wischnack, & Jekel, 2000; Sacher et al., 2001); however they are not 
believed to be harmful to humans or aquatic organisms (Kümmerer, 2001; Steger-
Hartmann, Länge, & Schweinfurth, 1999).  
 
2.5.  Occurrence of PhACs in surface water, groundwater, and drinking water 
(Table 2.2) 
 PhACs have been found in surface water, groundwater, and, occasionally, 
drinking water, in more than 10 countries, predominantly in Europe and North America 
(Heberer, 2002a).   PhACs are ubiquitous in surface water; a study by Ternes (2001) 
found PhACs in 31 of 40 streams and rivers sampled.  They occur more rarely in 
groundwater and drinking water.  The same study by Ternes (2001) found 15% of 
groundwater samples to be contaminated by PhACs at concentrations of more than 0.1 
µg/L.  A number of these contaminated samples, however, were from groundwater wells 






Conc. (µg/L) Class PhAC 
Med. Max. 
Source Reference 
0.15 1.9 Surface water, U.S. Kolpin et al., 2002a 
0.03 0.48 Surface water, Germany Hirsch et al., 1999 
n/a 0.410 Groundwater, Germany Sacher et al., 2001 
Sulfametho-
xazole 
n.d. 0.47 Groundwater, Germany Hirsch et al., 1999 
Anhydroery-
thromycin 
n/a 0.049 Groundwater, Germany Sacher et al., 2001 
Chlortetra-
cycline 
0.42* 0.69 Surface water, U.S. Kolpin et al., 2002a 
Roxithro-
mycin 












n/a 590 Agricultural drainflow, U.K. Boxall et al., 2002 
0.18 0.54 WWTP effluent, Canada Lee et al., 2004 
0.048 0.79 Surface water, U.S. Kolpin et al., 2002a 
0.052 0.51 Surface water, Germany Ternes, 1998 
0.066 0.112 Surface water, Canada Metcalfe, Miao et al., 2003 
n/a 0.340 Groundwater, Germany Heberer et al., 1998 
Gemfibrozil 
n/a <0.70 Drinking water, Canada Mittelstaedt, 2003 
n/a 0.060 Surface water, Germany Heberer et al., 2004 
n/a 0.103 Surface water, Canada Boyd et al., 2003 
0.066 0.55 Surface water, Germany Ternes, 1998 
0.059 0.175 Surface water, Canada Metcalfe, Miao et al., 2003 
n/a 7.300 Groundwater, Germany Heberer et al., 1998 
n/a 0.125 Groundwater (raw drinking 
water), Germany 
Heberer et al., 2004 
0.010-
0.165 
0.165 Drinking water, Germany Stan et al., 1994 
Clofibric acid 
n/a 0.0053 Drinking water, Italy Zuccato et al., 2000 
n/a 0.060 Surface water, Germany Heberer et al., 2004 
0.35 3.1 Surface water, Germany Ternes, 1998 
0.052 0.200 Surface water, Canada Metcalfe, Miao et al., 2003 
Bezafibrate 
<LOQ 0.027 Drinking water, Germany Ternes, 2001 
Lipid 
Regulators 
Atorvastatin n/a 0.015 Surface water, Canada Metcalfe, Miao et al., 2003 
0.48 0.97 STP effluent, Canada Lee et al., 2004 
0.07 0.53 Surface water, Germany Ternes, 1998 
0.141 0.790 Surface water, Canada Metcalfe, Miao et al., 2003 
n/a 0.200 Groundwater, 
Germany 
Heberer et al., 1998 
0.l2** n/a Drinking Water, U.S. Loraine & Pettigrove, 2006 
n/a 0.0007 Seawater, Norway Weigel et al., 2004 
Ibuprofen 





Diclofenac n/a 0.370 Surface water, 
Switzerland 
Buser et al., 1998 
*These median values do not include nondetects – see Till (2003) 
 ** Mean 
 
Table 2.2.  Occurrence of PhACs in aquatic environments: some findings of note 
(n/a=not available, n.d. =below detection, LOQ=limit of quantitation, 

















n/a 0.025 Surface water, Germany Heberer et al., 2004 
0.15 1.20 Surface water, Germany Ternes, 1998 
0.026 0.042 Surface water, Canada Metcalfe, Miao et al., 2003 
n/a 0.380 Groundwater, Germany Heberer et al., 1998 
n/a 0.590 Groundwater, Germany Sacher et al., 2001 
n/a 0.010 Groundwater (raw drinking 
water), Germany 
Heberer et al., 2004 
 
Diclofenac 
<LOQ 0.006 Drinking water, Germany Ternes, 2001 
0.024 0.95 Surface water, Germany Ternes, 1998 Propy-
phenazone n/a 1.465 Groundwater, Germany Heberer et al., 1998 
n/a 1.250 Groundwater, Germany Heberer et al., 1998 
n/a 0.025 Groundwater, Germany Sacher et al., 2001 
Phenazone 
<LOQ 0.050 Drinking water, Germany Ternes, 2001 
0.070 0.39 Surface water, Germany Ternes, 1998 
n/a 0.107 Surface water, U.S. & 
Canada 
Boyd et al., 2003 
0.207 0.551 Surface water, Canada Metcalfe, Miao et al., 2003 
n/a 0.105 Surface water, U.S. Gross et al., 2004 
Naproxen 






Ketoprofen n/a 0.008 Drinking water, Finland Vieno et al., 2005 
0.029 0.042 Sewage effluent, Canada Ternes et al., 1999 
<LOQ 0.0043 Surface water, Netherlands Belfroid et al., 1999 
n/a 0.0046 Surface water, U.K. Williams, Johnson, Smith, & 
Kanda, 2003 








Mestranol 0.017 0.407 Surface water, U.S. Kolpin et al., 2002a 
n/a 2.3 STP effluent, Canada Metcalfe, Koenig et al., 2003 
n/a 0.330 Surface water, Germany Heberer et al., 2004 
0.25 1.1 Surface water, Germany Ternes, 1998 
0.185 0.650 Surface water, Canada Metcalfe, Miao et al., 2003 
n/a 1.1 Groundwater, Germany Ternes, 2001 
n/a 0.070 Groundwater (raw drinking 
water), Germany 
Heberer et al., 2004 
Carbamazepine 
n/a < 0.70 Drinking water, Canada Mittelstaedt, 2003 




n/a 0.040 Groundwater (raw drinking 
water), Germany 
Heberer et al., 2004 
n/a 0.046 Surface water, Canada Metcalfe, Miao et al., 2003 SSRIs Fluoxetine 
0.012* 0.012 Surface water, U.S. Kolpin et al., 2002a 
Cyclophos-
phamide 
<LOQ 0.020 STP effluent, 
Germany 
Ternes, 1998 Cytostatics 
Ifosfamide 0.0093 0.040 STP effluent, Germany Kümmerer et al., 1997 
Diatrizoate n/a 1.2 Raw drinking water, 
Germany 
Putschew et al., 2000 X-Ray Agents 
Iopromide n/a 1.6 Surface water, Germany Putschew et al., 2000 
Sotalol n/a 0.560 Groundwater, Germany Sacher et al., 2001 Beta-Blockers 
Metoprolol 0.045 2.2 Surface water, Germany Ternes, 1998 
 







2.6.  Environmental impacts of PhACs 
 
2.6.1.  Impacts of PhACs in drinking water on human health  
 PhACs have been detected in drinking water in Canada (Mittelstaedt, 2003) and 
other countries (Stan et al., 1994) at ng/L concentrations or lower.  However, there is 
currently no evidence that these levels of PhACs have detrimental effects on human 
health.  Concentrations of PhACs in drinking water are several orders of magnitude 
below therapeutic doses of pharmaceuticals in humans (Webb et al., 2003).  
Environmental risk assessments considering endpoints in terms of human health indicate 
that levels of PhACs in drinking water are unlikely to harm healthy adults (Christensen, 
1998; Schulman et al., 2002; Webb et al., 2003). However, a lack of evidence of effects 
does not constitute a lack of effects, and the possibility of subtle, chronic effects of long-
term PhAC consumption cannot be eliminated, nor can the possibility of effects on 
sensitive sub-populations such as embryos and fetuses (Pomati et al., 2006).  Concerns 
also exist in terms of potential effects of PhACs on people with chemical sensitivities or 
compromised immune systems, and with regard to the development of antibiotic 
resistance (Christensen, 1998; Daughton & Ternes, 1999).   
 
2.6.2.   Impacts of PhACs in surface water on aquatic organisms 
 Certain PhACs have been found to affect aquatic organisms at µg/L to ng/L 
concentrations.  A well-known example is the feminization of fish in surface water 
contaminated by 17α-ethinylestradiol (EE2), the active ingredient in oral contraceptives, 
from WWTP effluent (Jobling et al., 1998; Larsson et al., 1999; Purdom et al., 1994).  
Environmental risk assessments for PhACs indicate that several PhACs, including 
ibuprofen, paracetamol, carbamazepine, gemfibrozil, mefenamic acid, and 
oxytetracycline, are likely present in some aquatic environments at levels sufficiently 
high to harm aquatic organisms (Ferrari et al., 2003; Henschel et al., 1997; Jones et al., 
2002; Sanderson et al., 2003; Stuer-Lauridsen, Birkved, Hansen, Holten Lützhoft, & 
Halling-Sorensen, 2000; Tauxe-Wuersch et al., 2005).  PhACs can be expected to have 
effects on aquatic organisms, as they are often highly bioactive even at low 





et al., 2000), have several target receptors, and follow complex biological pathways 
(Daughton & Ternes, 1999).  Furthermore, the continuous release of PhACs to surface 
waters means that aquatic organisms are constantly exposed to the 
contaminants, throughout several life-cycles (Daughton & Ternes, 1999).  Not only can 
PhACs affect vertebrates such as fish, but they have also been found to affect 
invertebrates in laboratory studies (Brooks et al., 2003; Pascoe, Karntanut, & Müller, 
2003); in fact some invertebrates may be more sensitive to PhACs than many vertebrates 
(Ferrari et al., 2003).  Effects on algae (Halling-Sorensen, 2000; Wilson, Smith, 
Denoyelles, & Larive, 2003) and bacteria (Guardabassi et al., 1998; Kümmerer, Al-
Ahmad, & Mersch-Sundermann, 2000; Kümmerer & Henninger, 2003) have been 
documented as well.  PhACs are unlikely to have acute effects, such as fish kills, at most 
environmental concentrations (Farré et al., 2001; Sanderson et al., 2003).  The recent 
discovery that vultures in Asia have been dying from eating cattle containing relatively 
low concentrations of the drug diclofenac (Oaks et al., 2004), however, illustrates that 
acute effects as a result of exposure to relatively low levels of PhACs are possible.  Most 
scientists are concerned about the potential for subtle, long-term, possibly multi-
generational effects on aquatic organisms (Daughton & Ternes, 1999; Jones et al., 2002; 
Jorgensen & Halling-Sorensen, 2000; Stuer-Lauridsen et al., 2000).  It is extremely 
difficult to predict how PhACs might affect non-target organisms (Daughton & Ternes, 
1999).  Therefore standard acute toxicity tests are likely of limited use in assessing the 
environmental impacts of PhACs (Ferrari et al., 2003; Länge & Dietrich, 2002; 
Sanderson et al., 2004; Sanderson et al., 2003).   More sophisticated environmental 
assessment methods are needed, potentially including QSAR modelling (Sanderson et al., 
2004; Sanderson et al., 2003), microcosm and mesocosm studies (Brain et al., 2004; 
Brooks et al., 2003), and methodologies designed to test for endocrine disrupting effects 
(Environment Canada, 1999; Sutcliffe, 2001; US EPA, 2004).  
 
2.7.  Mixture effects 
 Assessment of the effects of PhACs is complicated by the presence of PhACs – 
and other compounds – as mixtures in environmental conditions. Environmental 





effects.  The complex nature of the pharmacodynamic behavior of pharmaceuticals, 
however, poses a particular challenge and concern (Daughton & Ternes, 1999; Sanderson 
et al., 2004).  For instance, a recent study found that interactions among a mixture of 
drugs at environmental (ng/L) concentrations caused a reduction in cell proliferation in 
vitro (Pomati et al., 2006).   Cleuvers (2003) found that concentration addition effects 
occurred when daphnia were exposed to mixtures of clofibric acid and carbamazepine, 
but independent action was found for algae exposed to the same mixture.  Ibuprofen and 
diclofenac exerted additive effects on both species when mixed.  Silva, Rajapakse and 
Kortenkamp (2003) found that mixtures of xenoestrogens displayed effects according to 
the concentration addition model.  In the concentration addition model, substances 
present at concentrations below their NOEC (No Observed Effects Concentration) can 
contribute to a total mixture effect; this is not the case for independent action.  As 
concentration addition appears to be the appropriate model for mixture effects more 
frequently than independent action, it is likely that many PhACs found in the 
environment contribute to effects on organisms as part of mixtures, despite being present 
at concentrations lower than the NOEC for the organism in question. 
 
2.8.  Gaps in scientific understanding of PhACs in aquatic environments 
  
2.8.1.  Human health effects 
 While risk assessments suggest that exposure to PhACs at ng/L concentrations in 
drinking water is unlikely to be detrimental to human health, media reports of 
pharmaceuticals in water are raising concerns about effects such as endocrine disruption 
and antibiotic resistance among the public (Brooymans, 2005; Mittelstaedt, 2003). 
Research confirming that sensitive sub-populations of humans are not at risk is needed.  
Exposure of prenatal and neonatal babies to PhACs is of particular concern.  Recent 
research has produced evidence that pharmaceutical mixtures at environmental 
concentrations (ng/L) can affect embryonic cell growth (Pomati et al., 2006).  Exposure 
to hormonally active substances during critical development periods such as adolescence 
should be considered as well (Barlow et al., 1999; Foster, 2001).  Animal studies can be 





low doses, but scientists are rightly cautious about extrapolating from animals to humans 
(Purchase & Randall, 1998; Slovic et al., 1995).  The use of epidemiological data is 
fraught with difficulties, including the separation of background effects, such as the 
consumption of PhACs or hormonally active substances in food, from the effects of 
PhACs in drinking water (Foster, 2001; Webb et al., 2003).  Researchers are coming to 
the realization that for environmental exposure of humans to substances that may interact 
with hormonal systems, timing may be more important than dose.  While not all PhACs 
are hormonally active, more PhACs may affect hormonal systems than is obvious at first 
glance.  For instance, Trudeau et al. (2004) found that the lipid regulator gemfibrozil 
reduced testosterone levels in goldfish, likely because the drug affects levels of 
cholesterol, from which testosterone is manufactured.  Human exposure to hormonally 
active substances during critical windows of growth and development may result in 
health effects, when at another time exposure to such low levels might not be harmful 
(Barlow et al., 1999; Daughton & Ternes, 1999; Ibarreta & Swan, 2002).  Furthermore, 
the effects of hormonally active agents on humans may only appear decades, sometimes 
even generations, after exposure (Ibarreta & Swan, 2002).  The potential importance of 
timing, and the possibility of delayed effects of PhACs on humans, makes the already 
challenging assessment of effects on humans extremely problematic.   
 
2.8.2.  Ecosystem effects 
 The primary concern with regard to the environmental impacts of PhACs is 
ecosystem health, rather than human health (Sanderson et al., 2003; Schulman et al., 
2002).  However, the effects of PhACs on aquatic ecosystems are poorly understood; 
much more research is needed into this aspect of the problem.  Because PhACs can act in 
a variety of unexpected ways on non-target organisms (Daughton & Ternes, 1999), and 
because of the complexity of ecosystems, it will be very difficult to predict the ways in 
which aquatic ecosystems might be affected .  Microcosm and mesocosm studies (Brain 
et al., 2004; Brooks et al., 2003) and laboratory experiments focusing on sub-lethal 
effects (Trudeau et al., 2004) resulting from low-level, chronic exposure of aquatic 
organisms to PhACs, preferably over several generations, will be most helpful in this 





organisms, in areas where PhACs are found in the water – in agricultural areas and 
downstream from WWTP effluent, for instance – will also help to ascertain the effects of 
PhACs on aquatic organisms (Jobling et al., 1998).  It is essential that research into 
ecosystem effects of PhACs be as anticipatory as possible, so that damage to ecosystems 
is minimized. 
 
2.8.3.  Effects of mixtures 
 The effects of mixtures of environmental contaminants remain poorly understood 
and require more research.  While most risk assessment methods focus on one substance 
at a time, aquatic organisms inhabiting lakes and streams, and humans consuming 
groundwater, are exposed to multiple contaminants.  Toxicological studies must not only 
examine the effects of individual PhACs on organisms, but must assess the effects of 
exposure to several PhACs at once (Cleuvers, 2003) (See Section 2.7 for more detail on 
possible types of mixture effects). 
 
2.8.4.  Fate and transport 
 There is a need to better understand the fate and transport of PhACs, from 
consumption or initial release to the environment, to their occurrence in surface water, 
groundwater, and drinking water.  Currently analyses of PhACs in WWTP influent and 
effluent focus mainly on the parent compound; but the occurrence and effects of 
metabolites must also be considered (Kolpin et al., 2002a; Ternes, 2001).  The effects of 
sewage treatment on PhACs remain poorly understood; in particular the generation of 
byproducts by treatment methods such as chlorination and ozonation requires research 
(Boyd et al., 2005; McDowell, Huber, Wagner, Von Gunten, & Ternes, 2005; Snyder et 
al., 2003; Tabata et al., 2003).  The distribution of PhACs in sewage sludge and manure, 
and the potential for groundwater or surface water contamination as a result of land 
application of the sludge (biosolids) or manure, must be explored (Colucci & Topp, 
2001).   Contributions of sources such as septic tanks and leakage from underground 
sewage pipes and sewer overflows to loadings of PhACs to aquatic environments should 






2.9  Priority PhACs  
 An understanding of fate, transport, and effects can help us to assess which 
pharmaceuticals may represent the greatest concern in terms of environmental impact.  
These ‘priority PhACs’ include the compounds to which aquatic organisms are most 
likely to be exposed, and which are most likely to have adverse effects on organisms.  
Table 2.3 presents a rough ranking of some commonly detected PhACs of concern.  The 
ranking is based on scores out of ten for a) persistence during sewage treatment, based on 
literature values for WWTP removal rates (Table 2.1); b) persistence in the environment, 
based on half-lives found in the literature (Table 2.1), and c) likelihood of adverse effects 
on aquatic organisms, based on findings of effects and on risk assessments reported in the 
peer-reviewed literature.  It should be noted, however, that there are many other factors 
which are also important in determining which contaminants are of more concern than 
others.  For instance, this ranking does not account for the frequency of detection of the 
PhACs in surface water or groundwater, although those compounds being ranked are 
those most frequently discussed in the literature.  The ranking also does not account for 
localized use; for example, clofibrate has been used to a greater extent in Europe than in 
North America; therefore research on clofibric acid may be more important in the EU 
than in Canada or the U.S.  The purpose is not to give an exact, quantitative ranking of 
risk, but merely to make use of the data and information available in the literature, to 
provide a general picture of which PhACs may be of greatest concern.  A ranking of 
classes of PhACs and personal care products according to environmental risk, based on 
QSAR (quantitative structure activity relationship) modelling, can be found in Sanderson 
et al. (2004).  A ranking based on the criteria of persistence, bioaccumulation, and 
toxicity (PBT) can be found in a booklet published by the Stockholm County Council 
(Stockholm läns landsting, 2005). 
 In Table 2.3, the substances having scores of 20 or more, are the ‘high priority’ 
PhACs.  The ranking suggests that carbamazepine, clofibric acid, ifosfamide, 17α-
ethinylestradiol (EE2), oxytetracyline, ciprofloxacin, and diclofenac are ‘high priority’ 
substances and therefore merit the greatest research efforts.  These substances are very 
persistent in surface water, aquifers, or soils, are poorly removed by wastewater 














Carbamazepine Anti-epileptic 9 10 6 25 
Clofibric acid Lipid 
regulator 
9 10 5 24 





5 7 9 21 
Oxytetracycline Antimicrobial 4* 10 7 21 
Ciprofloxacin Antimicrobial 2 10 8 20 




10 7 2 19 
Gemfibrozil Lipid 
regulator 





4* 9 4* 17 
Fluoxetine SSRI 4* 4* 8 16 
Bezafibrate Lipid 
regulator 
5 4* 5 14 
Ketoprofen Analgesic 6 4* 4* 14 
Ibuprofen Analgesic 2 7 5 14 
Ofloxacin Antimicrobial 4* 4 6 14 
Naproxen Analgesic 5 4 4 13 
Propranolol Beta blocker 3 5 4* 12 
Sulfamethoxazole Antimicrobial 4 2 6 12 
Salicylic acid Analgesic 1 4* 5 10 
Acetominophen Analgesic 1 4* 4* 9 






Table 2.3.  Priority ranking of PhACs based on WWTP removal, persistence in the 
environment, and a qualitative scoring of effect.  Values on which scores for WWTP 







substances with rankings from 12-19 are the ‘moderate priority’ PhACs; they are not top 
priorities as they are either removed reasonably effectively by WWTPs, degrade 
relatively quickly in the environment, or have no evidence of detrimental effects; but 
their removal or degradation is not complete, and they remain a concern.  Research on 
these substances is certainly worth pursuing, although their priority in terms of research 
effort is lower than for the ‘high priority’ substances.  Lastly, there are the PhACs with 
total scores of less than 12, identified as ‘low priority’ substances.  These substances are 
not persistent and are unlikely to be harmful to aquatic organisms; they require a low 
level of concern.  It should be noted that uncertainty remains high with regard to removal, 
degradation, and especially effects of PhACs, so future findings may change the order of 
priority with regard to the risks these substances present. 
 
2.10.  Conclusions 
 In recent decades there has been an increase in interest in pharmaceuticals in the 
environment.  As analytical technology has allowed for the detection of lower and lower 
concentrations of these substances in aquatic systems, their ubiquity in the environment 
has become apparent.  However, the risks that PhACs present to human and ecosystem 
health, remain unclear.  While some PhACs have been found to have subtle, chronic 
effects on the reproduction, development and/or behavior or aquatic species, much more 
research on their effects on aquatic organisms and ecosystems is required.  At this time, 
the level of scientific uncertainty with regard to the risks of PhACs in surface water, 
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Chapter 3:  Framework and theoretical background for the management of PhACs 
in the environment 
 
3.1.  Introduction  
 The issue of PhACs in the environment is essentially a question of risk to the 
health of aquatic organisms, ecosystems, and humans.  Therefore, the management of 
PhACs should ideally be addressed within a risk management framework.  However, 
given the high level of uncertainty currently associated with the effects of PhACs (see 
Ch. 2), risk management will have to be applied flexibly, foregoing some of the 
quantitative analysis typically involved.  Other planning and management theories must 
be integrated with risk management to lend the framework the flexibility to deal with 
uncertainty.  The precautionary principle (CEPA, 1999; Quijano, 2003; Rogers, 2001; 
United Nations General Assembly, 1992) and the theory of adaptive planning 
(Briassoulis, 1989; Holling, 1978; Lessard, 1998) are particularly appropriate for coping 
with uncertainty.  This chapter discusses how a risk management framework can be 
modified, using the precautionary principle and adaptive planning, to function under 
conditions of high uncertainty.  The framework developed will provide a basis, in a broad 
sense, for discussions of risk management throughout the remainder of the thesis. 
 
3.2  Key concepts 
The concepts of risk, uncertainty, and the nature of risk management, are central to this 
chapter, therefore merit some detailed elaboration: 
 
3.2.1.  What is risk? 
 The term ‘risk’ is subject to much debate in the academic community, particularly 
between natural scientists and social scientists, and merits clarification here.  The more 
common definition of risk is the positivistic definition, used by scientists and engineers: 
risk is operationally defined as “the chance of injury or loss as defined as measure of the 
probability and severity of an adverse effect to health, property, the environment, or other 
things of value.” (Canadian Standards Association, 1997, p. 3).  Risk is the product of the 





Shortreed, 2000).  Many social scientists and social theorists, however, question this 
positivistic definition of risk, pointing out that risk is socially constructed, and can always 
only be subjectively perceived, not objectively evaluated (Beck, 1992; Covello, 1989; 
Slovic, 2001).  Therefore, they argue that ‘perceived risk’ or ‘risk perception’, and ‘risk’, 
are one and the same.  For example, Beck (1992) states, "Risk may be defined as a 
systematic way of dealing with hazards and insecurities induced and introduced by 
modernization itself." (p. 21), and, “Because risks are risks in knowledge, perceptions of 
risks and risks are not different things, but one and the same." (p. 55).  In this thesis, the 
term ‘risk’ refers to the positivistic definition of risk, whereas ‘risk perception’ or 
‘perceived risk’ will be used to refer to a normative definition of risk.  This is not to 
suggest that risk can be objectively measured or calculated, nor to undermine the 
importance of values and other normative considerations in decisions regarding risk; on 
the contrary, these are essential to good risk management.  The purpose is simply to make 
readers aware of the discussion surrounding the term ‘risk’, and to clarify its use in this 
dissertation. 
 
3.2.2.  What is uncertainty? 
 Another term essential to the management of PhACs in the environment, which 
requires some clarification, is the term ‘uncertainty’.  This term appears to have no 
unique definition, as it has different meanings according to various authors.  According to 
Hrudey, (1996) uncertainty is comprised of true uncertainty, which is theoretically 
(although often not practically) reducible, and variability or indeterminacy, which is 
inherent in natural systems and cannot be reduced.  Stirling (2001) defines uncertainty as 
follows: "Uncertainty...applies to a condition under which there is confidence in the 
completeness of the defined set of outcomes, but where there is acknowledged to exist no 
uniquely valid theoretical or empirical basis for the assigning of probabilities of these 
outcomes." (p. 78), distinguishing it from ignorance: "Ignorance...applies in 
circumstances where there not only exists no basis for the assigning of probabilities (as 
under uncertainty), but where the definition of a complete set of outcomes is also 
problematic.  In short, it is an acknowledgement of the possibility of surprises." (p. 78).  





when relationships between hazard and harm are postulated based on intuition; in the case 
of uncertainty, there is scientific knowledge or evidence on which these relationships can 
be based.  For the purpose of simplicity, in this thesis, ‘uncertainty’ will refer to Hrudey’s 
(1996) definition of true uncertainty; the term ‘uncertainty’ will include both ignorance 
and uncertainty as defined by Stirling (2001) and Rogers (2003).   
 
3.2.3  What is risk management? 
 Risk management, in an environmental context, and in its broad sense, can be 
defined as the process through which decisions regarding the mitigation of risks to the 
environment are made.  Ruckelhaus (1990) describes risk management as follows: “Risk 
management in its broadest sense means adjusting our environmental policies to obtain 
the array of social goods – environmental, health-related, social, economic, and 
psychological – that forms our vision of how we want the world to be.” (p. 113).  Risk 
management involves integrating information such as the results of risk analyses, other 
scientific data about environmental and health impacts, societal concerns, perceptions and 
public values, financial costs of risks and risk mitigating actions, etc., and balancing these 
factors so as to yield an optimal decision on how to act (in other words, which policy to 
implement) faced with a risk (McColl et al., 2000).  The purpose of risk management is to 
identify risks and to take appropriate and reasonable action to minimize these risks, 
including communicating with stakeholders on the nature of the risks (Canadian 
Standards Association, 1997).   
 
3.3  Components of risk management 
 Although different risk management frameworks exist, they all have a number of 
elements in common.  They include, toward the beginning of the risk management 
process, a scientific assessment or analysis of the risk (Figs. 3.1 & 3.2).  For 
environmental contaminants, the scientific analysis or assessment of risk includes a step 
where a hazard is identified, based on the physico-chemical properties of a contaminant, 
its known toxicological effects, and other scientific data.  Furthermore, a scientific 


































Figure 3.1.  Canadian Standards Association risk management framework (1997)(Note: 















































































Figure 3.2.  Risk management framework from the U.S. Presidential/Congressional 





























adverse effects, an assessment of exposure of humans or other organisms to the 
contaminant, and characterization of the risk.  Traditionally, risk characterization has 
referred to a probabilistic estimation of risk (Canadian Standards Association, 1997; 
McColl et al., 2000). In other words, risk in its positivistic sense is the focus of this first 
component of risk management. 
 A second component of risk management goes beyond a scientific analysis of risk 
to include an assessment of social and economic factors and consultation with 
stakeholders (Figs. 3.1 & 3.2).  The steps in this second portion include, as a minimum, 
the development of management options; consultation with stakeholders; the evaluation 
of options based on social, economic, scientific and other information; and a decision as 
to which management option is to be implemented (Canadian Standards Association, 
1997; Health Canada, 1998; The Presidential/Congressional Commission on Risk 
Assessment and Risk Management, 1997).  In the past, communication and consultation 
with stakeholders, and social aspects of risks, where perhaps undervalued (Fig. 3.3) 
(National Research Council, 1983).  However these elements now have a much more 
prominent role in risk management frameworks (Figs. 3.1 & 3.2) (Canadian Standards 
Association, 1997; The Presidential/Congressional Commission on Risk Assessment and 
Risk Management, 1997).  It is in this component of the risk management framework that 
risk perceptions come into play. 
 





3.4.  Risk communication: addressing perceptions of risk 
 Risk perceptions are “intuitive risk judgments” (Slovic, 1987, p. 280), or 
impressions people have about the nature and magnitude of risks (Leiss & Chociolko, 
1994).  Public risk perceptions are normative and value-based (Slovic, 1993), and as such 
they often differ from expert judgments of risk, which are meant to be positivistic and 
purely scientifically based.  Scientific assessments, however, are known also to be based 
in value judgment (Hood et al., 1992; Turner, 1994), including the valuation of science 
for its own sake (Beck, 1992).  Characterization of lay risk perceptions as incorrect and 
irrational and expert judgments as correct and rational, however, is misguided (Leiss & 
Chociolko, 1994; Weterings & Van Eijndhoven, 1989).  Lay perceptions of risk often 
have roots in concepts such as fairness, equity, controllability, and the distribution of risk 
(Renn, 2004; Slovic, 2001).  Slovic (1987) points out, "There is wisdom as well as error 
in public attitudes and perceptions.  Lay people sometimes lack certain information about 
hazards.  However, their basic conceptualization of risk is much richer than that of the 
experts and reflects legitimate concerns that are typically omitted from expert risk 
assessments.” (p. 285).  And Covello (1989) states, "there are multiple truths about risk, 
and multiple ways of seeing, perceiving and interpreting risk events." (p. 12).  The best 
risk management outcomes will result when both scientific and intuitive assessments of 
risk are valued, and are used in a complementary fashion in decision making (Healey, 
2001; Renn, 2004).  
 The purpose of risk communication, therefore, should not be to diffuse public 
concerns or to ‘educate’ an ignorant public (Covello, 1989); in fact attempts to alleviate 
public fears through ‘education’ about the low risk of nuclear energy failed drastically in 
Canada, heightening fears rather than calming them (Somers, 1995).  Risk 
communication must aim to produce a thoughtful, involved, informed and collaborative 
public (Covello, 1989).  This requires a strong effort to provide for public participation at 
all stages of risk-related decision making (Renn, 2004; Slovic, 2001; Weterings & Van 
Eijndhoven, 1989).  Furthermore, to allow for collaboration, and to avoid amplifying risk 
perceptions, trust and confidence in public officials is needed (Covello, 1989; Slovic, 
1993).  To maintain the public’s trust and confidence, governments need to have open, 





(Covello, 1989; Hance, Chess, & Sandman, 1989).  Value-based concerns must be 
acknowledged, not dismissed (Healey, 2001; Renn, 2004); and the use of technical jargon 
must be limited, as it can create suspicion (Covello, 1989; Jardine & Hrudey, 1997; 
Weterings & Van Eijndhoven, 1989).  The public must be informed about health and 
environmental risks, including the scientific uncertainty surrounding them, as 
governments learn about them; withholding information will only generate mistrust when 
the public becomes aware of the risks (Hance et al., 1989).  This is of particular 
importance with respect to PhACs in the environment, as there have been suggestions 
that the public should not be informed of the issue because of the high level of 
uncertainty surrounding it (Aumonier, 2003).  Such suggestions are misguided.  As media 
reportings of PhACs in the environment continue to emerge (Brooymans, 2005; 
Mittelstaedt, 2003), it will be essential for governments and industry to discuss the issue, 
and the uncertainty surrounding it, in a straightforward fashion with the public, and to 
avoid making trust-destroying mistakes such as the withholding of information. 
 
3.5.  Dealing with uncertainty 
 Uncertainty can present a challenge, not only during risk communication, but also 
during risk assessment, as is the case for PhACs. As discussed in Chapter 2, traditional 
risk assessment methods are not appropriate for the detection of the effects of PhACs in 
the environment (Länge & Dietrich, 2002; Sanderson et al., 2004); as a result, little 
information, and nearly no reliable quantitative or probabilistic information, is available 
concerning exposure-effect relationships for PhACs.  However, field and laboratory 
evidence (Fong, 1998; Jobling, Nolan, Tyler, Brightly, & Sumpter, 1998), as well as 
scientifically-based intuitive reasoning (Daughton & Ternes, 1999), do suggest that 
PhACs may have detrimental effects on some aquatic species.  As Cairns (1999) points 
out, "Unrecognized risks are still risks; uncertain risks are still risks; and denied risks are 
still risks." (p. A56).  Therefore, it is essential that the risk management process not be 
brought to a halt by the existence of uncertainty, or the difficulty of quantification.  The 
risk management framework must be modified with a tool for addressing uncertainty and 






3.6.  The precautionary principle 
 The precautionary principle is a decision making tool meant to guide society 
towards a sustainable future, in the face of scientific uncertainty.  The principle fills the 
void left in the risk management framework when risk analysis produces uncertain results 
(Fig. 3.4).  Essentially, it states that where some evidence of the potential for harm to the 
environment or human health exists, scientific uncertainty in causal relationships or other 
aspects of the risk should not be allowed to delay risk management (Government of 
Canada, 2001; Harremöes et al., 2002; Quijano, 2003).  Implicit in the precautionary 
principle is the concept that deciding to do nothing -- to maintain the status quo -- is a 
policy decision, and that a decision to do nothing should be considered and reviewed as 
carefully and as skeptically as a decision to mitigate risk (Santillo, Stringer, Johnston, & 
Tickner, 1998).  There is no single, universal definition of the precautionary principle, but 
the best known definition is likely the following: “Where there are threats of serious or 
irreversible damage, lack of full scientific certainty shall not be used as a reason for 
postponing cost-effective measures to prevent environmental degradation.” (United 
Nations General Assembly, 1992, Principle 15, p. 4).  A definition with less emphasis on 
the irreversibility of damage or the cost-effectiveness of risk management action was 
developed at the Wingspread Conference (Wingspread Conference on the Precautionary 
Principle, 1998): “When an activity raises threats of harm to human health or the 
environment, precautionary measures should be taken even if some cause and effect 
relationships are not fully established scientifically.” (p. 2).  The precautionary principle 
originated with the Vorsorgeprinzip, or principle of forecaring, which was born out of a 
concern with growing environmental problems in 1970s Germany.  It has since grown 
and has been referred to in several international agreements such as the North Sea 
Agreement (Dratwa, 2002), and it is part of the Canadian Environmental Protection Act 
(CEPA, 1999). 
 The precautionary principle has a number of elements at is core: 1) prevention of 
harm is preferable to remediation (Kriebel et al., 2001; Quijano, 2003), 2) a lack of 
scientific certainty (Government of Canada, 2001; McGarvin, 2001; Quijano, 2003; 































Figure 3.4.  a) Without the precautionary principle, the risk management process may 
impeded by the inability to conduct a sound, quantitative risk assessment.   
b)  The precautionary principle fills the gap in risk management when quantitative risk 




















 2002; Government of Canada, 2003; Quijano, 2003), 4) duty to act (deFur & Kaszuba, 
2002; Government of Canada, 2003; Santillo et al., 1998), 5) the burden of providing 
evidence of lack of harm falls on the proponent of an action (Government of Canada, 
2003; Jordan & O' Riordan, 1999; Kriebel et al., 2001; Quijano, 2003), 6) need to 
consider a range of alternative solutions to the problem (Kriebel et al., 2001; Quijano, 
2003), 7) importance of public participation (Kriebel et al., 2001; O' Riordan, 2001; O' 
Riordan, Jordan, & Cameron, 2001; Stirling, 2001), and  8) openness and availability of 
information (Quijano, 2003). 
 The first four elements express the central concept of precaution; that evidence of 
harm, however limited and uncertain, demands some form of mitigative action.  Evidence 
does exist that PhACs in the environment may have detrimental effects on aquatic 
organisms.  This evidence is not sufficient to meet the requirement for probabilistic 
calculation of risk or construction of exposure-effect curves required in formal, 
quantitative risk assessment.  If traditional, acute risk assessments were used, it would 
likely be found that PhACs at environmental concentrations do not affect aquatic species 
(Henschel, Wenzel, Diedrich, & Fliedner, 1997); alternatively it would be necessary to 
delay risk management until the proper risk assessment methodology for the detection of 
the subtle, chronic effects of PhACs was developed.   However, applying the 
precautionary principle allows for the use of whatever limited evidence of environmental 
impacts exists as a basis for risk management, including qualitative assessments of risk 
(Commission of the European Communities, 2000).  The precautionary principle is 
therefore an essential component of the risk management process for PhACs in the 
environment. 
 The seventh and eight elements listed above, public participation and transparency 
and honesty, while not central to the precautionary principle as it was originally 
developed, area increasingly gaining in importance (O' Riordan et al., 2001).  Public 
participation is becoming an essential element of the precautionary principle as it grows 
from simply a tool for dealing with scientific uncertainty, to become part of a movement 
towards environmental responsibility and sustainability (O' Riordan, 2001; O' Riordan et 
al., 2001).  Openness and honesty are essential to the inclusion of stakeholders such as 





perspectives, such as traditional indigenous knowledge, is also becoming part of the 
concept of precaution (Harremöes et al., 2002; Stirling, 2001).  Thus the precautionary 
principle emphasizes that, for PhACs, the concerns of stakeholders, including scientists 
and lay people, must be considered; and lay concerns about PhACs in the environment 
must be respected, regardless of whether or not they agree with expert assessments of 
risk. 
 The precautionary principle requires that some form of risk mitigation action be 
considered for PhACs in the environment; however it provides limited guidance in terms 
of the form this action might take.  Government discussion documents on the 
precautionary principle emphasize the need for management action to be proportional to 
risk, and to be based on some form of analysis of costs and benefits (Commission of the 
European Communities, 2000; Government of Canada, 2001, 2003).  Doerr-MacEwen 
and Haight (2005) found that stakeholders for the issue of PhACs in the environment, 
were concerned that risk management action resulting from the application of precaution 
be balanced, involve consideration of the distribution of resources to mitigate various 
risks, and consider the new risks which might be generated by management action.  
However the precautionary principle itself simply calls for risk management action; as a 
broad principle, it does not help to define the types of action appropriate under conditions 
of uncertainty. 
 
3.7.  Adaptive planning  
 As the ‘options analysis’ stage of risk management is entered, therefore, a new 
concept is required to help select among policy or management alternatives in conditions 
of uncertainty: the theory of adaptive planning.  The purpose of adaptive planning and 
management is not to produce stable social, economic, or environmental behavior, but to 
benefit from change and the unexpected (Briassoulis, 1989; Holling, 1978).  Underlying 
the theory is the concept that, “Attempts to eliminate uncertainty are delusory and often 
counterproductive.” (Holling, 1978, p. 5).  Management strategies generated through 
adaptive planning, therefore, should be resilient, flexible, and capable of being modified 
in responses to change and surprise (Holling, 1978; Marttunen & Vehanen, 2004).  





allowing for changing directions as new information about the problem becomes 
available (Briassoulis, 1989; Marttunen & Vehanen, 2004).  Human intervention into 
environmental processes or structure is experimental (Holling, 1978; Mitchell, 1997), and 
planners and managers are meant to accept and acknowledge error, and to learn from 
their mistakes (Briassoulis, 1989).  Adaptive planning recognizes the dynamic, complex 
nature of the environment (Briassoulis, 1989), and gives risk managers a mandate to 
acknowledge uncertainty, and to act despite uncertainty (Holling, 1978; Lessard, 1998).  
Public participation is essential at all steps of the adaptive planning process, especially in 
determining what the desired future environmental conditions are, and how they should 
be reached (Lessard, 1998).  With respect to pharmaceuticals in the environment, 
adaptive planning favours, at this time, cost-effective, flexible management strategies 
requiring minimal technological investment.  If scientific research increasingly suggests 
that pharmaceuticals in the environment are harmful to aquatic organisms, ecosystems, or 
even to human health, more effective but less flexible, more costly management 











Figure 3.5.  If, with time, scientific evidence increasingly indicates that PhACs in the 
environment are harmful to aquatic organisms or to human health, more permanent and 
costly management strategies may be needed.  Initially, however, while uncertainty is 













3.8 Application of the precautionary principle and adaptive planning to risk 
management 
 By applying the precautionary principle and the theory of adaptive planning to 
risk management, a modified framework, capable of handling the uncertainty inherent in 
the issue of PhACs in the environment, is developed (Fig. 3.6).  This framework contains 
a risk assessment stage; however, modified by the application of the precautionary 
principle, the risk assessment may be qualitative in nature (Commission of the European 
Communities, 2000), and is based on whatever evidence is available in the scientific 
literature, through lay knowledge, or can be generated via original research.  Of course, 
management action based on limited information carries the risk of being unsuccessful 
(Goldstein, 1999).  To compensate for this, the theory of adaptive planning is then 
applied at the options analysis stage.  It favors the selection of flexible management 
strategies, which can be adjusted as understanding of PhACs in the environment evolves 
(Briassoulis, 1989; Holling, 1978; Lessard, 1998).  Furthermore, both the precautionary 
principle and adaptive planning emphasize the need for stakeholder participation and 
dialogue, including openness and honesty with the public, in the management of 
pharmaceuticals in the environment.  This framework will provide the basis for 
discussions of the management of PhACs in the environment throughout this thesis.  
Chapters 4 to 6 illustrate the application of the precautionary principle and adaptive 
planning, within the risk management framework developed here, to the management of 
pharmaceuticals in the environment.  The concluding chapter (Ch. 7) discusses the 
lessons that can be drawn from the practical application of the framework to PhAC 
management at a local (Ch. 4) and national/international scale (Ch. 5 & 6). 
 
3.9.  Conclusions 
 As the issue of PhACs in the environment is essentially a question of 
environmental risk, and possibly human health risk, it is reasonable to make use of risk 
management for the development of strategies to address the issue.  However, risk 
management includes a risk assessment stage which traditionally demands a probabilistic 





Association, 1997; McColl et al., 2000).  Scientific understanding of PhACs in the 
environment is currently insufficient to provide such an assessment of risk; however 
existing research suggests that PhACs may have sublte, chronic detrimental effects on 
aquatic organisms (Daughton & Ternes, 1999; Fong, 1998; Purdom et al., 1994).  It is 























Figure 3.6.  Risk management framework (The Presidential/Congressional Commission 
on Risk Assessment and Risk Management, 1997)  modified through the application of the 






















considerations of risk management for PhACs.  Instead, it is suggested that the 
precautionary principle be applied to PhACs in the environment.  The principle prevents 
uncertainty from causing delays in management action to mitigate environmental risks; it 
allows management decisions to be made based on whatever evidence of risk exists, even 
if causal relationships are not established and exposure-response curves cannot be 
constructed (Adams, 2002; Commission of the European Communities, 2000; Quijano, 
2003).  However, engaging in management action when scientific understanding is weak, 
means that management decisions may be found to be inappropriate or erroneous, and 
management strategies may need to be changed (Goldstein, 1999).  To avoid negative 
repercussions from change and surprise as the understanding of PhACs in the 
environment evolves, adaptive planning theory must be applied to the management of 
pharmaceuticals in the environment.  This theory favors the development of flexible 
management strategies which can be modified as more knowledge regarding PhACs is 
acquired (Briassoulis, 1989; Holling, 1978; Lessard, 1998).  By modifying a traditional 
risk management framework to include the precautionary principle and adaptive 
planning, a management process is created which is optimized to account for the 
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Chapter 4: Case study on the management of human PhACs in the environment 
(Region of Waterloo, ON) 
 
4.1 Introduction 
 The management of human pharmaceuticals (or PhACs, pharmaceutically active 
compounds) in aquatic environments can be conducted at several scales, from local to 
international.  Large-scale approaches, such as those at international, national, and 
provincial levels, are important in terms of developing regulations and providing funding.  
However, high concentrations of pharmaceuticals in the environment are often localized.  
Human pharmaceuticals are usually found at their highest concentrations in densely 
populated urban areas, especially downstream from municipal wastewater treatment 
plants (Carballa et al., 2004; Heberer, Schmidt-Bäumier, & Stan, 1998; Stumpf, Ternes, 
Wilken, Rodrigues, & Baumann, 1999; Ternes, 1998).  Municipalities can, therefore, 
make important contributions in mitigating environmental contamination by 
pharmaceuticals. 
 The Regional Municipality of Waterloo (Ontario, Canada), located in the Grand 
River Watershed (Fig. 4.1), provides a good location for a case study to examine possible 
local management strategies for PhACs in the environment.  It is a mid-sized 
municipality of approximately 450 000 residents, comprised of the lower-tier 
municipalities of Waterloo, Kitchener, and Cambridge, as well as several smaller 
townships (Region of Waterloo, 2005).  The Region of Waterloo is known for its efforts 
to protect the local environment; it has won awards for its forward-looking environmental 
planning and management, including its water protection programs (Canadian Centre for 
Pollution Prevention, 2005; Region of Waterloo, 2002).  The Region therefore is likely to 
be interested in addressing the issue of PhACs in local surface water and groundwater in 
the future. 
 Management of environmental risks requires both a scientific evaluation of risk, 
and consideration of the values and concerns of stakeholders, as discussed in Chapter 3.  
However, the effects of PhACs on aquatic organisms and ecosystems at environmental 
concentrations are poorly understood and current risk assessment methodology is 












(Bound & Voulvoulis, 2004; O'Brien & Dietrich, 2004; Sanderson et al., 2004; Seiler, 
2002) (Ch. 2).   Predicted no effects concentration (PNEC) data are available for some of 
the most commonly detected pharmaceuticals, but they are based on acute toxicity tests, 
which are not appropriate for the detection of the subtle effects of pharmaceuticals 
(Länge & Dietrich, 2002; Sanderson et al., 2004; Sanderson, Johnson, Wilson, Brain, & 
Solomon, 2003).  Even when chronic toxicity tests have been performed, difficulties in 
the selection of appropriate test species, endpoints, and the complexities of mixture 
effects, among other factors, make the relevance of the PNEC values questionable.  As a 
result, calculations of risk quotient, PEC/PNEC (PEC: predicted environmental 
concentrations) must be interpreted with care.  The main purpose of this chapter is 
therefore not to determine whether environmental concentrations of pharmaceuticals in 
the Waterloo Region exceed a critical value, as such a value cannot be accurately 
determined at this time.  Instead, based on four premises, it is assumed that some 
municipalities, in Canada and other countries, may consider taking management action to 
reduce the release of pharmaceuticals to the environment in the near future.  The premises 
are: 1) The scientific literature contains examples where PhACs have had effects on the 
development, reproduction, and behaviour, of aquatic organisms, among other effects, at 
low concentrations.  Effects have been found in both field (Jobling, Nolan, Tyler, 
Brightly, & Sumpter, 1998; Larsson et al., 1999) and laboratory (Brooks et al., 2003; 
Pascoe, Karntanut, & Müller, 2003; Wilson, Smith, Denoyelles, & Larive, 2003)  studies; 
for example, the feminization of fish exposed to 17α-ethinylestradiol (EE2) (Jobling et 
al., 1998; Purdom et al., 1994), and the spawning of mussels exposed to fluoxetine 
(Brooks et al., 2003; Fong, 1998, 2001); as well as effects of the antibiotic ciprofloxacin 
on algal community structure and function (Wilson et al., 2003) have been observed.  2)  
The precautionary principle suggests that when there are grounds for concern about the 
environmental impact of a substance, reasonable and proportional management action 
should be taken to mitigate the environmental impacts (Commission of the European 
Communities, 2000; Government of Canada, 2001; United Nations General Assembly, 
1992).  The precautionary principle is embodied in the Canadian Environmental 
Protection Act (CEPA, 1999) and is considered by many to be a principle of international 





management in the face of uncertainty is possible and indeed desirable.  Uncertainty can 
be accommodated by adjusting management strategies as understanding of the 
environmental impacts of PhACs evolves. (Briassoulis, 1989; Holling, 1978; Lessard, 
1998); and 4) stakeholders, especially the public, may want management action taken to 
reduce the release of PhACs to aquatic environments.   
This chapter consists of two components; a natural scientific component (a 
technical assessment of water chemistry) and a social scientific component (an 
assessment of local values and concerns).  The purposes of the scientific component of 
this study are threefold: 1) To determine whether detectable concentrations of human 
pharmaceuticals are being released from wastewater treatment plants (WWTPs) to 
aquatic environments in the Waterloo Region; 2) to determine whether or not the loading 
of PhACs to the environment from wastewater treatment plants (WWTPs) in Waterloo is 
comparable to those of other urban areas.  If PhAC loading is similar to or higher than in 
other municipalities, Waterloo may be a good candidate for management action; if PhAC 
concentrations are much lower than in other urban areas, the Region of Waterloo may 
prefer to focus on other environmental concerns.  3)  to determine which pharmaceuticals 
are being released at the highest concentrations, or at high concentrations in comparison 
with other municipalities, as this knowledge may be of aid in the development of 
management strategies. 
 The second component of this study involves assessment of the values and 
concerns of local citizens.  Public consultation is an essential component of all planning 
decisions, playing a key role in planning theory (Arnstein, 1969; Friedmann, 1987; 
Lessard, 1998) and practice (Beierle & Konisky, 2001; McDaniels, Gregory, & Fields, 
1999).  The public represent a key stakeholder group whose consultation is an important 
and necessary component of risk management (Canadian Standards Association, 1997; 
Dyck, Del Bel Belluz, & Craig, 1999; Petts, 1994).   Other stakeholders such as the 
pharmaceutical industry are better included at a broader scale; Ch. 5 discusses 
consultation with members of the pharmaceutical industry and other stakeholders.  This 
part of this study will assess the values, attitudes, desires and behaviours of residents of 
the Region of Waterloo, regarding human pharmaceuticals in the environment.  This 





consultation if the Region of Waterloo decides to further explore management action for 
PhACs in the environment. 
 
4.2 Location selection  
 To assess possible management strategies for PhACs in the environment in which 
the Region of Waterloo might engage, two communities within the region were chosen to 
conduct the natural scientific and social scientific components of the study: The 
municipality of Kitchener and the retirement community of Foxboro Green, located on 
the Western side of the Region (Fig. 4.2).  Kitchener has a mid-sized urban population 
served by a municipal wastewater treatment plant and is the largest municipality within 
the Region of Waterloo.  It provides a good basis to assess and make recommendations 
regarding management of PhACs in the Region.  Such information is required to make 
comparison with municipalities elsewhere in the world.  Foxboro was chosen because it  
 
 







is a retirement community.  Its residents – seniors -- are expected to use a greater number 
of pharmaceuticals that other age groups, and are therefore likely to contribute highly to 
the release of PhACs to the environment.  Furthermore, the community has its own 
wastewater treatment plant, to which the residents are the only contributors of PhACs.  
Water chemistry data from Kitchener and Foxboro are combined with value assessment 
in this local study of PhAC management opportunities. 
 
4.3  Methods 
4.3.1 Analysis of PhACs in wastewater 
 4.3.1.1  Sample collection 
 Samples of wastewater influent and effluent were collected from the Foxboro and 
Kitchener WWTPs using an autosampler.  For each site and effluent type, 3 L of 
wastewater were collected in the form of composite samples over a 24-hour period.  The 
3 L samples were then split into 3 1L sample bottles, for the analysis of acidic 
pharmaceuticals, neutral pharmaceuticals and antibiotics.  A water blank, trip blank and  
travel blank were also collected. Samples were collected in amber glass bottles, pre-
cleaned with solvent, acid, and deionized water and baked.  In addition, samples were 
collected and analyzed for water quality parameters related to the working of the plant 
(Table 4.1). 
 Twenty-four hour composite sampling, with sub-sample collection every 30 
minutes, was conducted for both influent and effluent at the Kitchener and Foxboro 
WWTPs.  At the Foxboro WWTP, influent sampling  began at 9:40 am on Tuesday July 
27th, 2004,  and effluent sampling began at 12:40 on the same day, to account for the 3 
hour retention time at the plant (Ministry of the Environment, 2001).  The sampling 
period for the Kitchener WWTP influent began at 15:00 Wednesday, July 28th, 2004, and 
sampling of the effluent began at 7:00 am on Thursday July 29th, to account for the 16 
hour retention time at the plant (Region of Waterloo, 2003).  Samples were kept cool (8-
120C). After collection, samples were refrigerated at ~4oC, in the dark, and shipped to 
Trent University for analysis on Thursday, July 29th.  Ideally, samples would have been 





and representativeness of data.  Due to a lack of funding, this was not possible; therefore 
care should be taken in interpreting data, as it may not be representative of 
pharmaceutical loading from the plants on other days and at other times of year. 
 
 4.3.1.2  Analysis of PhACs 
 Analyses of PhACs in wastewater samples were conducted by C. Metcalfe and X. 
Zhao, at Trent University.   Volumes of 25 mL of raw wastewater or 50 mL of final 
wastewater were extracted by solid phase extraction (SPE) for the analysis of 
sulfonamide and fluoroquinolone antibiotics and acidic and neutral drugs, according to 
the methods described by Miao, Bishay, Chen & Metcalfe, (2004) and Metcalfe, Miao, 
Koenig and Struger (2003). Extracts were analyzed by liquid chromatography tandem 
mass spectrometry (LC-MS/MS), using electrospray ionization (ESI) for the 
fluoroquinolone antibiotics and acidic drugs and atmospheric pressure chemical 
ionization (APCI) for the neutral drugs and sulfonamide antibiotics.  The LC-MS/MS 
system was an Agilent 1100 series binary pump with autosampler and QTrap mass 
spectrometer (MDS SCIEX, Toronto) equipped with either the ESI or APCI source, and 
operated by Analyst 1.4 software. The chromatography was conducted with Genesis C18 
columns of 150 × 3 mm or 150 × 2.1 mm, depending on the ion source utilized.  Specific 
instrumental conditions for the analyses of the various classes of pharmaceuticals can be 
found in Appendix A; detection limits for the analytes and results of analyses of blanks 
are listed in Appendix B.   
 
4.3.2.  Social surveys 
 Surveys were conducted in Kitchener and in Foxboro to assess the attitudes, 
values and behaviors of the public, related to pharmaceuticals in the environment.  The 
surveys were comprised of mainly close-ended questionnaires (Appendix C).  
Convenience surveys were used, with respondents being recruited in person (i.e. 
respondents were stopped on the sidewalk and asked to participate; they were not 
sampled randomly).  Recruitment in Foxboro and Kitchener occurred at a recreation 
complex and in a mini-mall, respectively.  A total of 128 respondents were surveyed, 





Respondents were given the option of completing the survey with the help of the survey 
administrator, or completing the surveys on their own.  The majority of respondents 











Ammonia-N 5.34 18.8 22.4 20.6 
BOD --  Biochemical 
Oxygen Demand (5-day) 
209 10.9 237 24.0 
Nitrate-N <0.10 0.85 <0.10 <0.10 
Nitrite-N <0.050 0.428 <0.050 <0.050 
TKN -- Total Kjeldahl 
Nitrogen 
30.7 21.9 49.7 22.9 
TSS -- Total Suspended 
Solids  
210 8.8 414 30.5 
Phosphorous 5.11 0.748 10.8 3.88 
pH (Composite) 8.28 7.89 7.76 7.69 
 
 
Table 4.1.  Parameters related to WWTP plant functioning, from samples collected at the 
Kitchener and Foxboro WWTPs July 28, 2004.  Note: MOE guidelines for effluent are: 
total phosphorous, 1.0 mg/L; BOD 25 mg/L; total suspended solids 25 mg/L. 
 
4.4.  Wastewater treatment plant parameters 
4.4.1  Kitchener wastewater treatment plant 
 The Kitchener wastewater treatment plant is located on the south bank of the 
Grand River, to which effluent is discharged.  It treats wastewater for a population of  
180 000 residents, in addition to businesses and industries.  No effluent from 
pharmaceutical manufacturers is treated by this plant.  It receives an average flow of 
approximately 60 000 m3/d, but is designed for a maximum capacity of 122 740 m3/d 
(Region of Waterloo, 2003).  The plant employs a conventional activated sludge process 
to treat wastewater.  The primary treatment component involves screening removal, grit 
removal, and primary clarification; the secondary treatment component includes 





wasting, anaerobic sludge digestion in a two stage process, chlorine disinfection, 
phosphorus removal and sludge transfer (See Appendix D for photos) (Region of 
Waterloo, 2003).   Total retention time is between 13-19 hours, with a hydraulic retention 
time of 4-7 hours during the aeration stage.  The plant is operating within the Ministry of 
Environment Guidelines (Table 4.1) for parameters including biochemical oxygen 
demand (BOD), total phosphorus and total suspended solids.  Sludge from the treatment 
process is used as a fertilizer and soil conditioner for agricultural lands throughout the 
region (Region of Waterloo, 2003).  
 
4.4.2  Foxboro Green wastewater treatment plant 
 The wastewater treatment plant for the Foxboro retirement community has a 
capacity of  78 m3/d and serves 65 residences.  The wastewater treatment plant is 
comprised of a primary settling tank with a retention time of 2 hours; two rotating 
biological contactors with a total surface area of 3000 m2; a denitrification chamber of 
1887 m2, using molassess as a carbon source and a final clarifier of 4.8 m3 with a final 
sludge collection zone (See Appendix D for photos).  Treated wastewater is released 
through a subsurface sewage disposal system comprised of 3 conventional absorption 
trench leaching beds (Ministry of the Environment, 2001).  The Foxboro WWTP has a 
lower treatment efficiency than the Kitchener WWTP (Table 4.1). 
 
4.5  Discussion of results 
 
4.5.1  PhACs in wastewater 
 Twenty-one of the 26 PhACs analyzed in the wastewater treatment samples from 
both plants were detected at ng/L and µg/L concentrations (Table 4.2).  The  
residuals of acid and neutral drugs in the Kitchener influent were in the same range as 
those reported in the literature internationally (Table 4.3; Fig. 4.3) and were similar to 
those found by Lee, Sarafin, Peart & Svoboda (2004) in for a wastewater treatment plant 
in Guelph, Ontario, a city of comparable population.  Concentrations were generally 
lower than those found by Metcalfe et al. (2003) for a range of Canadian WWTP 


















Neutral Drugs          
Caffeine 1.25 7.20 1.56 24.40 
Carbamazepine 0.666 0.321 0.024 0.090 
Cotinine 0.122 2.028 0.188 0.292 
Cyclophosphamide 0.006 0.018 <0.003 <0.001 
Fluoxetine 0.02 0.02 <0.01 <0.005 
Pentoxifylline 0.03 0.007 <0.002 <0.001 
Trimethoprim 1.968 12.000 0.109 0.012 
          
Acidic Drugs         
Bezafibrate 0.164 0.407 1.823 NA 
Clofibric Acid <0.007 <0.007 <0.007 NA 
Diclofenac 0.12 0.29 0.19 NA 
Fenoprofen <0.02 <0.008 <0.02 NA 
Gemfibrozil 0.086 0.169 2.111 NA 
Ibuprofen 0.28 4.47 2.99 NA 
Indomethacin 0.3 0.1 0.9 NA 
Ketoprofen <0.008 <0.008 <0.008 NA 
Naproxen 0.96 1.76 2.22 NA 
          
Sulfonamides         
Sulfacetamide <0.02 <0.02 <0.02 <0.02 
Sulfapyridine 0.02 0.21 0.12 <0.005 
Sulfadiazine <0.002 <0.004 <0.002 <0.004 
Sulfamethoxazole 3.05 21.291 0.677 0.041 
Sulfisoxazole <0.001 <0.001 0.001 0.023 
Sulfamethazine <0.002 <0.003 0.002 0.018 
          
Fluoroquinolones         
Ciprofloxacin 0.11 0.99 1.41 0.53 
Norfloxacin 0.01 0.47 0.50 0.22 
Ofloxacin 0.47 0.49 0.22 0.16 
 
 
Table 4.2.  Concentrations of pharmaceutical analytes in wastewater. N.A: not available 
due to analytical difficulties.  Note: standard deviations, detection limits, and analyses of 

































Bezafibrate 0.407  0.6 ~1.18  ~3.0 
Caffeine 7.20    230  
Carbamazepine 0.321  0.7  1.78 ~1.7 
Clofibric Acid <0.007  ND ~1.0 0.46 ~0.3 
Cyclophosphamide 0.018  ND    
Diclofenac 0.29 0.07 1.3 ~0.78 3.02 ~1.8 
Fenoprofen <0.008  1.8    
Gemfibrozil 0.169 0.14 0.7 ~0.35   
Ibuprofen 4.47 6.22 38.7 ~0.33  ~3.1 
Indomethacin 0.1 0.19  ~0.92 0.8 ND 
Ketoprofen <0.008 0.07 5.7 ~0.58 0.3 ~0.2 
Naproxen 1.76 2.31 40.7 ~0.60 0.44 ~0.4 


























Bezafibrate 0.164 1.823  0.2 ~0.57 2.2 
Caffeine 1.25 1.56     
Carbamazepine 0.666 0.024  0.7  2.1 
Clofibric Acid <0.007 <0.007  ND ~0.66 0.36 
Cyclo-
phosphamide 
0.006 <0.003  ND  ND 
Diclofenac 0.12 0.19 0.08 ND ~0.19 0.81 
Fenoprofen <0.02 <0.02  ND  ND 
Gemfibrozil 0.086 2.111 0.08 1.3 ~0.17 0.40 
Ibuprofen 0.28 2.99 0.11 4.0 ~0.08 0.37 
Indomethacin 0.3 0.9   ~0.17 0.27 
Ketoprofen <0.008 <0.008 0.07 ND ~0.17 0.20 
Naproxen 0.96 2.22 0.36 12.5 ~0.15 0.30 
Pentoxifylline 0.03 <0.002  0.5   
1 Mean calculated from duplicate samples 
2 Median based on sampling of multiple WWTPs 
3 Interpreted from graph; for single WWTP 
4 Averages from multiple WWTPs, compiled from various sources 
5 Median from multiple WWTPs, interpreted from graph 
 
Table 4.3.  Concentrations of acidic and neutral PhACs in WWTP influent and effluent in 




















































































Figure 4.3.  Concentrations of acidic and neutral PhACs in wastewater treatment plant 
influent, in this study and others internationally.  Note: Not all studies measured 
concentrations of each PhAC. 
 
Kitchener and Foxboro were also within the range of concentrations found internationally 
(Table 4.3; Fig. 4.4).  PhAC concentrations for Foxboro were higher than Kitchener but 
were similar to those previously reported for WWTPs in the Great Lakes Region 
(Metcalfe, Koenig et al., 2003) and in Berlin (Ternes, 1998).  
 The results were somewhat different for antibiotics.  The concentrations of 
antibiotics in the effluent from the Kitchener and Foxboro plants were generally higher 
than those found in other Canadian and international studies (Table 4.4, Fig. 4.5).  In 
particular, the concentration of sulfamethoxazole in the Kitchener effluent was at least 
three times greater than the concentration measured in the effluents of other WWTPs.  
Concentrations of the fluoroquinolone antibiotics were especially high in the Foxboro 
effluent, with ciprofloxacin and norfloxacin concentrations being an order of magnitude 
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Figure 4.4.   Concentrations of acidic and neutral PhACs in wastewater treatment plant 
effluent, in this study and others internationally.  Note: Not all studies measured 
concentrations of each PhAC. 
 












et al. (2003)2 
Ciprofloxacin 0.11 1.41 0.118  0.071 
Norfloxacin 0.01 0.50 0.050  0.051 
Ofloxacin 0.47 0.22 0.094   
Sulfacetamide <0.02 <0.02 0.064   
Sulfadiazine <0.002 <0.002 0.019   
Sulfamethazine <0.002 0.002 0.363 ND  
Sulfamethoxazole 3.05 0.677 0.243 0.40  
Sulfapyridine 0.02 0.12 0.081   
Sulfisoxazole <0.001 0.001 0.019   
1 Median based on sampling of multiple WWTPs 
2 Average of multi-day sampling from one tertiary WWTP 
 
Table 4.4.  Concentrations of antibiotics in wastewater treatment plant effluents in this 






































































Figure 4.5.  Concentrations of antibiotics in wastewater treatment plant effluent in this 
study and others internationally.  Note:  Not all studies measured concentrations of each 
antibiotic. 
 
sulfamethoxazole in the Kitchener effluent is somewhat surprising.  However, given the 
limited sampling conducted, it is possible that the concentration is an outlier, due to an 
unusual loading of sulfamethoxazole on the day of sampling.  The high concentrations of 
acidic and neutral drugs, and sulfamethoxazole, in the Foxboro effluent, are less 
surprising, however, for two reasons: 1) the elderly population of the Foxboro retirement 
community likely consumes greater quantities of medications than ‘average’ urban 
populations.  2) the Foxboro plant is operating sub-optimally (Section 4.4.2, Table 4.1) 
and other studies have found that WWTPs which operate sub-optimally with regard to 
normal parameters such as BOD, usually do not successfully remove PhACs (Clara, 
Kreuzinger, Strenn, Gans, & Kroiss, 2005; Vieno, Tuhkanen, & Kronberg, 2005).  The 
elevated concentrations of antibiotics in Waterloo Region effluents are somewhat 
concerning, as antibiotics in wastewater and the environment may contribute to resistance 
among microbes (Goñi-Urriza et al., 2000; Guardabassi, Petersen, Olsen, & Dalsgaard, 





Furthermore, concerns have been raised about the ecotoxicity of some of the antibiotics 
measured, particularly ciprofloxacin (Hartmann, Alder, Koller, & Widmer, 1998; 
Kümmerer, Al-Ahmad, & Mersch-Sundermann, 2000; Wilson et al., 2003).  In a large-
scale German study, ciprofloxacin was one of only two substances which had a predicted 
environmental concentration (PEC) exceeding its predicted no-effects concentration 
(PNEC) (Bund/Länderausschuss für Chemikaliensicherheit (BLAC), 2003).  The report 
suggests that ciprofloxacin should be classified as potentially harmful to the environment.  
Table 4.5 illustrates the risk quotients for several pharmaceuticals in the Grand River, 
determined from the effluent concentrations from the Kitchener WWTP, a dilution factor 
of 10, and the PNEC values of the German report.   
 






Carbamazepine 0.03 2.5 0.01 
Ciprofloxacin 0.1 0.018 6 
Diclofenac 0.03 100 0.0003 
Ibuprofen 0.4 7.1 0.06 
 
 
Table 4.5.  Risk Quotients calculated for selected pharmaceuticals in the Grand River.  
PECs (Predicted Environmental Concentrations) are based on a 10-fold dilution factor 
between concentrations in the Kitchener WWTP effluent and the river.  A 10-fold dilution 
factor between WWTP and surface water is typical for calculations of PEC for 
environmental risk assessments for pharmaceuticals (CPMP, 2001; Golet, Alder, & 
Giger, 2002). However, using a factor of 10 does not allow for highly accurate 
predictions of environmental concentrations, as it does not account for the size of the 
mixing zone or the flow conditions and dilution of a specific river.  For the Grand River 
in low flow, dilution at the point of entry of wastewater into the river is approximately 3-
fold (calculated based on data from the Grand River Conservation Agency, 2007).  
PNECs (Predicted No Effects Concentrations) are taken from a study by the German 






The risk quotient for ciprofloxacin in the Grand River is greater than 1 because of 
its toxicity to bacteria.  This raises concerns about the potential impact of ciprofloxacin 
on aquatic species in the Grand River.  While PhACs in the Foxboro effluent are not 
likely to impact local groundwater, due to the presence of an extensive aquitard (pers. 
comm., D. Andrews, manager of wastewater operations, Region of Waterloo, 2005), 
Foxboro residents could nevertheless be concerned about the release of antibiotics such 
as ciprofloxacin to the subsurface, particularly given recent media attention to the issue of 
PhACs in the environment.   (Brooymans, 2005; Mittelstaedt, 2003; Stevenson, 2003).  
Reducing the concentrations of antibiotics in local WWTP effluents can therefore be 
considered a worthwhile goal of potential management action in the Waterloo Region.  
This is necessary for both scientific or risk-related reasons but also to improve public 
perception of water quality.  
Most studies of PhACs in the environment are based on measurements of 
concentrations, but it is also of interest to calculate the loading of pharmaceuticals to the 
environment.  The loading of PhACs entering and leaving the Kitchener and Foxboro 
wastewater treatment plants is shown in Table 4.6.  Loading rates were calculated based 
on the average daily volume of wastewater treated by each plant; 60 000 m3/d and 78 
m3/d in Kitchener and Foxboro, respectively (See Section 4.4).  The environmental 
loading of PhACs from the Kitchener plant is several orders of magnitude higher than 
from the Foxboro plant because it treats a much larger volume of wastewater on a daily 
basis. 
 Also of interest is the loading of PhACs per person; or the contribution of each 
resident to the environmental loading of PhACs.  PhAC loading rates were calculated for 
Kitchener and Foxboro, based on populations of 180 000 and 100 residents, respectively 
(Table 4.7).  The exact population of Foxboro is not known, but as stated in Section 4.4, 
the retirement community consists of 65 residences; as most residences are inhabited 
either by individuals or couples, it is reasonable to estimate the population at 100.  Figure 
4.6a illustrates the loading per person in the WWTP influents. The influent loading of 
caffeine is more than twice as high in Foxboro compared with Kitchener, and the influent 
loadings of sulfamethoxazole and trimethoprim are several orders of magnitude higher in 



















Neutral Drugs          
Caffeine 75.0 432 0.12 1.9 
Carbamazepine 40.0 19.3 0.0019 0.0070 
Cotinine 7.32 122 0.015 0.023 
Cyclophosphamide 0.4 1.1 N.D. N.D. 
Fluoxetine 1.0 1.0 N.D. N.D. 
Pentoxifylline 2 0.4 N.D. N.D. 
Trimethoprim 118 720 0.0085 0.00094 
          
Acidic Drugs         
Bezafibrate 9.84 24.4 0.14 NA 
Clofibric Acid N.D. N.D. N.D. NA 
Diclofenac 7.3 17 0.015 NA 
Fenoprofen N.D. N.D. N.D. NA 
Gemfibrozil 5.2 10.1 0.16 NA 
Ibuprofen 17 2.6x101 0.23 NA 
Indomethacin 2.0x101 3 0.07 NA 
Ketoprofen N.D. N.D. N.D. NA 
Naproxen 58 106 0.17 NA 
          
Sulfonamides         
Sulfacetamide N.D. N.D. N.D. N.D. 
Sulfapyridine 1 12 0.0090 N.D. 
Sulfadiazine N.D. N.D. N.D. N.D. 
Sulfamethoxazole 183 1277 0.053 0.041 
Sulfisoxazole N.D. N.D. 0.0001 0.0018 
Sulfamethazine N.D. N.D. 0.00012 0.0014 
          
Fluoroquinolones         
Ciprofloxacin 6.4 59 0.11 0.041 
Norfloxacin 0.5 28 0.039 0.017 




Table 4.6.  Loading of PhACs in wastewater treatment plant influent and effluent, in 
Kitchener and Foxboro, measured in g/day. Note: ND = no pharmaceutical detected, so 



















Neutral Drugs          
Caffeine 0.417 2.40 1.2 19 
Carbamazepine 0.222 0.107 0.019 0.070 
Cotinine 0.0407 0.676 0.15 0.23 
Cyclophosphamide 0.002 0.00060 N.D. N.D. 
Fluoxetine 0.006 0.006 N.D. N.D. 
Pentoxifylline 0.01 0.002 N.D. N.D. 
Trimethoprim 0.656 4.00 0.085 0.0094 
          
Acidic Drugs         
Bezafibrate 0.0547 0.136 1.4 NA 
Clofibric Acid N.D. N.D. N.D. NA 
Diclofenac 0.040 0.095 0.15 NA 
Fenoprofen N.D. N.D. N.D. NA 
Gemfibrozil 0.029 0.0563 1.6 NA 
Ibuprofen 0.093 1.5 2.3 NA 
Indomethacin 0.1 0.05 0.7 NA 
Ketoprofen N.D. N.D. N.D. NA 
Naproxen 0.32 0.587 1.7 NA 
          
Sulfonamides         
Sulfacetamide N.D. N.D. N.D. N.D. 
Sulfapyridine 0.007 0.069 0.090 N.D. 
Sulfadiazine N.D. N.D. N.D. N.D. 
Sulfamethoxazole 1.02 7.10 0.53 0.032 
Sulfisoxazole N.D. N.D. 0.0010 0.02 
Sulfamethazine N.D. N.D. 0.0012 0.014 
          
Fluoroquinolones         
Ciprofloxacin 0.0036 0.33 1.1 0.41 
Norfloxacin 0.003 0.16 0.39 0.17 





Table 4.7.  Per-person loading of PhACs in wastewater treatment plant influent and 
effluent, in Kitchener and Foxboro, measured in mg/person/day. Note: ND = no 


























































































































































































































by differences in caffeine consumption.  Interestingly, the per-person influent 
pharmaceutical loading is very similar for most PhACs in Foxboro and Kitchener, 
including for carbamazepine, cotinine, and the fluoroquinolone antibiotics.  However, a 
different picture is evident when examining the per-person PhAC loading in the effluent 
(Fig. 4.6b).   With the exception of the anomalously high trimethoprim and 
sulfamethoxazole loadings, the per-person environmental loading of pharmaceuticals is 
much lower in Kitchener than in Foxboro.  In general, the per-person loading of 
pharmaceuticals to the environment is one order of magnitude higher in Foxboro than in 
Kitchener.  Interestingly, a study of per-person pharmaceutical loading in Ontario WWTP 
effluent by Lishman et al. (2006) yielded median values greater than the loading from the 
Kitchener plan, but below the loading values for Foxboro as determined here.  In 
summary, the total daily loading of pharmaceuticals to the environment is several times 
greater at the Kitchener WWTP than Foxboro.  However, the contribution of each person 
to the loading of PhACs to the environment is an order of magnitude higher in Foxboro 
than in Kitchener. 
 Removal rates for PhACs in WWTPs are helpful in understanding whether or not 
upgrading wastewater treatment plants would reduce the release of PhACs to the 
environment.  Unfortunately, it is not possible to definitively determine a removal rate for 
pharmaceuticals in WWTPs, as retention times within WWTPs vary, such that 
composition of effluent does not necessarily reflect the composition of influent (Metcalfe, 
Koenig et al., 2003).  However, the difference between the concentrations of PhACs in 
the WWTP influent and effluent, accounting for the total plant retention time, can be 
calculated and can be used to estimate removal rates.  Table 4.8 lists the differences 
between influent and effluent concentrations for detected PhACs.  Figures 4.7, 4.8 and 
4.9 illustrate these differences for the Foxboro and Kitchener WWTPs.  Where negative 
percentages (<0) are found, influent concentrations are measured as being higher than 
effluent concentrations.  This may be due to analytical difficulties, or may be due to de-
conjugation of pharmaceutical glucuronides in wastewater treatment plants.  
Pharmaceutical conjugates are not detected in the analysis, so de-conjugation to the 
parent PhAC in WWTPs may give the appearance of an increase in total concentration 





concentrations was 51% for the Kitchener plant, which is similar to the value of 60% 
reported by Ternes (1998).  For the Foxboro plant, the difference between influent and 
effluent concentrations was 35%.  The concentrations of fluoroquinolone antibiotics in 
the Foxboro effluent were no lower than in the influent, suggesting that the plant may not 
be effectively removing the pharmaceuticals.  This is further supported by other data 
suggesting relatively poor performance of the Foxboro plant in general (Table 4.1, 
Section 4.4.2).  Lindberg et al. (2006) found that 97% and 96% of norfloxacin and 
ciprofloxacin were removed, respectively, by a secondary, activated sludge WWTP.  
Accordingly, the poor removal of antibiotics in the Foxboro plant is likely due to sub-
optimal plant operation.  Because influent concentrations of acidic drugs could not be  
 




Bezafibrate 60 NA 
Caffeine 83 94 
Carbamazepine <0 73 
Ciprofloxacin 89 <0 
Cotinine 94 36 
Cyclophosphamide 67 ND 
Diclofenac 58 NA 
Fluoxetine 5 ND 
Gemfibrozil 49 NA 
Ibuprofen 94 NA 
Indomethacin <0 NA 
Ketoprofen 45 NA 
Naproxen 89 <0 
Norfloxacin 98 <0 
Ofloxacin 5 <0 
Pentoxyfilline <0 ND 
Sulfamethazine ND 92 
Sulfamethoxazole 86 <0 
Sulfisoxazole ND 95 
Trimethoprim 84 <0 
Mean 51 35 
 
Table 4.8.  Differences between effluent and influent concentrations of PhACs detected at 
the Foxboro and Kitchener WWTPs.  NA: not available (due to analytical difficulties); 































































Figure 4.7.  Difference between influent and effluent concentrations of neutral drugs  in 



















































































































Figure 4.9.   Difference between influent and effluent concentrations of antibiotics  in the 
Kitchener and Foxboro WWTPs. 
 
measured, it is difficult to comment on whether poor plant performance also contributed 
to the high effluent concentrations of acidic and neutral drugs for the Foxboro plant.  
However, this result would not be surprising given similar findings in the literature (Clara 
et al., 2005; Vieno et al., 2005).   
The high concentrations of sulfamethoxazole in the Kitchener effluent are 
difficult to explain, as the difference between the influent and effluent is 86%, suggesting 
relatively effective removal by the plant.  Furthermore there is no known reason why the 
Kitchener plant might be receiving a greater loading of sulfamethoxazole than other 
plants.  The moderate to high concentrations of pharmaceuticals being released to 
groundwater by the Foxboro plant, and to the Grand River by the Kitchener plant do 
suggest that the Waterloo Region is an appropriate location for management action to 
reduce the release of pharmaceuticals to the environment.  Management action will be 
most effective if it is focused on locations releasing high concentrations of 






4.5.2  Social surveys 
 The social surveys included a variety of questions related to the management of 
pharmaceuticals in the local environment.  Because consumption of pharmaceuticals is 
the main contributor to the environmental loading of PhACs, respondents were asked 
about their frequency of pharmaceutical usage (Appendix C).  Respondents over 60 
reported consuming greater quantities of pharmaceuticals than other age groups.  Seniors 
in the Kitchener survey consumed at least 30% more pharmaceuticals than other age 
cohorts in that location, and approximately 20% more prescription pharmaceuticals than 
those in the Foxboro community (Fig. 4.10).  This observation may be partly related to 
socioeconomic differences.  For example, the education level in Foxboro is somewhat 
higher than in Kitchener (Fig. 4.11), suggesting a higher socioeconomic status.  
Furthermore, the Foxboro retirement community is a relatively affluent community 
compared with the Kitchener location where the survey was conducted.  Although seniors 
consumed more pharmaceuticals such as cholesterol, heart, blood pressure and pain 
medication, younger respondents generally consumed more hormones and antibiotics 
(Fig. 4.12).  Antibiotics were among the PhACs whose concentrations were highest in the 





















Figure 4.10.  Daily prescription use by survey respondents in Kitchener and Foxboro. 
Graph illustrates the percentage of each age group from the Kitchener survey, and of the 







































































































































































































































































 Figure 4.12.  Consumption of medications by age group in Kitchener survey.  Graph 
illustrates the percentage of each age group who consumed a given type of medication 
within the past year. 
 
is the PhAC for which effects have been most clearly demonstrated on aquatic organisms.  
Therefore the findings of high antibiotic and hormone usage rates among youth suggest 
that consumption of pharmaceuticals by younger age groups should not be 
underestimated as a contributor to environmental impacts by PhACs.   
 In Kitchener, antibiotics and pain medication were among the prescription 
medications most frequently used (Fig. 4.13).  When prescription medications taken on a 
daily basis were considered, pain medication, heart and blood medication, and hormones 
were most abundant (Fig. 4.14).  In Foxboro, cholesterol and heart and blood medications 
were consumed by the greatest number of respondents on a daily basis (Fig. 4.14), with 
pain medication, cholesterol, and heart and blood pressure medication being most 
abundant among the medications consumed in general (not only on a daily basis) (Fig. 
4.13).  Pain medications, together with herbals and vitamins, were the non-prescription 

































































































































Figure 4.13.  Percentages of respondents from Kitchener and Foxboro reporting having 

























































































































Figure 4.14.  Percentages of respondents from Kitchener and Foxboro reporting taking a 
given prescription medication on a daily basis. 
 
Foxboro (Figs. 4.15, 4.16).  In both communities, acetaminophen was the non-
prescription medication consumed by the most respondents, with 42% and 20% of the 
Kitchener and Foxboro respondents, respectively, having taken it over the past year (Fig. 
4.15).  On a daily basis, herbals and vitamins were taken by the most respondents, 
followed by ASA (acetylsalycilic acid) (Fig. 4.16).  Ibuprofen was the third most 
commonly used non-prescription pain medication (Figs. 4.15, 4.16).  These consumption 





















































































































Figure 4.15.  Percentages of respondents from Kitchener and Foxboro reporting having 
taken a given non- prescription medication over the past year. 
 
(also known as paracetamol) is the most dispensed medication by mass, while 
acetylsalicylic acid and ibuprofen are the 9th and 10th most frequently dispensed (Khan & 
Ongerth, 2004).  Despite being consumed less frequently than acetaminophen or ASA, 
however, ibuprofen may represent a greater environmental concern, as there are 
indications that it persists in the environment longer than than ASA or acetaminophen 



















































































































Figure 4.16.  Percentages of respondents from Kitchener and Foxboro reporting taking a 
given non-prescription medication on a daily basis. 
 
Although improper disposal of pharmaceuticals is also a mechanism causing 
environmental contamination by PhACs, it is believed to be a minor contributor 
compared with consumption and excretion (Heberer, 2002a; Reddersen, Heberer, & 
Dünnbier, 2002).  Nevertheless, some estimates suggest that as much as 1/3 of domestic 
pharmaceuticals are disposed of as waste, in the toilet or garbage (Greiner & Rönnefahrt, 
2003).  The results of the surveys support the view of disposal as a relatively minor 
contributor to the environmental loading of PhACs.  Most respondents reported disposing 















































Figure 4.17.  Frequency with which survey respondents dispose of their unused/expired 
medications. 
 
did dispose of unused or expired pharmaceuticals, many did not do so properly.  In 
Kitchener, 55% of respondents put their pharmaceuticals in the garbage and 20% flushed 
them down the toilet (Fig. 4.18).  In Foxboro, 35% of respondents put pharmaceuticals in 
the garbage and 23% put flushed them down the toilet (Fig. 4.18).  These results are 
similar to the results of a study by COMPAS for Health Canada (2002), which found that 
50% and 39% of Canadians dispose of non-prescription and prescription drugs, 




























































Figure 4.18.  Methods used by respondents to dispose of unused or expired medications. 
 
drugs are disposed in the toilet or sink.  In a study conducted in the U.K., 63.2% of 
respondents placed medications in the garbage, 11.5% in the sink or toilet, and 21.8% 
returned them to the pharmacy (Bound, Kitsou, & Voulvoulis, 2006). Garbage disposal 
rates in an American study were 54% (Kuspis & Krenzelok, 1996), and the rate of 
disposal via toilet was 35.4%.  This toilet disposal rate is higher than in the current study, 
or the studies in Canada and the U.K. mentioned above (Bound et al., 2006; Compas for 
Health Canada, 2002).  The American study was conducted a decade before this study 
and the issue of pharmaceuticals in the environment received little attention before the 





methods, such as the rates of toilet disposal.  Both garbage and toilet disposal provide a 
pathway for PhACs to enter the aquatic environment.  Toilet disposal ultimately leads to 
contamination of WWTPs and landfills potentially contaminate groundwater where no 
liner and leachate collection exists.  Where leachate is collected, it is usually sent to 
WWTPs for treatment (pers. comm., D. Andrews).   
Proper disposal of pharmaceuticals entails returning pharmaceuticals to the 
pharmacy, where they will be sent for incineration, and actions which prevent the 
pharmaceuticals from entering the environment, such as bringing them to a hazardous 
waste disposal day.  Incineration effectively destroys pharmaceuticals and has extremely 
low atmospheric emissions (Bridges, Bridges, & Potter, 2000; Porteous, 2001).  In 
Kitchener, 28% of respondents said they returned their unused or expired medications to 
the pharmacy, a rate slightly higher than the 21.8% return rate found in the U.K. by 
Bound et al. (2006).  Three percent of respondents disposed of pharmaceuticals properly 
in a different way.  In Foxboro, the rate of proper disposal was higher; 42% of 
respondents returned unused medications to the pharmacy and 5% to hazardous waste 
day.  Because of the relatively large difference between the results for Foxboro and 
Kitchener, the disposal methods reported in the Kitchener survey were classified by age 
group, to assess whether the age of the Foxboro respondents might be related to disposal 
rate.  The data illustrated that the rate of proper disposal increased with age.  Fifty percent 
of seniors in the Kitchener survey properly disposed of their pharmaceuticals, whereas 
only 6% of respondents between ages 18-30 properly disposed of their unused or expired 
medications (Fig. 4.19).  However, the percentage of each age group who put medications 
in the toilet increased with age (Fig. 4.19).  Younger respondents were much more likely 
to dispose of pharmaceuticals in the garbage (89% for ages 18-30) than in the toilet (6% 
for ages 18-30), whereas seniors were more likely to put pharmaceuticals in the toilet 
(33%) than in the garbage (25%).  The reason for the increasing rate of toilet disposal 
with age is likely that, in North America, residents were told in previous decades that 
they should dispose of pharmaceuticals in the toilet, so that children could not consume 
them and be poisoned (Kuspis & Krenzelok, 1996).  Older respondents are more likely to 
have received the ‘toilet disposal’ message in the past. Younger respondents were likely 



































Figure 4.19.  Methods of disposal of unused and expired medication by age group in 
Kitchener. 
 
message has now been replaced with advice to return medications to the pharmacy, for 
environmental reasons.  The reason why the younger respondents are less diligent in 
returning medications to the pharmacy than older respondents, however, is more difficult 
to assess.  Possible reasons include a lack of awareness of the issue of pharmaceuticals in 
the environment, of the possibility of returning drugs to the pharmacy, or attitudes 
differing from those of older respondents. 
 Respondents were asked whether or not they were aware that water contamination 
by pharmaceuticals was an environmental concern, and whether or not they were aware 
that pharmaceuticals could be returned to the pharmacy for disposal.  In Kitchener, 49% 
of respondents were aware of the issue of pharmaceuticals in the environment; in 
Foxboro, the number of respondents aware of the issue was higher, at 62%.  The findings 
in Kitchener are very similar to those in the study by Bound et al. (2006), where just over 
half of their U.K. respondent felt that pharmaceuticals could be harmful to the 
environment.   In Kitchener, 42% of respondents knew that they could return unused or 
expired medications to the pharmacy; in Foxboro, the number was 58%.  Again, the 
results were examined to see if age might have contributed to the difference between 





pharmacy did increase with age, with 63% of seniors in Kitchener saying they knew of 
this disposal method, whereas only 16% of those aged 18-30 were aware of it (Fig. 4.20).  
However, awareness of the issue of pharmaceuticals in the environment was somewhat 
less age dependent; although seniors in Kitchener were again the group displaying the 
greatest awareness, at 63%, 53% of the youngest respondents had also heard about 
pharmaceuticals polluting water (Fig. 4.21).  The group least aware of this environmental 
issue was the 31-45 year olds, at 33%.  It may be that young people have recently heard 
about pharmaceuticals in the environment through educational institutions which some 
attend, such as colleges and universities, explaining their relative awareness of the issue.  
Their lack of awareness that pharmaceuticals can be returned to the pharmacy for 
disposal may be because they use relatively few medications (Fig. 4.10), are therefore 
less likely to be at a pharmacy or interact with a pharmacist, and are thus less likely to 
receive information regarding disposal, than seniors.  This lack of awareness may partly 
explain the poor drug disposal habits of the younger age group. 
 To ascertain whether or not increasing awareness through education programs 
might enhance the rate of proper drugs disposal, the responses of those who said they 
knew pharmaceuticals could be returned to the pharmacy for disposal were compared 
with the actual disposal methods used.  In Kitchener, 54% of respondents who knew it 
was possible to return unused medications to the pharmacy did so (Fig. 4.22).  Seventy-
seven percent of the respondents who were aware both that pharmaceuticals represented 
an environmental concern and that it was possible to return unused drugs to the pharmacy 
did so. In Foxboro, however, awareness of the issue of pharmaceuticals in the 
environment did not improve disposal behaviour.  Seventy-four percent of Foxboro 
respondents who were aware that unused medications could be returned to the pharmacy 
did so, whether or not they were aware that pharmaceuticals represented an 
environmental concern.  Of those who did know that water pollution by pharmaceuticals 
was a concern, 69% returned their unused medications to the pharmacy (Fig. 4.22).    
Thus Foxboro residents appear to be returning medications to the pharmacy as a general 
practice, rather than because of a specific environmental concern, to a greater degree than 






























Figure 4.20.  Awareness of Kitchener respondents that unused or expired medications 

























Figure 4.21.  Awareness of Kitchener respondents that water pollution by 
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Figure 4.22.  Disposal behaviour of respondents according to awareness of the 
possibility of returning unused/expired medications to the pharmacy, and awareness of 
the issue of pharmaceuticals in the environment. 
 
communities, with the Foxboro seniors consuming more pharmaceuticals and therefore 
visiting the pharmacy more often. Possibly returning unused or expired medications may 
be more convenient and more likely to become a habit of the cohort. 
 To determine whether inconvenience might be a barrier to the return of unused 
and expired medications to the pharmacy, respondents were asked how inconvenient it 





feel the practice would be inconvenient (Fig. 4.23).  Eighty-one percent of Foxboro 
respondents, and 73% of Kitchener respondents disagreed strongly or somewhat with the 
statement, “Returning my unused or expired medication to the pharmacy for disposal 
would be inconvenient.”  In Foxboro, 74% strongly disagreed that returning medications 
to the pharmacy was inconvenient, compared with 44% in Kitchener.  This supports the 
theory that Foxboro respondents return their unused drugs due to habit, because of 
convenience.  This may explain why awareness of the issue of PhACs in the environment 

































































Figure 4.23.  Responses to the statement, “Taking my unused or expired medication to 






respondents.  In comparison with a survey by Compass for Health Canada, respondents in 
both locations were more likely to disagree that returning medications to the pharmacy 
for disposal was inconvenient; 63% disagreed in the Likert-style question asked in the 
Compas survey for Health Canada (2002).  However, the results of the Kitchener survey 
may have been influenced by the presence of a pharmacy in the plaza where the survey 
was being conducted.  This may have resulted in fewer respondents feeling that bringing 
medications back to the pharmacy was inconvenient. 
 In addition to asking about respondents’ attitudes specifically related to the 
disposal of pharmaceuticals, attempts were made to assess their attitudes towards the 
protection of the environment in general.  The purpose of this question was to get a sense 
as to whether or not respondents would like to see management action taken to address an 
environmental issue such as pharmaceuticals in the environment.  The approach of trying 
to ascertain respondents’ attitudes towards an issue ‘such as’ PhACs in the environment 
was used because residents were not expected to have in-depth knowledge of the problem 
of environmental contamination by PhACs, and teaching each respondent about the 
details of the issue would have been too time-consuming.  Instead, respondents were 
asked about general environmental problems with similar characteristics to PhACs issue, 
such as a greater risk to ecosystem health than human health (See Appendix C, questions 
8-10).  Respondents generally exhibited attitudes strongly in favour of managing 
problems such as pharmaceuticals in the environment.  They felt that all water 
contamination should be mitigated, even if the effect of the contamination was unclear; 
they were concerned about problems which only affected ecosystem health, not human 
health; and they were concerned about environmental problems which did not affect them 
directly (Fig. 4.24, 4.25, 4.26).  Respondents generally ranked the environment as their 
second priority in a broad list of concerns, below human health but above education or 
jobs (Table 4.9). However, the eagerness for management to address water contamination 
was considerably more muted when financial considerations were introduced.  When 







Figure 4.24.  Responses to the statement, “We should only spend money on 
environmental problems that affect human health, not on problems that only affect other 
species or ecosystems.” 
 
 
Figure 4.25.  Responses to the statement, “We should try to prevent all water pollution, 
even if we have no evidence that a pollutant will harm human or ecosystem health.” 
 
 
Figure 4.26.  Responses to the statement, “If an environmental problem doesn’t affect my 















































































































































































































































































Concern Kitchener Foxboro 
Human health 1.3 1.1 
Environment 2.4 2.2 
Education 2.7 2.9 
Jobs 3.7 3.8 
Transportation 4.5 4.6 
 
Table 4.9.  Aggregated rankings of concerns in order of importance to respondents, with 
a score of 1 representing the most important concern. 
 
pharmaceuticals through sewage treatment and to generally improve environmental 
quality by upgrading WWTPs, the responses in both Foxboro and Kitchener were much 
more mixed (Fig. 4.27).  Many of those who said they would not be willing to pay to 
upgrade WWTPs stated that they felt the pharmaceutical industry should pay for the 
upgrades instead.  Others simply felt their taxes were too high already.  Some 
respondents stated that the city should pay, apparently not making the link between the 
city paying and an increase in municipal taxes.  One respondent acknowledged that it was 
illogical to expect the city to pay for upgrades to WWTPs while refusing to pay her share 
in taxes, but said that, nevertheless, this was how she felt.  The difference between the 
responses in the attitudinal questions and the willingness to pay question likely reflects 
differences between the ideal and the real.  Respondents know they should protect the 
environment, but when faced with the real possibility of funding management action out 
of their own pockets/through their taxes, are much less willing to support management 
action.  Even the willingness to pay question may overestimate respondents’ true 
willingness to contribute financially to the management of PhACs in the environment, as 
respondents are more likely to object when actually sent a bill, than when asked 
theoretically, with no obligation to pay, how much they would be willing to contribute 



























































































Figure 4.27.  Willingness to pay to upgrade wastewater treatment to reduce water 
contamination by pharmaceuticals (PhACs), and to generally improve water quality, 
among survey respondents.  Respondents were asked how much they would be willing to 
pay per year to achieve these two objectives. 
 
willingness to pay for upgrades to WWTPs, even knowing that such an upgrade could 
improve water quality in general, suggests that the Region of Waterloo would likely face 
protests from residents if expensive wastewater treatment technologies were installed and 







4.5.3  Expense of upgrading WWTPs 
 While residents would likely protest the installation of expensive wastewater 
treatment technology, not all effective advanced treatment options are highly expensive.  
Ozonation can effectively remove PhACs from water/wastewater (Huber, Canonica, 
Park, & Von Gunten, 2003; Ternes et al., 2003), especially when DOC concentrations are 
not excessively high (Zwiener & Frimmel, 2000).  While there is some concern about 
ozonation byproducts, Ternes et al. (2003) suggest that such byproducts are unlikely to be 
pharmacologically active.  They estimate that the cost of installing and operating 
ozonation at a large-scale treatment plant would be no more than 0.05 Euros/m3 of 
wastewater ($ 0.073  CDN/m3).  The Kitchener wastewater treatment plant treats 60 000 
m3/day.  The yearly cost of upgrading the Kitchener WWTP to include ozonation, per 
resident of Kitchener, would therefore be: 
(0.073 $/m3 x 60 000 m3/d x 365 d/yr)/180 000 residents = $ 8.9/yr per resident 
While one must be cautious in extrapolating the results of the Kitchener survey to the 
population as a whole, given that the survey was not random, it is of interest that 62% of 
Kitchener respondents said they would be willing to pay $10 or more to upgrade the local 
WWTP to better remove PhACs, and 68% said they would pay $10 or more to generally 
improve water quality.  This suggests that many Kitchener residents would find the cost 
of installing an ozonation system in the WWTP acceptable.  The Region should therefore 
consider adding ozonation to the Kitchener WWTP as a future management strategy to 
mitigate the environmental impacts of PhACs.  However it should also take into account 
the energy-intensive nature of ozonation, which uses 40-50% more energy than a regular, 
secondary WWTP (Larsen, Lienert, Joss, & Siegrist, 2004), and the generation of 
ozonation by-products (McDowell, Huber, Wagner, Von Gunten, & Ternes, 2005).   
 Membrane filtration, while effectively removing PhACs from water (Heberer, 
Feldmann, Reddersen, Altmann, & Zimmerman, 2002) appears to be somewhat less 
feasible as a treatment option, as it is both more expensive and more energy-intensive 
than ozonation (Larsen et al., 2004).  Côté, Masini and Mourato (2004) estimate that the 
total lifecyle cost of treating sewage wastewater to a quality suitable for irrigation reuse 
with an integrated membrane bioreactor (MBR) would be $0.20/m3 for a large plant such 





dollars would be $0.24/m3, and the cost per resident of installing such as system at the 
Kitchener WWTP would be:  
(0.24 $/m3 x 60 000 m3/d x 365 d/yr)/180 000 residents = $ 29/yr per resident 
Only 33% of respondents in the Kitchener survey were willing to pay more than $25 per 
year to reduce water contamination by pharmaceuticals, although 46% were willing to 
pay the same amount to generally improve water quality.  Nevertheless membrane 
filtration should not be entirely ruled out as a future treatment method to remove PhACs 
from wastewater, as it has one significant advantage over ozone: it does not generate any 
reaction products. 
 
4.5.  Conclusions: Implications for management 
 The results of the analyses of WWTP influent and effluent and the social surveys 
have several implications for management.  The concentrations of PhACs in the WWTP 
effluents are comparable with those found in international studies, although PhAC 
concentrations leaving the Foxboro plant are elevated.  Antibiotic concentrations are 
particularly high in Foxboro and sulfamethoxazole concentrations are surprisingly high in 
Kitchener, although they may be outliers rather than typical values.  PhAC concentrations 
in Foxboro effluent are generally higher than in Kitchener but environmental 
contamination by Foxboro wastewater will also be more localized, as the wastewater is 
released to the subsurface through a septic tile bed.  Although a groundwater well is 
located near the Foxboro WWTP, the presence of a thick aquitard means that the 
contamination of the underlying aquifer and therefore the production well, is unlikely 
(pers. comm.., D. Andrews, manager of wastewater operations, Region of Waterloo, 
2005).  In  Kitchener, PhAC concentrations in effluent are lower, but wastewater is 
discharged to the Grand River, making PhACs from the Kitchener plant more likely to 
impact aquatic ecosystems locally or downstream.  Furthermore, the environmental 
loading of pharmaceuticals is higher in Kitchener.  Taking a precautionary approach to 
the protection of groundwater and the quality of the Grand River, given that PhAC 
concentrations in the Kitchener and Foxboro effluents are similar – and for some PhACs, 
higher – than those found in other urban areas, it is reasonable to consider management 





 The results of the survey suggest that residents are interested in managing an 
environmental problems such as water contamination by PhACs, as they are concerned 
about water contaminants, even if their effects are unclear and even if the contaminants 
are not likely a threat to human health.  However, many residents would not support 
expensive management strategies.  Ozonation is a technology which effectively removes 
PhACs from water and wastewater (Huber et al., 2003; Ternes et al., 2003; Zwiener & 
Frimmel, 2000), yet is not overly expensive, at an estimated cost of $ 8.9 per year per for 
Kitchener residents.  It therefore represents a viable management option which the 
Region of Waterloo might install to mitigate the release of PhACs from the Kitchener 
WWTP, although the additional 40-50% energy requirements for ozonation and the 
generation of by-products, must also be considered (Larsen et al., 2004; McDowell et al., 
2005).   In Foxboro, a general lack of effectiveness in plant operations may require an 
upgrade in the near future.  Such a general upgrade may help to improve the removal of 
PhACs at the plant, without resorting to expensive or energy-intensive technologies.  
Furthermore, optimization of plant parameters, such as sludge retention time (SRT), may 
represent a means of improving PhAC removal at both Foxboro and Kitchener WWTPs 
without the expense of high-tech upgrades (Clara et al., 2005; Metcalfe, Koenig et al., 
2003). 
  Disposal of unused and expired medications is another aspect of environmental 
PhAC loading which could be addressed relatively inexpensively.  Furthermore, this 
flexible management strategy meets the requirements of adaptive planning (Holling, 
1978; Lessard, 1998) (see Ch. 3), as it is easier to modify than technological strategies 
such as advanced wastewater treatment. Many residents of Kitchener and Foxboro 
dispose of medications in the toilet or garbage, which contributes to the environmental 
loading of PhACs.  Many of the residents are not aware of the possibility of returning 
their unused or expired medications to the pharmacy or to household hazardous waste 
day, nor are they aware of the environmental reasons for doing so.  Those residents who 
are informed of the possibility of returning unused/expired medications to the pharmacy 
are more likely to do so.  Return rates for unused/expired drugs are approximately 25 % 
higher among residents aware that they can return unused/expired drugs to the pharmacy, 





improve the pharmaceutical disposal habits of local residents.  Education programs need 
not be expensive; instead, the Region of Waterloo may want to collaborate with 
pharmacies to make residents aware of the possibility of and need for proper disposal. In 
Europe, the pharmaceutical industry is often involved in pharmaceutical returns programs 
(Greiner & Rönnefahrt, 2003; SIGRE, 2002).  This is also the case in British Columbia 
(Government of British Columbia, 1997).   Education programs could be as simple as 
handing out pamphlets on pharmaceutical disposal to all respondents who purchase 
behind the counter medications, or verbally mentioning disposal as a part of counselling 
by the pharmacist.  Educating local residents about the need to protect the environment 
through proper disposal of pharmaceuticals may have several added benefits.  It may 
increase the awareness among residents that their individual actions, such as waste 
disposal, have an environmental impact.  This may increase their environmental 
consciousness in general, and may lead to a greater sense of responsibility towards the 
environment – a sense of environmental stewardship.  If residents are taught that all of 
their actions have environmental relevance, and that all products require proper disposal – 
whether recycling, composting, or special returns programs – environmental 
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Chapter 5: Consultation with stakeholders from academic, public, and industrial 
sectors 
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 Consultation with stakeholders is an essential component of risk management 
(Canadian Standards Association, 1997; McColl, Hicks, Craig, & Shortreed, 2000; The 
Presidential/Congressional Commission on Risk Assessment and Risk Management, 
1997).  Stakeholders can be defined as “Any individual, group, or organization able to 
affect, be affected by, or believe it might be affected by, a decision or activity.  The 
decision-maker(s) is a stakeholder.” (Canadian Standards Association, 1997).  This 
chapter presents the results of consultation with international stakeholders from 
academia, governments and the pharmaceutical industry, through structured interviews.  
These stakeholders have expertise in the science and management of pharmaceuticals in 
the environment.  The interviews therefore focused largely on eliciting the interviewees’ 
expert opinions regarding the nature of the problem of pharmaceuticals in the 
environment, and potential management strategies, especially those being used in their 
respective countries.   Expert elicitations are often used to obtain assessments of 
environmental problems beyond the understanding that can be gleaned from peer-





Small, 2004).   Interviewees from the government and industrial sectors were also asked 
to provide insight into the perspectives of their organizations and sectors on the issue of 
pharmaceuticals in the environment when possible.  Understanding gained through the 
interviews described in this chapter will be used in the evaluation of management 
strategies in the subsequent chapter. 
 
5.2.  Methods 
 Structured interviews were conducted with 27 expert stakeholders working for 
governments, universities, and the pharmaceutical and consulting industry, from Canada, 
the United States and Europe (Table 5.1) (Doerr-MacEwen & Haight, 2006).  
Environmental non-governmental organizations (ENGOs) were also contacted, but 
declined to participate in the interviews, citing a lack of personnel and resources to 
devote to the study.  Interviewees were selected through purposive sampling: based on 
their contributions to the literature on pharmaceuticals in the environment, participation 
in conferences on pharmaceuticals (PhACs) in the environment, and on recommendations 
of professional organizations or colleagues.  The interviewees were recruited by e-mail.  
Interviews were conducted in person when possible (n=18), by telephone (n=5) and e-
mail (n=4).  Participation rates were highest among potential interviewees within the 
academic sector (~71%), followed by the public (government) sector (~64%), then 
representation from the pharmaceutical industry (~18%).  Sampling was non-random as 
the purpose of the interviews was not to generate statistics that could be applied across 
entire populations of stakeholders, but to gain an in-depth understanding of the views of 
some stakeholders from different sectors.  Interview questions asked of members of the 
pharmaceutical industry differed somewhat from those asked of other interviewees, as 
these respondents were in a position to provide insight into the particular perspective of 
the industry.  A mixture of open-ended and close-ended questions were used (Greene, 
Caracelli, & Graham, 1989), with close-ended questions included rating scales and 
Likert-style questions (Foddy, 1993; Krosnick & Fabrigar, 1997; Palys, 1997.  The 
purpose of the mixed-methods approach was twofold; some questions were 
complementary, meant to clarify the results of other questions (Greene et al., 1989).  For 






Interviewee Affiliation Location Field of Specialty 
1 University Canada Environmental Toxicology 
2 University Canada Ecotoxicology 
3 University Canada Environmental Toxicology 
4 University Canada Drinking Water Treatment 
5 University Canada Ecotoxicology 
6 University Canada Endocrinology 
7 University United States Environmental Chemistry 
8 University Europe Chemical/Environmental 
Engineering 
9 University Europe Environmental Chemistry 
10 Government Canada Microbiology 
11 Government Canada Wastewater Operations 
12 Government Canada Veterinary Epidemiology 
13 Government Canada Environmental Assessment 
14 Government United States Toxicology & Microbiology 
15 Government United States Environmental Toxicology & 
Chemistry 
16 Government United States Hydrology 
17 Government Europe Biology 
18 Government Europe Risk Assessment 
19 Government Europe Clinical Physiology 
20 Government Europe Environmental Safety 
Assessment 
21 Government Europe Environmental Science/Policy 
22 Industry (Phm1.) Canada Environmental Management 
23 Industry (Phm1.) Canada Scientific Affairs 
24 Industry (Phm1.) United States Safety Assessment 
25 Industry (Phm1.) Europe Environmental Risk Assessment 
26 Industry (Phm1.) Europe Risk Assessment 
27 Industry (Con2.) Europe Ecotoxicology 
1 Pharmaceutical Industry 
















to close-ended questions.  However, in general, the purpose of the mixed methodology 
was simply to expand the breadth of inquiry (Greene et al., 1989), using whichever 
format seemed most appropriate given the nature of the question; in other words, a 
pragmatic approach (Datta, 1997; Greene & Caracelli, 1997). The interview questions for 
the academic and public sector participants and the environmental consulting industry, 
are provided in Appendix E.  Questions asked only of participants from the 
pharmaceutical industry can be found in Appendix F.  All interviewees were asked 
questions relating to the scope and nature of the problem of pharmaceuticals in the 
environment and their opinions of risk management strategies.   
 
5.3 Results & Discussion 
5.3.1  Scope and Nature of the Problem 
 In the scientific literature on pharmaceuticals in the environment, the scope and 
nature of the problem continue to be debated: How much of a concern do PhACs in 
aquatic environments really represent for ecosystem health?  Are they likely to 
detrimentally affect human health?  How do they compare to other surface water and 
groundwater concerns?  The answers provided by the interviewees bring new 
perspectives, not previously expressed in the academic literature. 
 
 5.3.1.1 Concern for Ecosystem and/or Human Health? 
 When asked if PhACs in aquatic environments represented a concern for 
ecosystem health, human health, both, or neither, the majority (62%) of interviewees 
indicated that they felt PhACs were of concern with respect to both human health and 
ecosystem health (Fig. 5.1) (Doerr-MacEwen & Haight, 2006). The reasons for seeing 
PhACs in the environment as a human health concern varied.  Interviewee 18 commented 
that PhACs are a human health concern because of their bioactive nature and because 
they are present in groundwater, drinking water and recreational waters, not just in 
surface water removed from human use.  Interviewee 6 suggested that regardless of 
whether or not evidence existed that PhACs in aquatic environments might harm human 
health, action should be taken to protect humans against consumption: “What are these 





quality of drinking water in general?”  Several interviewees identified factors other than 
scientific evidence that should be considered when addressing the problem from a 
policy/management perspective.  Interviewee 1 stated, “I believe it is only ecosystem 
health from a science perspective.  But from a public policy perspective, I think it’s both 
[a human health and an ecosystem health concern]”.  Two interviewees believed a 
precautionary approach should be taken to the management of the problem, and this 
meant including human health as an area of concern.  Interviewee 10 emphasized the 
need to take public concerns seriously and not to dismiss perceptions of risk which differ 
from those of scientific experts: “Impacts on human health will be marginal, but there is 
human concern and apprehension regarding this issue, which must be considered.”  These 
comments underline the importance of normative, value-based considerations in the 
management of PhACs in the environment.   
Several interviewees who did not believe that PhACs were of concern for human health 
cited low PhAC concentrations in drinking water, together with extensive testing of 
pharmaceuticals for human safety, as a basis for their opinions.  For example, interviewee 
25 stated, “No human health concern as all publications so far show a very high margin 
of safety between measured environmental concentrations and worst-case intake of 2 L of 
surface water per day.”  Interviewee 26 explained, “It seems to me that there’s a very, 
very wide margin of safety, that you’d have to take certain drugs every day of your life 
for 70 years and you’d still have a very wide safety margin.”   
The potential for effects of PhACs on ecosystems was generally seen as a greater 
concern than the potential for human health effects; 81% of interviewees believed that 
pharmaceuticals were an ecosystem health concern.   Interviewees cited three main 
reasons for their view that PhACs were of concern for aquatic ecosystem health: 1) the 
bioactive nature of pharmaceuticals, 2) continuous exposure of aquatic species to PhACs 

















































Figure 5.1. Responses of interviewees when asked if pharmaceuticals in surface water 
and groundwater represented a concern for human health, ecosystem health, both, 
neither, or other  a) percentages of total number of responses, b) number of responses in 
each category according to geographic location, c) number of responses divided 










































































especially primary organisms.  Interviewee 18 explained why ecosystem impacts were of 
particular concern as follows: “The difference being that for humans, it still would only 
be periodic, sporadic exposure; for aquatic species, they’re going to be swimming in it.”  
Interviewee 12 stated, “It just makes scientific sense that when you’re introducing agents 
as powerful as antimicrobials into the ecosystem, that you’re going to be effecting a 
change.”  However some interviewees did not believe PhACs were detrimental to aquatic 
ecosystems, citing a lack of evidence of effects, with the exception of the reasonably well 
understood localized effects of 17α-ethinylestradiol (Jobling, Nolan, Tyler, Brightly, & 
Sumpter, 1998; Purdom et al., 1994).  For example, Interviewee 26 reasoned, ”Let’s say 
we’ll make a guess more drugs are used today than were used 20 years ago.  The macro 
analysis actually is the ecosystem doesn’t seem to be getting any worse.” It is perhaps of 
note, however, that four of the five respondents who did not believe PhACs were of 
concern for ecosystems (answering “neither” or “other”, shown in Figure 5.1c), were 
representatives of the pharmaceutical industry. Interviewees from different sectors may 
tend towards certain perceptions of the issue of pharmaceuticals in the environment, with 
employees of the pharmaceutical industry possibly having more conservative views than 
those from the academic (university) and public (government) sectors. 
 
 5.3.1.2  Likelihood and magnitude of effects 
 It was of interest to assess the respondents’ perception of the likelihood and 
magnitude of the effects of concern.  Because of the complexities of assessing the effects 
of environmental mixtures of PhACs on aquatic ecosystems and human health (see 
discussion in Chapter 2), it is impossible at this time to calculate probabilities for such 
effects.  Thus a rough, qualitative assessment of probability of “serious or irreversible 
damage” was sought.  This was completed using bipolar Likert-style questions, two 
levels of intensity (very and somewhat) towards each pole, and a neutral position in the 
middle (Appendices E & F )(Krosnick & Fabrigar, 1997).  The terms “serious or 
irreversible damage” were employed as an indication of magnitude of effects, because of 
their use in the Rio Declaration on Environment and Development (United Nations 
General Assembly, 1992) and the Canadian Environmental Protection Act (CEPA, 1999), 





ecosystem effects was that PhACs were somewhat likely to induce serious or irreversible 
damage to aquatic ecosystems (Fig. 5.2a).  61% of interviewees believed PhACs were 
either very or somewhat likely to cause serious or irreversible damage to aquatic 
ecosystems.  Interestingly, 75% of European interviewees held this view, as compared 
with 53% of North Americans (Fig. 5.2b).  Also of interest are the variations between the 
responses given by member of different sectors; 83% of interviewees from academia, 
60% from government, and none of the interviews from the pharmaceutical industry, 
thought PhACs would cause serious or irreversible damage to aquatic ecosystems (Fig. 
2c).  Interviewees who believed serious or irreversible damage to aquatic systems was 
very or somewhat likely explained this view largely based on known effects, including 
fish feminization due in part to surface water contamination by 17α-ethinylestradiol, and 
the death of vultures which had ingested the drug diclofenac through the consumption of 
dead cattle.  Interviewee 18 most clearly expressed this perspective, held by several other 
interviewees: 
If you think about the impact of diclofenac on the vultures, well you might think 
this is an irreversible impact on the avian population, because we’re already 
eradicated 95% of the population.  That’s an extreme example of thing that might 
happen.  Perhaps the same happened somewhere in some nice ecosystem that had 
some very rare species that we’re not aware of, because they’re all gone.  In risk 
terms, it’s very likely things will happen.   
Interviewee 19 discussed the temporal nature of the risks presented by PhACs in the 
environment, suggesting that a delay in action to mitigate the release of PhACs to the 
environment would allow for serious and irreversible damage in the future:  
If nobody takes care then it will be very likely that there will be damage.  I mean 
we have started to understand that there is some kind of hazard, for some 
compounds even a risk, within the past 5-10 years, so it’s very new.  So if 
something is done and the input into the environment is reduced, fine.  If not, then 










































































































Figure 5.2.  Responses of interviewees when asked how likely or unlikely it is that 
pharmaceuticals in surface water and groundwater will cause serious or irreversible 
damage to aquatic ecosystems, a) percentages of total number of responses, b) number of 
responses in each category according to geographic location, c) number of responses 






Interviewees who did not believe serious or irreversible damage to aquatic ecosystems 
was likely mainly cited the resilience of ecosystems as a reason.  They believed that any 
damage would be reversible; once evidence of damage was found, proper treatment to 
mitigate environmental contamination could be put in place, and the ecosystem would 
return to its original state.  Interviewee 22 explained:  
If you did have a particular hot spot of pharmaceutical contamination, and if there 
was a sub-lethal impact, and then you said, O.K., we’ll install an appropriate 
treatment system for that particular locality, I think you would actually get 
recovery very quickly, because that’s what life does.   
The interviewees who found serious and irreversible damage unlikely believed in the 
ecosystem resilience as a characteristic that could be relied upon to avert damage.  This 
was in direct contrast with the view of ecosystems as sensitive, vulnerable, and 
unknowable/unpredictable, expressed by those interviewees who believed serious and 
irreversible damage to aquatic ecosystems was likely.  
 In terms of damage to human health, the responses of interviewees were skewed 
towards the negative (unlikely to cause serious or irreversible damage), and were less 
varied than those regarding damage to ecosystems (Fig. 5.3).  Only one respondent 
thought that serious or irreversible damage to human health was at all likely.  In the case 
of human health, 61% of interviewees felt serious or irreversible damage was somewhat 
or very unlikely, whereas for aquatic ecosystems, the same number thought it was likely.  
The reasons for believing serious or irreversible human health damage was unlikely were 
similar to those the interviewees mentioned when asked if human health was a concern at 
all.  They felt concentrations of PhACs in drinking water were too low to cause such 
damage.  It should be noted, however, that several interviewees who rated serious or 
irreversible human health damage as “somewhat unlikely”, were nevertheless concerned 
about human health effects; in particular, effects on sensitive sub-populations and 
humans at sensitive stages of  development, such as adolescents, were described.  
Interviewee 8 expressed a concern that mixtures of environmental contaminants were 
contributing to decreased sperm counts and increased rates of cancer and allergies, and 
































































































Figure 5.3. Responses of interviewees when asked how likely or unlikely it is that 
pharmaceuticals in surface water and groundwater will cause serious or irreversible 
damage to human health. a)  percentages of total number of responses, b) number of 
responses in each category according to geographic location, c) number of responses 





to detrimental effects on human health.  In other words, while many interviewees did not 
think human health impacts were likely, several nonetheless believed that the effects of 
long-term consumption of mixtures of low levels of pharmaceuticals and other substances 
are not thoroughly understood.  Consequently, the possibility of subtle health effects such 
as endocrine disruption, cannot be ruled out. 
 
5.3.1.3  Ranking of Surface Water and Groundwater Contaminants 
 As pharmaceuticals represent only one group of water contaminants of concern, 
and as resources for mitigating environmental contamination are limited, it is of interest 
to determine how PhACs compare to other contaminants in terms of need for 
management action.  Interviewees from government and academia were asked to rank 7 
common surface water and groundwater contaminants in terms of need for management 
action, in their respective countries (Fig. 5.4).  The graphs indicate the frequency with 
which each contaminant was assigned a ranking by interviewees.   The interviewees gave 
a very wide range of responses when ranking the need to manage PhACs, compared to 
their responses for other contaminants like metals and pesticides.  Table 5.2 illustrates the 
overall ranking when the individual rankings by interviewees are aggregated, as well as 
the aggregated rankings for North America and Europe.  PhACs rank 5th out of 7 
contaminants in the overall aggregated ranking and the North American ranking, but 4th 
in the European aggregated rankings (Doerr-MacEwen & Haight, 2006).  Several 
interviewees suggested that chemical contaminants need to be addressed not as separate 
groups of substances but in terms of the environmental impact of chemical mixtures.   
 
North America Europe Total Aggregated 
Pathogens Nutrients Pathogens 
Pesticides Pesticides Nutrients 
Nutrients Metals Pesticides 
Metals Pharmaceuticals Metals 
Pharmaceuticals Pathogens Pharmaceuticals 
Organic Solvents Organic Solvents Organic Solvents 
Road Salt Road Salt Road Salt 
Table 5.2  Ranking of groundwater and surface water contaminants in order of 
































Figure 5.4.  Interviewees ranked seven contaminants in order of greatest need for 
management action, with 1 representing the greatest need for action.  These graphs 


































































































































































It is quite striking that pathogens were ranked 1st by North Americans, but 5th – lower 
than pharmaceuticals – in terms of need for management action, by Europeans.  This may 
be a reflection of different approaches to precaution in Europe and North America.  
Examples of precautionary action in Wiener and Rogers (2002) suggest that Europeans 
tend to take a more precautionary stance with respect to chemical contamination and 
similar issues which present risks to the environment at large.  In contrast North 
Americas tend to have a more precautionary attitude towards human health risks, such as 
Bovine Spongiform Encephalopathy (BSE) and smoking, which do not necessarily affect 
ecosystems.  PhACs are seen as representing a greater risk to ecosystems than to human 
health (see Sections 5.3.1 and 5.3.2) whereas contamination of surface water and 
groundwater by pathogens is of greater concern in terms of human health than ecosystem 
health (O'Connor, 2002).   
 
5.3.2  Uncertainty  
 Because of complexities such as mixture effects, the academic literature suggests 
that a high degree of uncertainty – perhaps ignorance (see Chapter 3, Section 3.2.2.) – 
exists regarding the effects of PhACs on aquatic ecosystems.  The interviewees were 
asked to score this uncertainty on a scale of 1 to 5, with 1 representing complete certainty 
(i.e. the ability to calculate risk in probabilistic terms) and 5 representing complete 
uncertainty (i.e. ignorance).  When the scores of the interviewees were aggregated, a 
score of 3.6 was obtained, indicating a high level of uncertainty, but perhaps not the 
complete lack of knowledge and understanding occasionally suggested by the literature.  
All of the interviewees who explained why they had assigned a moderate, rather than a 
high score in terms of uncertainty, cited known cases of impacts of PhACs on aquatic 
species.  Interviewee 9 explained, “We have cases where we can be quite sure that there 
is a risk for the environment, for some hormones; that is almost settled,” and Interviewee 
21 stated, “We are pretty certain drugs are not at levels which are causing acute impacts 
(death).  We have a lot of knowledge about endocrine disrupting effects.” Reasons for 
giving a high score to the level of uncertainty were manifold; Table 5.3 lists the sources 
of uncertainty mentioned, and the number of interviewees who mentioned each source.  





chronic effects and a lack of appropriate risk assessment methodology.  Clearly these are 
interrelated, as are many other sources in Table 5.3.  Therefore the sources were 
categorized according to the two main steps in assessing risk to aquatic ecosystems:  
assessment of exposure and assessment of effects.  Sources of uncertainty related to 
effects were mentioned 21 times, whereas sources related to exposure were only 
mentioned 5 times.  This may reflect the wording of the question, which emphasized 
effects, or the number of toxicologists participating in the interviews (Table 5.1).  
However, given that measurements of PhACs in the environment – i.e. of exposure – 
have been made and published for over a decade (Eckel, Ross, & Isensee, 1993; Stan, 
Heberer, & Linkerhagner, 1994), Table 5.3 may also reflect a sense that it is mainly a 
lack of toxicological understanding which constitutes the uncertainty in scientific 
understanding of the effects of PhACs on aquatic ecosystems. 
 
Source of Uncertainty Category Times Mentioned 
Mixture effects Effects 5 
Chronic, low-level effects Effects 4 
Appropriate risk assessment methodology Effects 3 
Exposure-effect relationship (dose-response) Effects/Exposure 2 
Effects on low trophic levels: invertebrates, 
bacteria 
Effects 2 
Effects on whole ecosystems Effects 2 
Mechanisms of action of PhACs Effects 2 
Understanding of metabolites: presence, 
effects, etc. 
Effects/Exposure 2 
Analysis of PhAC concentrations in 
environmental samples 
Exposure 1 
Effects assessment: looking at the right 
endpoints 
Effects 1 
Exposure pattern Exposure 1 
Fate, persistence Exposure 1 
Bioaccumulation Effects 1 
Metabolism of PhACs within organisms Effects 1 
 
Table 5.3  Sources of uncertainty in terms of the impacts  of PhACs on aquatic 







5.3.3  Research Needs 
 The research needs described by the interviewees included many of the areas 
listed as sources of uncertainty regarding effects of PhACs on aquatic ecosystems, but 
other research needs were also mentioned.  Table 5.4 lists the research needs identified by 
the interviewees, and the number of interviewees who mentioned each research need.  
These areas requiring research included a combination of research to better understand 
exposure, effects and means of mitigating the environmental release of PhACs.  It is of 
interest that, as with the sources of uncertainty, research needs related to assessment of 
the effects of PhAC were mentioned almost twice as often as research needs related to 
exposure, and four times as often as research into pollution prevention strategies.  This 
may reflect the makeup of the interviewees, many of whom are toxicologists (Table 5.1).  
However it may also reflect the state of research into pharmaceuticals in the environment. 
Research into PhACs began with a focus on detecting PhACs in aquatic and soil 
environments, but has now progressed into effects assessment, and will, if evidence of 















Figure 5.5.  Movement of the focus of research on PhACs in the environment from 
exposure/environmental occurrence, to effects, to pollution prevention.
research 
focus



















Research Need Category Times Mentioned 
Detection of sub-lethal, chronic effects Effects 11 
Fate, persistence,  transport Exposure 9 
Environmental concentrations: exposure Exposure 5 
Systems for testing effects (risk assessment); 
use of appropriate endpoints 
Effects 5 
Wastewater and drinking water treatment 
methods 
Pollution prevention 5 
Analytical chemistry: methods development Exposure 4 
Ecosystem & population level effects Effects 4 
Mixture effects Effects 4 
Antibiotic resistance Effects 2 
Effects on/interaction with cell membranes Effects 2 
Hormones and endocrine disruption Effects 2 
Reduction of PhAC release at source Pollution prevention 2 
Extrapolation from mammalian toxicity data 
to ecotoxicity 
Effects 1 
Human exposure through drinking water Exposure 1 
Human health effects Effects 1 
Localized contamination hot spots: effects? Exposure/Effects 1 
Mechanism of Action Effects 1 
Metabolites Exposure/Effects 1 
Modelling Exposure/Effects 1 
Pharmacodynamic effects Effects 1 




Exposure: 21  
Effects: 36 
Pollution prevention: 7 
 
 
Table 5.4  Research needs for the issue of  pharmaceuticals in the environment, 
suggested by interviewees.  Research needs are categorized as being related to exposure, 
effects, and/ or pollution prevention, and the number of interviewees suggesting each 







5.3.4  State of Government Activity 
 
 5.3.4.1  Research 
 Government research on PhACs in the environment is, according to the 
interviewees, more widely distributed throughout the domains of exposure, effects and 
pollution prevention, than priority research areas suggested by the interviewees (Table 
5.5). Governments in Canada, the U.S., and Europe, are conducting extensive 
environmental monitoring studies for PhACs.  Ecotoxicological effects, and 
water/wastewater treatment methods, are also among the research areas most activity 
engaged in by governments internationally.  Governments need to engage in all of these 
research areas, as they have a responsibility to collect and publicize data on local 
occurrences of PhACs in aquatic environments; to contribute to research on effects; and 
also to explore means of preventing the release of PhACs to aquatic environments. 
 
Research Activity Category Times Mentioned 
Exposure: environmental monitoring Exposure 10 
Ecotoxicology: effects assessment Effects 7 
Water and wastewater treatment Mitigation of Release 7 
Fate and transport Exposure/Mitigation 
of Release 
4 
Analytical chemistry: methods Exposure 1 
Antibiotic resistance Effects 1 
Ecosystem-wide effects Effects 1 
Hormones & endocrine disruption Exposure/Effects 1 
Mixture effects Effects 1 
Prioritization of PhACs Effects 1 
Sediment: presence of PhACs Exposure 1 
Exposure: 14.5 
Effects: 13.5 
Pollution prevention: 9 
 








5.3.4.2  Management Action 
 The role of government in management activity to mitigate environmental 
impacts by PhACs has been minimal, although some countries have made greater strides 
forward in this area than others.  Much of the management activity of governments, as 
described by the interviewees, is focused on research and environmental risk assessment 
legislation.  This seems to be the case for both European and North American 
governments, although some European governments seem willing to look beyond risk 
assessment and research.  Interviewee 6 expressed his frustration at the slow pace of the 
Canadian government in moving from research to management action: “You know, the 
Canadian way is to study it to death and then realize it’s a problem when everybody’s 
been saying it for years.”  Even in terms of risk assessment legislation, Canada is behind 
the U.S. and Europe.  The U.S. has risk assessment regulations for pharmaceuticals 
(FDA, 1998); the E.U. has similar regulations for veterinary pharmaceuticals (VICH, 
2000), and has draft regulations for human pharmaceuticals (CPMP, 2001).  Canada has 
indicated an interest in developing risk assessment regulations for pharmaceuticals, but 
progress appears to be hampered by disagreements over whether the regulations should 
fall under the Canadian Environmental Protection Act or the Food and Drugs Act (Health 
Canada, 2005).  Thus, Canada has not produced any draft risk assessment regulations.  
 Many of the risk management strategies beyond environmental assessment 
regulations are incidental to pharmaceuticals, rather than targeted at them.  These 
strategies should not be downplayed, however, as a holistic approach, targeting multiple 
environmental contaminants, may be the best form of environmental management.  
According to the interviewees, in Canada, the U.S., and Europe, governments have 
funded upgrading of wastewater treatment technology; in the E.U., all cities are required 
to have secondary wastewater treatment as a minimum.  Many European countries, 
including Germany, Switzerland, and the Netherlands, incinerate their municipal solid 
waste, rather than sending it to landfill.  This prevents PhACs from leaching into 
groundwater, or from ending up in a wastewater treatment plant through landfill leachate 
collection (pers. comm., D. Andrews, manager of wastewater operations, Region of 
Waterloo, 2005).  Switzerland has enacted regulations to prohibit the spreading of sewage 





surface water by PhACs running off from sludge spread on fields, a phenomenon which 
occurred in the Region of Waterloo (Lissemore, Yang, Hao, et al., 2006).  These 
management activities are often targeted at other contaminants, such as metals, nutrients, 
and pathogens, but they also reduce environmental contamination by PhACs. 
 Some of the most forward-looking initiatives for managing pharmaceuticals in the 
environment have been initiated not by federal governments, but by local governments, 
and in some cases, the pharmaceutical industry.  Stockholm County Council, Sweden, has 
engaged in a major initiative to classify pharmaceuticals according to criteria relating to 
their environmental impacts: toxicity, bioaccumulation, and persistence (Stockholm läns 
landsting, 2005).  Pharmaceuticals receive a score from 0 to 3 for each of these criteria, 
with the total score – the PBT index -- being the sum for the three criteria.  A substance 
with a PBT score of 0 is expected to readily biodegrade, not to bioaccumulate, and to 
have low ecotoxicity; a PBT score of 9 indicates the reverse.  Stockholm County Council 
publishes this information in the form of “Kloka Listan” (‘Wise List’) and encourages 
medical practitioners to select pharmaceuticals with low PBT scores when efficacy, 
safety, and price are comparable.  The council hopes to have the EU adopt their 
classification system and use it to label medications.  In Spain, a pharmaceutical returns 
program has been set up by an association of pharmaceutical companies, SIGRE, to 
collect unused and expired medications.  Consumers can deposit unused and expired 
medications in bins at pharmacies.  By 2002, 92% of pharmacies in Spain were 
participants in SIGRE’s returns program, and 38 million  Spanish citizens participated in 
the program (SIGRE, 2002).  Engagement by multiple levels of government and multiple 
stakeholders such as in the cases of Stockholm County Council and the SIGRE returns 
programs, seems to hold much promise for addressing the management of 
pharmaceuticals in the environment. 
 
5.3.5  Precautionary principle 
 5.3.5.1  Precautionary management action 
 Implementing strategies to manage pharmaceuticals in the environment involves 
taking a precautionary approach (see Ch. 3 for further discussion of the precautionary 





to prevent environmental degradation, despite uncertainty in scientific understanding of 
the impacts of PhACs on the environment.  The precautionary principle is usually 
directed towards risk management, not to risk assessment (Commission of the European 
Communities, 2000; Rogers, 2001).   All interviewees, however, including those working 
only in scientific disciplines, were consulted regarding their views on the precautionary 
principle and its application to pharmaceuticals in the environment.  The interviewees 
with a predominantly scientific background were included because scientists are, today, 
expected to participate in management decision-making (Steel, List, Lach, & Shindler, 
2004) and because the processes of risk assessment and risk management are more 
explicitly interlinked today than in the past (McColl et al., 2000; McGarvin, 2001; 
National Research Council, 1983). 
 A majority of interviewees supported the use of the precautionary principle, as 
illustrated in Fig. 5.6a). Sixty-three percent of the interviewees expressed positive 
opinions towards the principle, including 90% of Europeans, 50% of Canadians, and 40% 
of American interviewees.  When the responses were divided according to sector, 78% of 
academic (university) interviewees were supportive of the principle, as were 58% of 
public sector (government) interviewees and 40% of pharmaceutical industry 
interviewees (Doerr-MacEwen & Haight, 2005).  Figures 5.6b) and c) illustrate the 
number of positive, neutral, and negative responses to the precautionary principle, 
divided according to location and sector, respectively.  Table 5.6 contains examples of 
statements by interviewees considered to reflect positive, neutral, and negative views of 
the principle.  Several interviewees, including some who supported the use of the 
precautionary principle in environmental decision making, raised specific concerns about 
it.  These concerns can be categorized into several main theme areas (Table 5.7): 
Proportionality of the precautionary action, definition of the precautionary principle, 
socio-economic balance, and level of evidence required to invoke the principle.  Risk 
communication and adaptive planning also emerged as minor themes.  Addressing these 
concerns may increase scientists’ comfort with the principle and may minimize the 
divisive, dichotomous arguments which sometimes erupt over the precautionary principle 






5.3.5.2  Precautionary principle and pharmaceuticals 
 Tailoring the precautionary principle to manage the distribution of 
pharmaceuticals in the environment may also help to meet the needs of scientists and 
managers, while leading to the development of optimal management strategies for 
PhACs.  When asked what the precautionary principle meant for pharmaceuticals in the 
environment, 16 of the 27 interviewees stated that it meant management action beyond 
research or the development of risk assessment methodologies and regulations.  However 
many did feel that risk assessment regulations were necessary, although not sufficient, to 
the application of precaution to PhACs.  Seven of the interviewees believed that research 
entailed precautionary management action.  The interviewees who suggested specific 
management strategies as a result of applying the precautionary principle to PhACs in the 
environment, favored,  in particular, enhancement of sewage treatment technology; 
reduction of pharmaceutical over-use; development of ‘green’ (i.e. biodegradable, less 
toxic) pharmaceuticals; and environmental labeling of pharmaceuticals, although other 
management strategies were also suggested.  Two interviewees were concerned about 
possible negative implications: increased costs and difficulties in developing and 
marketing pharmaceuticals, and an artificial goal of zero concentration being set for 
pharmaceuticals in water.  Policy makers may want to consider the positive implications 
of the principle for the management of PhACs, suggested by the interviewees, and avoid 
the negative implications some interviewees were concerned about. 
 
5.3.6  Management Strategies 
 
 5.3.6.1  Management strategies suggested by interviewees 
 Interviewees were asked several questions about potential precautionary 
management strategies for pharmaceuticals in the environment.  Sixty-seven percent of 
the interviewees felt it was very or somewhat important that their government take 
management action to reduce the release of pharmaceuticals to the environment (Fig. 
5.7). They cited mainly evidence of environmental impacts of PhACs, such as the 



























































































Figure 5.6. Views of the precautionary principles, as expressed by a) all interviewees, b) 







Positive Neutral Negative 
“I think the appropriate application of the 
precautionary principle with the intention of the 
Preamble of CEPA and Rio is very appropriate.” 
– Interviewee 1 
“The precautionary 
principle sounds good on 
paper, but you’re still 
right back in the decision 
making process.” 
 – Interviewee 3 
“Probably, I do not 
support the precautionary 
principle…we need to be 
able to make connections 
between the release of 
compounds and 
environmental effects.”  
-- Interviewee 10 
“I think you have to, to a certain extent, 
depending on the agents, and their ability to alter 
ecosystems.  Some of these agents are pretty 
powerful and long-lived in nature, and as such we 
might not have all the evidence, we might not 
have all the pieces of the puzzle, but I think you 
have to assume certain things, where science isn’t 
available.” – Interviewee 12 
“I’m kind of middle of the 
road on it.  I don’t think 
that perceived risk with 
the number of issues that 
are out there, I think it’s 
not a value added exercise 
to try to address every 
perceived risk without 
having at least some 
measure of certainty.”  
– Interviewee 11 
“No I do not.  Again, 
that’s based on the use of 
our public dollars.” 
 – Interviewee 15 
“Yes, very much.  From a scientific point of view 
the precautionary principle is something that is 
not always, where you take positions which are 
not always based on research and data that you 
have obtained via research work.  But as a 
member of this society, I wouldn’t like not to rely 
upon the precautionary principle, because you 
never know what might happen.  And if you have 
indications that there is some hazard to yourself 
or to the environment, one should take action.” 
 – Interviewee 27 
“Different people 
interpret the precautionary 
principle in different 
ways.  My feeling is that 
all risks need to be 
balanced versus economic 
costs and other risks.  I 
don’t know if I can give 
you a yes or no answer.” 
 – Interviewee 7 
“They don’t know what 
they’re doing and it’s 
very complicated what to 
do as a result of saying 
such a thing.  
Precautionary principle.” 
– Interviewee 22 
“Basically yes, but if such concerns can be 
reasonably ruled out, then restrictions should be 
loosened.” – Interviewee 25 
 “I think it’s actually a 
very dangerous 
principle.” 
 – Interviewee 26 
“Yes – It is better to avoid environmental 
problems than to mediate after the fact.”  
– Interviewee 5 
  
“Yes, yes, yes!” – Interviewee 19   
“Yes I do because time is irreversible and 
restoring is always much dearer than acting 
proactive.” – Interviewee 9 
  
“To a point, yes.  When there’s demonstrated 
low-level effects in model organisms, one has to 
assume that it would be true for other organisms.” 
– Interviewee 6 
  
 
Table 5.6  Interviewee responses to the use of the precautionary principle in 
















“It doesn’t mean you ban 
chemicals; it means you take 
an action, an appropriate 
action.  Some people interpret 
the precautionary principle as 
in if there’s any uncertainty, 
you ban it.   And that’s a very 
inappropriate response.”  
– Interviewee 1 
“The Rio Declaration, 
paragraph 15, is 
unintelligible and you 
cannot use it in public 
policy making.”  
– Interviewee 2 





 – Interviewee 
10 
“The question is, it’s 
still a grey area around 
how much information 
is enough…what’s the 
appropriate time to 
jump in?”  









– Interviewee 25 
“  If we put rats in an 
environment and then just fill 
it up with completely 100% of 
this particular compound, 
there’s an additional incidence 
of cancer of say 1 in 100.  
Well yes, that’s true, do you 
take that to the nth degree and 
say we have to remove this 
completely from the 
environment because it’s a 
carcinogen?” 
 – Interviewee 11 
“People need to very 
clearly understand what 
they mean by 
precautionary principle.  
And precautionary 





differently.  And that 
makes a huge difference 
in whether or not you 
…what you think of 
what the precautionary 
principle is.” – 
Interviewee 1 




some of them 
to these 
issues, and 




of an issue.” 
 – Interviewee 
11 
“The precautionary 
principle should apply 
when there’s doubt 
about a risk, but before 
you are allowed to 
have doubt you have 
to investigate, so you 
have to make risk 
assessment, and then if 
you’re left with 
questions of 
uncertainty, then 
…you can go and you 
can say, then we don’t 
want it, because we 
don’t know.”  




have to be 
informed 
properly so that 
they can act 
properly.”  
– Interviewee 9 
“What can you possibly do to 
somebody who needs to take a 
medicine?...Let’s assume it 
does something to the 
environment, let’s say if you 
think of a million people 
taking Advil all across the 
country, what possibly could 
Health Canada do that would 
solve the problem?” – 
Interviewee 22 
“I think that the 
appropriate application 
of the precautionary 
principle with the 
intention of the 
preamble of CEPA 
(Canadian 
Environmental 
Protection Act) and Rio 
is very appropriate.”  
– Interviewee 1 
“No I do not 
[support the 




based on the 
use of public 
dollars.” 
 – Interviewee 
15 
“All the examples I 
read are times where 
with hindsight you 
should have used the 
precautionary 
principle.  So I don’t 
know at this stage, 
how serious it has to 
get, that you use it up 
front.” 
 – Interviewee 20 
Dialogue/ 
Debate: 
“You need a 
dialogue, where 
people can 
actually have a 
debate, raise the 
questions.” 
 – Interviewee 26 
“There’s some people who 
say, you must not do anything 
because you don’t know what 
the future holds…If the guy 
who invented immunization 
was around today, the 
precautionary principle 
wouldn’t allow it to be 
developed.  You don’t know 
what immunization might do 
to people.  But how many 
people’s lives have been 
saved, and the quality of 
that?”  
– Interviewee 26 
“ The thing about the 
precautionary principle 
is that there are already 
diverging opinions 
about what it really 
means, how to use it.” – 
Interviewee 18 
“My feeling is 
that all risks 





other risks.” – 
Interviewee 7 
“The real question is 
how robust is the 
scientific evidence on 
which to base 
judgement as to 
environmental 
risks/threats for 
various types of drug 
molecules.”  
– Interviewee 23 
 
 Table 5.7  Examples of interviewees’ concerns about the precautionary principle, 









































































































Figure 5.7.  Interviewees’ responses when asked how important it was to them that their 
governments take action to reduce the release of pharmaceuticals to the environment. a) 
percentages of total number of responses, b) number of responses in each category 






Interviewee 7 summed up his reasons for recommending management action: “I think 
there are some legitimate concerns about ecosystem protection, aquatic ecosystems, 
especially in effluent dominated waters.” Some also felt that it was important to act to 
address public concerns: “We should be concerned regardless of toxicology because of 
wastewater recycling and risk perception issues – it’s a social psychology issue” 
(Interviewee 14).  Some of those who did not feel it was important for their government 
to take management action at this time argued that scientific evidence of the 
environmental impacts of PhACs was insufficient; for example, Interviewee 1 stated: 
I think it’s critically important that we do the science to support the risk 
assessment, and we shouldn’t take any major action until we know what those 
risks are... We need to make risk-based decisions and we don’t have the tools to 
assess those risks at this point in time, appropriately. 
Others felt that the costs of management action would be too high; Interviewee 15 
explained, “It’s difficult to expend that money when there’s so many other priorities.  I 
think that the public health could be better served through other aspects.”  There was also 
concern that management action might entail inappropriate restrictions on the availability 
of medications:  
If you were to act prematurely, you could find that you are actually leading to the 
withdrawal, thought the political process, of very important medicines for people 
with actually no significant environmental impact at all.  And what are you going 
to follow them up with?...the idea is, if you’re going to make decisions about risk 
management, surely we want to try and make decisions based on knowledge, not 
on ignorance, and certainly not on fear.  And for that reason I think it would be 
premature and irresponsible.  (Interviewee 26) 
These concerns reflect several of those voiced in relation to the precautionary principle; it 
is essential that management action remain proportional, balanced, and account for costs, 
financial and otherwise. 
 The interviewees advocated a number of risk management strategies for PhACs in 
the environment.  Table 5.8 lists management strategies favoured by the interviewees, 





popular risk management strategy among the interviewees was the implementation of 
returns programs for unused/expired medications, coupled with public education about 
the need to return drugs rather than throwing them down the toilet or in the garbage.  
Although the contribution of improper pharmaceutical disposal to the environmental 
loading of PhACs is not well understood – and is generally believed to be minor 
(Heberer, 2002) – Interviewee 16 explained why this was seen as such a positive 
management response: “I don’t think there’s a good feeling for how much of what we 
find in the environment is coming from disposal of unused and expired medication, but I 
it seems like a logical, easy portion to remove.”  Many interviewees advocated risk 
assessment regulations as a basis for further management action, such as labelling, or 
substitution of more environmentally harmful drugs for less harmful ones.  They also 
cautioned, however, that current, traditional risk assessment methods are inappropriate 
and insufficient – better methodologies must be developed for this to be an  
 
PhAC Management Strategy Times Suggested 
Pharmaceutical returns programs & public education for proper 
disposal 
13 
Risk assessment regulations 8 
Improvement of wastewater treatment technology 6 
Environmental labeling of PhACs (for use and disposal) 4 
Reduction of consumption/over-prescription through education of 
medical professionals and public 
4 
Development of ‘green’ pharmaceuticals (better targeted, more 
biodegradable, etc.) 
3 
Improvement of drinking water treatment technology 2 
Substitution of drugs with lower environmental risk for those 
posing greater risk 
2 
Dilution: reduce water use 2 
Best management practices in agriculture 1 
Improved treatment of industrial wastewater (pharmaceutical 
industry) 
1 
Environmental monitoring of PhACs 1 
Source water protection regulations for agriculture 1 
 







effective means of addressing PhACs in the environment.  Interviewee 2 suggested, “that 
researchers use risk assessment for this like for most other things, but we should ask the 
right questions and we should answer the right questions with the right tools, and we’re 
not doing that right now.”  Improving wastewater treatment facilities was also a popular 
option, partly because it was seen as relatively effective, but also because it addressed 
several sources of water contamination:  
[One strategy would be] to come up with guidelines around the treatment of 
domestic wastewater, so that you’re removing these compounds.  Mind you, I 
mean, that relates to a whole bunch of problems that we’re having in terms of 
discharges of untreated or inadequately treated wastewater here in Canada.  I 
mean, most people are appalled, in Europe at least, that there’s places like 
Halifax, St. John’s, Victoria, and other cities, Montreal, in which there’s just 
primary sewage treatment, so it’s not only just the pharmaceutical issue, it’s a 
whole range of issues around adequate treatment of our domestic wastewater.  
(Interviewee 3) 
The variety of strategies advocated by the interviewees suggest that they feel a mixture 
strategies addressing the various stages of the life cycles of pharmaceuticals should be 
used in management. 
 
 5.3.6.2  Views of Potential Management Strategies 
 In addition to asking which management strategies were favored, without being 
prompted with any particular strategy, interviewees from the government and academic 
sectors were asked to respond to a list of strategies both qualitatively, and with a 
quantitative scoring of strategies based on according to effectiveness and feasibility.  Fig. 
5.8 illustrates the scoring of management strategies based on effectiveness and feasibility.  
Pharmaceutical industry interviewees were asked to respond to a similar list based on the 
perspective of the industry, but as most were reluctant to give quantitative scores, only 
their qualitative responses are discussed in this thesis. Advanced wastewater treatment 
scored highest in terms of effectiveness, with an aggregated score of 8.0 out of 10 (Doerr-
MacEwen & Haight, 2006); this is not surprising, as the literature indicates that treatment 





than 95% for most PhACs (Heberer, Feldmann, Reddersen, Altmann, & Zimmerman, 
2002; Sedlak & Pinkston, 2001; Ternes et al., 2003; Zwiener & Frimmel, 2000), 
compared with an average of 60% for secondary wastewater treatment plants (Ternes, 
1998).  Interviewees pointed out that advanced treatment methods would be especially 
appropriate in large municipalities producing high volumes of waste, with existing 
infrastructure to support the advanced technology (Table 5.9).  They also raised concerns, 
however, relating to the expense and energy requirements of the technology, the end-of-







































































































































































Figure 5.8.  Aggregated scoring of management strategies by interviewees, according to 
effectiveness in mitigating the possible environmental impacts of PhACs. 
 
products, among other concerns.  Many of these concerns are reflected in the scoring of 
advanced treatment methods in terms of feasibility (Fig. 5.9); it ranked second to last 
among the management strategies, with an aggregated score of 4.9 out of 10. 
 Reducing the consumption of pharmaceuticals through education of medical 
professionals, to minimize over-prescription, was rated the second most effective option 
(Fig. 5.8), with a score of 7.1.  This option may have scored highly because consumption 
of pharmaceuticals is the main route through which PhACs enter the environment 
(Heberer, 2002) and because reducing consumption addresses the problem in a proactive 





seen as moderately feasible, being ranked 5th out of 8 management strategies (Fig. 5.9), 
with a score of 6.7.  Interviewees were uncertain of the feasibility of convincing doctors 
to reduce over-prescription when they are subject to so much advertising on the part of 
the pharmaceutical industry.  One interviewee from the industrial sector suggested the 
pharmaceutical industry was unlikely to see a need to reduce rates of drug consumption 


















































































































































































Figure 5.9.  Scoring of risk management strategies for PhACs in the environment by 






Positive Aspects/Benefits Negative Aspects/Concerns 
Useful if pre-existing infrastructure good: 
“It depends on the location.  If you have a very 
good system set up in Toronto or somewhere 
else, you have basically all the wastewater 
being treated, you have already some good 
infrastructure, you have a good treatment 
facility, you can put that in, ozonation,   and it 
has been shown that it does remove 
pharmaceuticals and other contaminants as 
well.” – Interviewee 2 
Ineffective if pre-existing infrastructure lacking: “I 
use the analogy you don’t put on a fancy filter on a 
leaky bucket.  You know, you want to fix that first, 
make sure that you don’t have a lot of storm runoff and 
straight line piping where you send untreated sewage 
into the environment and stuff like that, and then you 
start worrying about these things.”  
– Interviewee 2 
Useful for large municipalities: “I think at 
least selectively, I don’t know if we would want 
every single wastewater treatment plant 
everywhere to do that.  Maybe you could phase 
it in, maybe…start with the volume of waste.  
So if you’re a town or 300, compared with a 
town of 3 million…” – Interviewee 16 
End-of-pipe solution, does not address other sources 
of PhAC contamination: “Even if you spend loads of 
money improving your wastewater treatment plants, 
you can have other sources that can contaminate the 
surface water… it’s always better to look at the source 
of your contaminants than to do with kind of end of 
pipe procedure.” – Interviewee 27   
Useful for effluent-dominated waters: “May 
prove to be essential on some works with low 
dilution in the receiving watercourse.” 
 – Interviewee 21 
Treating drinking water may be preferable: 
“I would lean more towards ozonation for drinking 
water treatment.” – Interviewee 5 
Effectively removes PhACs & other 
contaminants: “I certainly think that most of 
the way we should deal with this is better 
treatment.  That’s my overall impression that 
that’s the way to deal with it.  Because there’s 
so much other junk  that’s going through there, 
that people put down, and you know they may 
not be pharmaceuticals products, they could 
actually be antifreeze, it could be brake fluid.  
People pouring it wherever they pour it.” 
 – Interviewee 22 
No systems can get rid of PhACs entirely: 
“We tested a system, one of the most advanced systems 
in the United States, where they used a series of 
membranes including reverse osmosis.  After reverse 
osmosis … there are some pharmaceuticals that make it 
completely through there.  Now the levels are low, 
they’re very much attenuated.  But if you’re not going 
to look at toxicology, you’re going to say, ‘if I detect 
this at any concentration it can’t be there', you’ll never 
win; there’s no treatment process capable of removing 
things to the atomic level.” – Interviewee 15 
 May produce reaction compounds with unknown 
environmental impacts: “Ozonation, the results show 
it can be successful, but the problem is the production 
of reaction compounds, new products.” 
 – Interviewee 8 
 Expensive and politically unpopular: “Very 
expensive. Leads to increases in peoples bills so not 
politically popular.” – Interviewee 21 
 Environmental impacts of energy use to run 
upgraded plants: “What we have to try to do, as the 
environmental portion of the company, is to think 
holistically about these things.  And if the 
environmental impact was greater on the atmosphere, 
because of running much higher complexity and more 
energy expensive wastewater treatment plant, with no 
environmental benefit, why do it?  To me that would be 
a step backwards.”  – Interviewee 26 







Positive Aspects/Benefits Negative Aspects/Concerns 
Help medical professionals to consider 
environmental impacts: “Education programs 
aimed at medical communities would encourage 
doctors and vets to think more about antimicrobial 
resistance and environmental impacts.” 
 – Interviewee 10 
Cannot compete with marketing by 
pharmaceutical industry:  “I don’t think it would 
work very well.  Over-prescription is driven in the 
U.S. by advertising and I think that the  
environmental concern is not going to affect that.” 
– Interviewee 7 
Allows for substitution of more environmentally 
friendly drugs: “I think that’s appropriate, again 
it’s management strategies that probably could be 
easily implemented and you could take that a step 
further and say well, at some point in time if you 
identify a bad actor, not ban it necessarily, but say if 
it’s an either or situation, here’s the one that’s 
environmentally friendly.  So equipping physicians 
to make an appropriate decision is a good thing.” 
 – Interviewee 11 
 
Need very early education to have an effect: 
“The education comes so often from the 
pharmaceutical industry to practitioners.  There’s 
that sort of, you come into a practice, and you 
adopt a practice norm in terms of pharmaceutical 
use.  And what’s there to alter that?  Usually it’s a 
pharmaceutical rep that comes in and says, here’s 
this wonderful drug.  So it’s tough, I think there 
has to be a very strong education program back at 
the veterinary or medical school; an early level of 
education.” – Interviewee 12   
 Government supports as part of health & 
environmental education: “Part of the education 
process, Health Canada tries to promote knowledge 
and promote best practices; Health Canada would 
be for this.” – Interviewee 13 
Industry does not feel medical practitioners 
over-prescribe: “The industry is going to be very 
cautious to make it appear that their customers are 
abusing their drugs, so I think they’re going to say, 
but we do that in our labelling, we give very 
specific instructions as to how drugs should be 
used.” – Interviewee 24   
Beneficial to human health: “Good idea for human 
health, not just pharmaceuticals” – Interviewee 14 
Patients demand drugs: “[It is] important to 
reduce quantities of pills sold…the problem is, 











Table 5.10.  Interviewees’ comments on education of medical professionals to reduce 






Pharmaceutical return programs coupled with public education regarding drug 
disposal, was ranked 3rd in terms of effectiveness, together with requirements for 
secondary wastewater treatment, with a score of 6.8.  This is in some ways surprising, as 
pharmaceutical disposal is considered a minor contributor to the environmental loading of 
PhACs, as some interviewees pointed out (Table 5.11.)  The score may reflect 
interviewees’ support for returns programs for a variety of reasons, including public 
awareness.  Pharmaceutical returns programs were ranked 2nd in terms of feasibility (Fig. 
5.9), with a score of 7.8.  Many European interviewees indicated that their countries 
already have returns programs (Table 5.11) and while legal barriers may make such 
programs less feasible in the U.S. (Table 5.11), their legislated existence in the Canadian 
province of British Columbia (Government of British Columbia, 1997) suggests they 
could be more extensively used in Canada. 
 The lowest score in terms of effectiveness was given to environmental risk 
assessment regulations, with a score of 5.4.  This is somewhat ironic, as appears to be the 
only management strategy, other than research, in which many governments currently are 
officially engaged (Section 5.3.4.2) (CPMP, 2001; FDA, 1998; Health Canada, 2002), 
and was the second most popular suggestion as to risk management strategies among the 
interviewees.  This may reflect a dichotomy between the ideal capacity of risk 
assessment, in terms of producing an understanding of the risk of PhACs and the real 
effectiveness of the process.  As many of the interviewees have a scientific background, 
they value the rational, science-driven basis for management provided by risk assessment.  
For example, several interviewees, including Interviewees 1 and 26, iterated several times 
throughout the interview, the need for a “risk-based approach” to the management of 
PhACs in the environment.  Some of these positive views of risk assessment are shown in 
Table 5.12.  As experts on pharmaceuticals in the environment, however, the 
interviewees also recognize that traditional risk assessments do not address the questions 
they are asking regarding pharmaceuticals in the environment: What are the chronic, 
sublethal effects?  What are the effects of mixtures (see Section 5.3.3)? Furthermore, the 






Positive Aspects/Benefits Negative Aspects/Concerns 
Effects on public awareness: “I think it’s a good 
program.  I think it will have a minor impact on the 
actual release of pharmaceuticals into the 
environment.  But it’s going to have a big impact on 
public perception of environmental issues.”  
– Interviewee 1 
Must ensure proper disposal after return: “As 
long as they’re taking care of it in an appropriate 
way.  You know, yeah, I take it back and they put 
in a landfill that has no leachate collection system, 
and guess what? Or that does have a leachate 
collection system and then pumps it back into the 
wastewater collection system!” – Interviewee 11  
Would be used by public: “If that could be 
implemented it would probably be something that 
the general public would use. Everyone’s got stuff 
up in the cupboard that it’s been there for a while, 
and I’m never going to use it again, and it kind of 
sits there for ten years.” – Interviewee 11 
U.S. law makes returns difficult: “The U.S. is 
different – the law says you can’t return drugs to 
the pharmacy because of the Controlled 
Substances Act; you can’t transfer controlled 
substances to anyone that the substance wasn’t 
prescribed to. U.S. pharmacies contract with 
reverse distributors but not for anything that was in 
consumers’ hands.  Maine has passed legislation 
for mail returns program but they don’t have the 
money to do it.” – Interviewee 14 
Legislation of returns programs creates level 
playing field for industry: “Right now for 
pharmaceuticals, we are paying a fee for getting rid 
of the containers in Ontario.  Not yet for the 
contents.  If you legislate it, it will work.  It can’t be 
voluntary.  Because voluntarily you’ll get all kinds 
of different companies giving reasons why I should 
only pay 0.1, and you should pay 0.3.” – 
Interviewee 22   
 
Questionable success of public education: “You 
know, human nature, I don’t know, I’m often quite 
sceptical of these public education campaigns.  
They often show effectiveness right after, and then 
someone looks back in a year and they’re 
reversed.” – Interviewee 12 
Especially helpful for products like patches and 
creams: “Yes, it may help to some extent.  In 
particular when it comes to containers, 
administration routes, patches or creams.  With 
above all hormones.  Because the fraction that is 
absorbed is very small, it’s a few percent in a week 
or so.” – Interviewee 19 
 
Limited effect on environmental concentrations 
of PhACs: “That won’t help at all.  I’m working 
with PHR, the pharmaceutical manufacturers’ 
association.  And they’ve already done this 
calculation, and it would not change the 
concentration in the environment at a measurable 
level.  The amount of things dumped down the 
toilet is so small, compared to the amount 
ingested, especially for the new pharmaceuticals.” 
– Interviewee 15 
Good for child safety: “There is a program here in 
Germany, that private households are asked to 
return their pharmaceuticals to the pharmacist.  I 
think this has been set up because of safety reasons, 
for children, to make sure that the risk for children 
to take some pills is reduced.” – Interviewee 27   
 
Public eager to engage: “Already done in Spain: 
people are very active once the problem is explained 
to them.” – Interviewee 8 
 
Table 5.11.  Interviewees’ comments on pharmaceutical returns programs together with 







Positive Aspects/Benefits Negative Aspects/Concerns 
Detects substances with acute effects:“I think that 
the systems we have are good at picking up any 
immediate effects; immediate effects would be 
picked up by the assessments.  We build in safety 
factors, we use reasonable worst cases, and we use 
assessment factors to adjust for different species.” – 
Interviewee 20   
Existing risk assessment methods 
inappropriate: “We need to ask the right 
questions, answer the right questions with the right 
tools, come up with the right answers.  We don’t 
do that very effective right now… If you look for 
new problems in an old-fashioned traditional way, 
you’re not going to find them.” – Interviewee 2 
Creates fair playing field for industry: “What’s 
very important is for commerce and for innovation, 
is to have that actually working on a level playing 
field, so that the different pharmaceutical companies 
are able to work to the same standard, and innovate 
to the same context.  So there is a role for 
transparent, sensible environmental regulation and 
its application.” – Interviewee 26 
Red tape & ignores real-life conditions: “You’re 
taking it in isolation from other compounds and 
the actual real environment, I mean you’re not 
going to go out and do that kind of environmental 
impact assessment at environmental conditions.  
So one of the down sides is it certainly adds more 
red tape to the overall approval process.” – 
Interviewee 3 
Helps develop management strategies: “There 
could be a case where you’re wanting to 
manufacture a drug, where you gather information 
as you’re required to do by law…[and] using 
information on the ecotoxicology of drugs or on its 
fate in the environment to help you design a 
wastewater treatment plant.” – Interviewee 26 
Real-life conditions not accounted for: “They 
may be looking more at acute effects, whereas 
long-term chronic low-level is really more of a 
concern.  What we haven’t mentioned today is the 
mixture issue – throwing a bunch of low level 
compounds together as a mixture in a stream, may 
have some unanticipated effects.  My current 
understanding is that it wouldn’t test for mixture 
effects.  It’s still a good idea, I just am not sure it 
would catch all the unanticipated effects.” – 
Interviewee 16 
Helps develop management strategies:  “The 
legislation states that it is intended to be used for 
labelling.  So you have to make a risk assessment, 
and where necessary or where possible, indicate 
how this risk can be reduced as much as possible… 
If you have the data, authorities can use it to make 
their management decisions.”– Interviewee 19 
Futile to try to prove absence of risk: “On an 
epistemological side, [there is] also the 
impossibility of rigorously proving the absence of 
risk with tests and strategies developed for 
evidencing the presence of effects (there will never 
be any certainty about safety)” – Interviewee 25 
 Banning not possible, so no clear management 
outcome: “For human pharmaceuticals in Europe, 
the directive says, banning a compound for 
environmental reasons, is not allowed, is not 
possible, for ethical reasons.  But what are you 
going to do with that information, that’s what I 
mean, there’s no clear scheme with regards to risk 
management.” – Interviewee 27 
 No clear management outcome: “Nobody’s 
found a practical control at the end, what you 
would do.  Are you saying you would actually not 
approve a medicine?  So you’re submitting data, 
people are spending time, effort, energy getting all 
these documents, and then they just approve it 
anyway.” – Interviewee 22 
 Many PhACs below assessment cutoff level 
“Most pharmaceuticals don’t exceed the 1 ppb 
cutoff, so they don’t get assessed” – Interviewee 
14 






regulations exist without a clear purpose; the assessment process is not linked to any 
management outcomes (Table 5.12).  Thus, while implementation of risk assessment 
regulations is seen as feasible (Fig. 5.9),  it is understandable that the interviewees believe 
risk assessment as it exists now is ineffective, but that it has potential as a future 
management strategy, as indicated by their responses in Section 5.3.6.1.  
 Incentives for the development of ‘green drugs’ were ranked as 7th out of 8 in 
terms of effectiveness, and last in terms of feasibility, with scores of  5.6 and 4.4, 
respectively.  The view that this strategy was ineffective and infeasible was not shared by 
all interviewees, however, as individual effectiveness scores ranged from as low as 0.5 to 
as high as 10, and feasibility scores ranged from 0 to 10.  The strong, polarized opinions 
on incentives for ‘green’ drug development are reflected in Table 5.13, with Interviewee 
1 calling the management strategy “naïve”, while Interviewee 13 called it a “great idea” 
(not shown in Table 5.13), and two interviewees from the pharmaceutical industry stated 
that the development of ‘green’ pharmaceuticals is already being pursued by the industry. 
 The remaining management strategies, all involving some aspect of wastewater 
treatment, received moderate scores in terms of effectiveness and feasibility.  Requiring 
all municipal WWTPs to have secondary treatment as a minimum, treating hospital 
wastewater separately with advanced methods, and optimizing existing wastewater 
treatment plants without upgrading technology, were all seen as similarly effective, with 
scores of 6.8, 6.7, and 6.3, respectively.  Interviewees suggested that each of these 
strategies would contribute somewhat to reducing the release of PhACs to aquatic 
environments, but that they would not be sufficient to prevent the bulk of the 
environmental PhAC loading (Tables 5.14, 5.15, 5.16).  In terms of feasibility, requiring 
all municipal WWTPs to use secondary treatment as a minimum, received a high score of 
7.9 to rank first among the management options.  European interviewees explained that 
secondary treatment was already required in their countries.  Many North American 
interviewees felt that as secondary treatment was already widespread, it would be feasible 







Positive Aspects/Benefits Negative Aspects/Criticisms 
PhAC manufacturers, like manufacturers of 
other substances, responsible for preventing 
impacts: “They [drug manufacturers] should be 
encouraged to look in these directions, and I think 
that they will.  I mean they will realize that they 
are producing chemical in relatively large 
amounts that will be released into the 
environment, just like a number of other 
industries, and they will have to take that into 
account.” – Interviewee 2 
Drug development process too complex and 
difficult:  “It’s a naïve idea.  The drug discovery 
process is extremely complex and extremely 
serendipitous, and to think that we’re going to be 
able to fund people to find green drugs is a needle in 
a haystack.” – Interviewee 1   
 Addresses environmental concern at source: 
“You’ve got to get to the source of the problem 
and make sure that you produce environmentally 
safe products like for anything else.  Then you 
don’t have to worry so much about effects and 
treatment.” – Interviewee 2 
Drug development process too complex and 
difficult: “If it was possible, yes maybe, but I don’t 
think we realize the complexity of trying to come up 
with something that has a certain affinity for 
receptors in the body, certain blockage, and then 
trying to say, “How can I change the molecule so it’s 
still effective, still interacting with this receptor, but 
also biodegradable?”.  I do not see that as a viable 
option.” – Interviewee 15 
Green pesticides exist, so green drugs can be 
made: 
“It would be possible to do from a scientific 
perspective because has been done with 
pesticides; the pesticide industry now makes 
rapidly degrading substances.” – Interviewee 17 
Drug development process too complex and 
difficult: “Extremely difficult already to find a 
molecule that does a defined job, has low incidence 
of adverse effects and other attributes for a ‘good’ 
pharmaceutical; adding further requirements will 
considerably reduce success chances.” – Interviewee 
25 
Toxicity and biodegradability can be changed: 
“The industries will see that there’s ways that 
they can either reduce the toxicity of the 
compounds or increase the biodegradability of the 
compounds and don’t get high exposures in the 
environment.” – Interviewee 2 
Drug development process too complex and 
difficult: “The problem is what’s degradable in the 
environment is going to be rapidly degraded in the 
body.  So you’d have to develop drugs that would be 
effective quickly, which means more potent, which 
means more risk.  So this is the problem that we face, 
and it may not be resolvable.” – Interviewee 6 
Include all ingredients in environmental 
considerations: 
“It’s important…all ingredients should be looked 
at, not just the active moiety.” – Interviewee 8 
Drug development process not driven by 
environmental concerns: “I think it’s very unlikely 
that it would work.  I think the drug development 
process is driven by a lot of other things, there’s a lot 
of money that goes into that, so I think you’d have to 
offer large incentives to get them to do that.  So 
they’re going to do what they’re going to do 
anyhow.” – Interviewee 7 
 
Table 5.13.  Interviewees’ comments on incentives for the development and 






Means of administering drugs can be made 
‘greener’:“New application methods like the use 
of patches, smaller packages, more specific 
prescriptions, for example gender-specific doses, 
are needed.” – Interviewee 17 
Drug development process too complex and 
difficult: “It’s a hard thing to find a good drug now.  
And if we had the potential to do it, we would do it.  
Because we’d love it.  It would be great for us, if you 
could find such a thing, it’s good.  But I’m saying 
it’s so hard right now to find drugs that work, that 
pass all the tests, that  get approved by FDA, by the 
government of Canada, it’s so hard to find stuff like 
that already.”– Interviewee 22  
Image concerns will drive manufacturers to 
produce ‘green’ drugs: “I think the funny thing 
is that the pharmaceutical companies, and the 
researchers, they are actually greener than the 
governments are.  So they are actually, they have 
a lot of good thoughts and are really researching 
to make this work.  It think it’s also in the market 
it’s better to be green, good for your health.  It’s 
something they are quite afraid of is of having a 
name, saying that it’s a very bad drug.  Because if 
it’s bad for the environment, how good can it be 
for health?” – Interviewee 18 
Drug development process too complex and 
difficult – consider other forms of green 
chemistry:“I think that it’s a very very complex 
area, and as a scientist, I think we should be very 
sober about what science can deliver in this area.  
But there’s an aspect of this question that I think is 
much more tractable, and that’ s actually greening, 
making more green, the total production process of 
drugs.  This is basically what green chemistry is.  
This process of trying to build environmental 
considerations into your drug development 
processes, as much as possible.” – Interviewee 26 
Market forces will drive production:“I think 
it’s the market that drives it… Often, I’ve noticed 
the companies that are trying to develop these are 
small, independent groups that would never have 
much of a market share… they will develop in 
order to meet the market need.”– Interviewee 12 
Not as easy as people think: “So I think it’ s a bit of 
a holy grail, this idea, from an honest scientific 
opinion, I think it actually could be a holy grail.  And 
what I’m a bit scientifically nervous about is when 
these articles get published in some journals, some 
people think that it’s easy.  They really think that 
finding safe new medicines is easy.”– Interviewee 26 
Regulatory concerns will drive development of 
‘green’ drugs: “I know the companies are 
concerned about having to provide phase 2 data 
[because of risk assessment regulations], it’s an 
extra development cost.  So I think if they could 
develop greener products, if you like, which in 
our case would stay in phase 1 [of the risk 
assessment], then you wouldn’t need to give them 
any incentive other than to point that out to 
them.”– Interviewee 20 
Drug development process too complex and 
difficult: “Structure and function are inextricably 
linked.  The attrition rate for drug candidates is 
already very high based on safety, efficacy, stability 
and manufacturing requirements.  Adding yet 
another requirement with respect to biodegradability 
for the structure of these molecules will probably 
result in a massive increase in the attrition rate of 
drug candidates.” – Interviewee 23 
Incentives may convince manufacturers to 
invest in developing ‘green’ drugs: “I think in 
the short term, one of the most effective things 
that one could do would be to look at those 
classes of products that appear to present the 
largest potential problems: statins, beta blockers, 
estrogens, and offer commercial incentives for 
organizations to come up with new products that 
would have reduced environmental impact.”  
– Interviewee 24 
 
Green drugs already being developed: 
“We are already developing and marketing 
several such active substances.” – Interviewee 25 
 
Table 5.13.  Continued from previous page.  Interviewees’ comments on incentives for the 





Positive Aspects/Benefits Negative Aspects/Criticisms 
Lower environmental concentrations of PhACs 
than without secondary treatment: “I think that 
secondary treatment should be a minimum standard, 
for a lot of reasons.  If we don’t have secondary 
treatment, you will have a hundred to a thousand 
times higher concentrations of pharmaceuticals in 
the environment, so, yes, secondary treatment is 
critical in the management of pharmaceuticals.”  
– Interviewee 1 
Financial strain for municipalities: “It comes 
down to money.  Municipalities are responsible for 
investing in it, and without some incentives for 
providing the funding to municipalities, I think 
that’s going to be a problem.”-- Interviewee 3 
 
Improving water quality in general: “I would 
think that it would be desirable that all systems at 
least have secondary treatment but that would 
achieve additional objectives other than dealing 
with these classes of substances.”  
– Interviewee 4 
 
High financial cost: “Last time we looked at it in 
detail, in the late 80s, it was about 4 billion dollars 
for Ontario to come up with secondary treatment.  
It’s probably significantly less than that now, 
because a lot of systems have gone that way.  But 
to require it to deal with PPCPs wouldn’t be value 
added.” – Interviewee 11 
 Little change in PhAC concentrations 
compared to current levels: “If you’re looking at 
a national issue, no it wouldn’t help at all, because 
everyone almost already has secondary.  So at a 
national scale it wouldn’t make at a big difference. 
Not at a broad scale.”  – Interviewee 15 
Table 5.14.  Interviewees’ comments on requiring all WWTPs to use secondary treatment 
as a minimum. 
Positive Aspects/Benefits Negative Aspects/Criticisms 
Easy to implement and cost effective: “I still think 
optimizing existing treatment systems once the priorities 
are identified would be an option that could be readily 
implemented and very cost-effective.  If you identified that 
a certain compounds was really, was a compound of 
concern, and you could triple its removal by increasing 
your SRT, solids retention time in the plant, if the negative 
impacts of doing that were not as much of a concern, why 
wouldn’t you do it?” – Interviewee 11 
May not be effective:  “Some drugs pass 
through the STP without being affected at 
all, and others are degraded to some extent.  
For those that are degraded of course, a 
longer retention time would be sufficient.  
But I think it’s a half-efficient method.” – 
Interviewee 19 
 
Can address several environmental contaminants:“Yes, 
it’s a great idea.  Again, a lot of these things tie in and 
happen at the same time; if you’re getting lower BODs, 
CODs, lower nutrients, you’re probably getting lower 
pharmaceuticals too.  You know, in general there’s a few 
compounds that are pretty sneaky at getting through, but in 
general that’s what I always suggest to our utilities, do the 
best you can.  Deal with what you’ve got, try to keep your 
SRTs and things like that as high as you possibly can, yes I 
think that’s a good idea.”– Interviewee 15 
May not be effective: “I really don’t know 
how well that works and how much room 
there is for optimization. The plants aren’t 
really made to get rid of pharmaceuticals.” 
 – Interviewee 18 
 
Cheaper option than upgrading technology: “An 
obvious choice before going to the expense of an 
upgrade.” – Interviewee 21 
 
Must be sure not to sacrifice other 
treatment objectives: “Consistent with 
meeting other treatment objectives, that’s 
only one objective.” – Interviewee 4 






Positive Aspects/Benefits Negative Aspects/Criticisms 
Important for harmful or persistn PhACs like 
antineoplastics: “Some of the anti-cancer drugs 
and some of the contrast media, things like that, 
are things that I think we should be concerned 
about from hospitals.  It doesn’t have to be a big 
complicated system, you just do some pre-
treatment which may then allow a sewage 
treatment plant to do the second part of the job.”  
– Interviewee 1 
Many PhACs used outside of hospitals:  
“I think that what we’re seeing is a lot of general use 
across the broad and it’s certainly not going to be in 
the hospitals, it’s going to be in clinics, it’s going to 
be in the home, some of these advanced drugs they 
take them at home, chemotherapy, is at home,  so 
having a treatment system in the hospital won’t help 
you.” – Interviewee 11 
Important for persistent compounds & those 
used largely in hospitals: “Good idea because 
some compounds appear in hospitals only and are 
difficult to remove, like iodinated contrast 
media…some compounds like antibiotics are 
produced on a large scale in hospitals.” 
 – Interviewee 8 
May not help at national scale: “Would it help the 
loading on a national level, I don’t think so, but I 
think there are advantages to doing it beside the 
pharmaceuticals.” – Interviewee 15 
 
Already exists in Europe: “That’s already 
occurring, and least in Europe, hospitals have to 
have their own sewage treatment, their own 
wastewater treatment, enhanced.” 
 – Interviewee 2 
May be more effective to improve municipal 
WWTPs: “In Germany cytostatics must be 
incinerated… for other aspects in hospital, there are 
not necessarily more medications used, plus it would 
be more useful to target the big picture with 
municipal wastewater treatment plants, so better to 
improve municipal sewage treatment plants.” – 
Interviewee 17 
 
Useful for large hospitals:  “If you have a big 
hospital that already has it’s own system, then 
you can say that’s the place where very likely you 
can put in the advanced treatment.” 
 – Interviewee 18   
 
 
PhAC levels in hospital wastewater relatively low: 
“No, it’s no use at all.  This is a common 
misunderstanding because sewage from hospitals 
usually contains less pharmaceuticals per litre than 
sewage from hospitals.  And you know why?  
Because in a hospital, there is usually 10 staff on 
each patient, that is the average, if you look on a 24 
hour basis.  And the use of water in a hospital per 
person is much higher than in a household.  So the 
dilution is more substantial.” – Interviewee 19 
Use of urine separation before treatment:  
“People in Switzerland from EAWAG… they 
promote very much urine separation processes in 
hospitals.  Those would be measures that can be 
applied.” – Interviewee 27 
Can only be done in new hospitals and only 
removes 30% of municipal PhAC load:  
“Only possible in new constructed facilities and only 
30 % of the total load in municipal sewage will be 
collected.”  – Interviewee 20 
 






however, were concerned about the cost of such upgrades. Optimization was also seen as 
feasible, with a score of 6.9.  The low cost of this strategy made it politically palatable, 
although some interviewees questioned whether it was possible to optimize plants for 
PhAC removal without reducing the removal of other contaminants (Table 5.15).  
Separate treatment of hospital wastewater scored somewhat less well in terms of 
feasibility, at 6.1, largely because of the cost of such treatment (Table 5.16).  Both 
feasibility and effectiveness are important considerations in the selection of management 
strategies for PhACs. 
 
 5.3.6.3  Perspective of the pharmaceutical industry 
 Interviewees who were members of the pharmaceutical industry were asked about 
the industry’s perspective on various management strategies.  Their responses suggest 
that the pharmaceutical industry must not be seen as a uniform body, but as a diverse 
group, within which there are a variety of views on PhACs in the environment.  For 
instance, Interviewees 24 and 25 were advocates of the concept of ‘green’ drug 
development, with Interviewee 25 stating that his company already develops such 
products.  Interviewee 24 commented, “it becomes entirely feasible, when there’s a 
commercial advantage.” Interviewee 24 believed that incentives such as patent extensions 
for companies which produce green drugs, would provide a commercial advantage.  
Interviewee 22 seemed initially sceptical of the concept, but thought the idea of providing 
companies with incentives for manufacturing green drugs “sounds like it would be 
helpful.”  He questioned, however, the feasibility of using patent extensions in fair 
manner, without allowing for loopholes.  Interviewees 26 and 23 were unreservedly 
opposed to the idea of developing ‘green’ drugs, suggesting that the drug development 
process was too complex to be able to include environmental considerations (Table 5.13).  
However, Interviewees 22 and 26 pointed out that the pharmaceutical industry does 
contribute to the protection of the environment by implementing green manufacturing 
processes, which minimize the use of solvents, and by treating wastewater from the 
manufacturing process with highly advanced technology.   
 Because of suggestions by Waterloo Region residents that the pharmaceutical 





PhACs (Ch. 4), interviewees were asked if they thought their companies might contribute 
to pharmaceutical returns programs, including public education, or to the upgrading of 
municipal WWTPs.  While support for enhancing wastewater treatment in general varied, 
not surprisingly, none of the interviewees felt the pharmaceutical industry should be 
asked to contribute to the cost of upgradient municipal WWTPs.  Interviewee 22 
suggested that it was not clear who should be considered responsible for environmental 
contamination by PhACs: “While the patients are taking the medicine, who’s 
responsible?  Is it us?  The doctor who prescribed the medicine?  The patient who gets 
treated by it?  So I think it’s a much more complex issue.”  Interviewee 24 was very 
concerned about the industry being saddled with the cost of upgrading WWTPs: “Frankly 
this is what I’m afraid of here in the United States, that if the industry doesn’t get out 
front of this issue, then a frustrated legislative body is basically going to pass a law 
saying, ‘you do it.’”.  The response to pharmaceuticals returns programs was somewhat 
more positive, with Interviewee 22 suggesting that manufacturers might contribute to 
such a program, as long as a level playing field was created through legislation (Table 
5.11).  Interviewees 24 and 26, while not vehemently opposed to returns programs, 
questioned their effectiveness. 
 Risk assessment legislation received a relatively positive response from industry 
interviewees.  Interviewee 26 believed that data collection through risk assessment 
regulations was essential, but emphasized the need for such regulations to be transparent, 
criticizing the use of assessment factors (safety factors), and universalized, reducing the 
need for extra experimentation to provide slightly different data in different countries.  
Interviewee 22 was concerned about the lack of clear risk management outcomes as a 
result of risk assessment, and expressed a view of risk assessment as purposeless 
paperwork (Table 5.12).  Interviewee 24 was, on one hand, concerned about regulatory 
action, but felt, on the other hand, that restrictions on registration of environmentally 
harmful drugs, where better alternatives existed, might lead to the creation of a market for 
‘green’ drugs:  
Environmental impact becomes a significant factor in not only the decision to 
approve a new medicine, but also in decisions to potentially withdraw existing 





alternatives exist.  The take home message from that becomes the environmental 
impact of your new pharmaceutical becomes a significant factor in the overall 
commercial success of that compound, not only in terms of whether or not you’re 
going to register it, but how long you’re going to be able to keep in on the market.  
So that what should happen is companies thinking about discovering and 
developing new medicines will start to plan from the get-go how to manage the 
environmental fate of their molecules, in terms of potentially building into the 
actual chemical scaffold an environmental degratory mechanism, a sensitivity to 
ultraviolet light, for example.   
The interviewee also cited a case where risk assessment led to the registration of an 
estrogen patch being refused for environmental reasons, because 90% of the active 
ingredient would remain in the patch after use and environmentally friendly alternates 
were available.  Thus, pharmaceutical industry interviewees were divided in their views 
of most management strategies, including risk assessment regulations, the manufacturing 
of ‘green’ drugs, pharmaceutical returns programs and upgrading wastewater treatment 
facilities. 
 
5.4  Conclusions 
 The interviewees had mixed opinions on the science and management of 
pharmaceuticals in the environment, although some interesting trends and tendencies 
were observed.  Interviewees generally saw PhACs in the environment as both a human 
health and an ecosystem health concern, although they believed it was more likely that 
PhACs would have serious or irreversible impacts on aquatic ecosystems than on human 
health.  They ranked pharmaceuticals below some well-known water contaminants such 
as nutrients, pesticides, and metals, in terms of need for management action, but above 
localized contaminants such as organic solvents and road salt.  European interviewees 
ranked PhACs higher than North American interviewees, and also tended to favour the 
use of the precautionary principle in environmental decision making.  Interviewees 
generally saw the uncertainty surrounding the scientific understanding of the impacts of 
PhACs on aquatic ecosystems as high; they suggested that research to improve the 





interviewees, governments internationally are conducting research on environmental 
exposure and effects of PhACs and pollution prevention, but are engaging in little 
management action other than introducing risk assessment legislation.  Although many 
interviewees said they would like to see risk assessment regulations implemented, they 
viewed them as ineffective as a means of mitigating the environmental impacts of 
pharmaceuticals.  Advanced wastewater treatment technology, education of medical 
professionals to reduce over-prescription, and pharmaceutical returns programs coupled 
with public education, were seen as the most effective management strategies for PhACs.  
Among these, pharmaceutical returns programs were seen as the most feasible 
management strategy and received some support from interviewees from the 
pharmaceutical industry.  The views of the interviewees on the nature of the problem of 
PhACs in the environment, on research needs and on potential management strategies, 
will be of use in evaluating precautionary options to mitigate the release of PhACs to the 
environment. 
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Chapter 6: Analysis of policy strategies for human PhACs in the environment 
 
6.1  Introduction 
 The ubiquitous presence of human pharmaceuticals in aquatic environments, 
coupled with concerns about the effects of these substances on ecosystems (possibly 
including humans), requires that management action to mitigate the release of 
pharmaceuticals to the environment be evaluated and possibly implemented.  As 
discussed in Chapter 3, under circumstances of scientific uncertainty such as those 
surrounding PhACs in the environment, the precautionary principle demands that 
reasonable action be taken to protect the environment.  The principle allows for such 
action to be taken without a quantitative risk assessment; qualitative assessment of risk is 
sufficient (Commission of the European Communities, 2000; McCarty & Power, 2000).  
Chapter 2 discussed evidence of risk in the form of findings of PhACs in surface water, 
groundwater, and drinking water, internationally, as well as in the form of discoveries of 
subtle, chronic effects of PhACs on aquatic organisms in field and laboratory studies.  
Chapter 4 furthermore presented evidence that PhACs are entering natural waters in a 
Canadian municipality; evidence of pharmaceutical contamination of the Canadian 
environment is supported by other researchers’ findings of PhACs in wastewater effluent 
and in surface water in several Canadian towns and cities (Lee, Sarafin, Peart, & 
Svoboda, 2004; Metcalfe et al., 2003).  Finally, Chapters 4 and 5 presented evidence 
suggesting that stakeholders are concerned about the presence of pharmaceuticals in the 
environment and would for the most part be in favour of some form of management 
action to mitigate environmental contamination by PhACs.  On the basis of scientific 
evidence of the presence and possible effects of PhACs in the environment, stakeholder 
concerns, and the precautionary principle, it is suggested that the development of 
management strategies to mitigate the release of PhACs to the environment is needed. 
 This final chapter involves an analysis of policies to reduce the release of PhACs 
in general, and more specifically those most likely to have detrimental effects, to the 
environment, with a predominantly Canadian context.  This is the ‘decision’ component 
of the risk management framework shown in Chapter 3, Figure 3.2, or the ‘options 





discussion of policies or management strategies is applicable internationally, but in 
certain circumstances policies appropriate for Canada are not appropriate elsewhere.  In 
particular, legal complications (as reported by several Ch. 5 stakeholders) make returning 
unused medications to pharmacies in the U.S. very difficult and under-consumption of 
medications in the Netherlands (as reported by a Ch. 5 stakeholder) makes reducing 
pharmaceutical consumption less feasible in that country.  Some discussion of 
jurisdictional issues related to the management of PhACs in Canada is included in 
Section 6.7., but in general jurisdictional issues are beyond the scope of the analysis. 
 
6.2.  Methods 
 Multiple methods for the analysis of policies exist, ranging from traditional, often 
quantitative forms of analysis, to highly qualitative, post-positivistic forms of analysis 
(Hanberger, 2001; Linkov et al., 2004).  Multi-criteria decision analysis (MCDA) is a 
popular form of quantitative, mathematical policy analysis, in which stakeholders or 
decision makers give policies numerical scores according to how they perform on certain 
criteria, whose weighting allows for the calculation of an optimal policy choice (Belton & 
Stewart, 2002; Linkov et al., 2004).  Such highly mathematical analysis has been 
criticized, however, for taking a reductionist approach, failing to explore the complexities 
of policy options, creating a false pretense of objective analysis, and insufficiently 
including or improperly addressing values and other normative concerns in the analysis 
(Fischer, 1995; Hanberger, 2001).  Qualitative, post-positivistic policy analysis 
emphasizes the normative, with the view that quantification is neither necessary nor 
desirable (Hanberger, 2001).  However, even post-positivistic, qualitative analysts 
recognize the value of using the structured framework of rational, quantitative policy 
analysis, as long as the analysis is not over-simplified by such an approach (Fischer, 
1995; Hanberger, 2001).  Therefore, the policy analysis method used here is a qualitative 
approach, based on the rational policy analysis framework presented by Patton and 
Sawicki (1993), and used in MCDA approaches (Belton & Stewart, 2002; Linkov et al., 
2004).  It is similar to the methodology used by Barron & Ng (1996) for an analysis of 
solid waste management strategies in Hong Kong.  Because governments usually 





(Barron & Ng, 1996), and as analyses of single policies in isolation have been criticized 
(Falconer, 1998), the management strategies are combined into policy packages using the 
feasible manipulations method of May (1981). 
 
6.3  Policy Goals and Objectives 
 All policies must have broad, overarching goals, as well as more specific 
objectives.  According to Ho (2000), some common goals include justice, economic 
efficiency, economic growth, and sustainable development.  Stone (2002) also describes 
some widely used, broad policy goals: equity, efficiency, security and liberty.  
Sustainable development is related to the goals of equity and security; for example, the 
Bruntland Commission definition emphasizes inter-generational equity: “Sustainable 
development is development that meets the needs of current generations without 
compromising the ability of future generations to meet their needs and aspirations." 
(World Commission on Environment and Development, 1987, p. 43).  Sustainable 
development through pollution prevention, and thereby the protection of the environment 
and human health from the risks of toxic substances, is the overarching goal of the 
Canadian Environmental Protection Act (CEPA, 1999).  As the policy problem under 
consideration here also involves finding ways of protecting human and environmental 
health from potentially detrimental contaminants, and as sustainable development 
encompasses other goals such as equity, sustainable development is chosen here as the 
underlying goal for the policy analysis.   
 Sustainable development is often considered to have 3 main components: 
environmental health, economic prosperity and social equity (Environment Canada, 1997; 
Shields, Šolar, & Martin, 2002).  Although the focus of this policy analysis is 
environmental health in particular, economic prosperity and social equity must also be 
maintained.  An ecosystem approach is taken here, meaning that rather than protecting 
the environment only for the sake of human health and security, the environment must be 
protected for its own sake. Humans are considered part of ecosystems, rather than 
separate from or dominating them (Boetzkes & Scott Robert, 2000; Great Lakes Research 
Advisory Board, 1978; Grumbine, 1994).  Thus a less anthropocentric view of 





 The first policy objective, under the sub-goal of protecting environmental health, 
is the reduction of the release of PhACs to as low as reasonably practical.  The second 
goal is the reduction of the release of the most harmful PhACs to the environment.  
Although it may seem logical that this second objective should be the main objective, the 
difficulty in determining which PhACs are likely to have detrimental effects, as discussed 
in Chapter 2, makes this objective problematic.  Furthermore, rather than effects-based 
management, exposure-based management, which aims to reduce all contamination as 
much as possible, is becoming the norm in environmentally conscious European 
countries such as Sweden (Falconer, 1998); and pollution prevention in general is one of 
Environment Canada’s main principles for sustainable development (Environment 
Canada, 1997).  For these reasons the first and main objective involves minimizing the 
release of all PhACs to the environment, rather than focusing exclusively on the most 
harmful PhACs. 
  
6.4.  Policy Criteria 
 An essential component of policy analysis is the evaluation of policies against 
pre-determined criteria (Patton & Sawicki, 1993).  Some of these criteria are specific to 
the problem at hand, and are meant, for example, to measure the degree to which policies 
are likely to meet objectives.  Others, such as financial cost, are important considerations 
in the evaluation of most policies.  Table 6.1 presents criteria used to evaluate policies, a) 
in a general context, by Patton and Sawicki (1993); b) in a solid waste management 
context, by Barron and Ng (1996); and c) in a pesticide management context, by Falconer 
(1998).   The criteria selected for use in this analysis are also shown. 
 Four criteria are common to studies by Patton & Sawicki (1993), Barron & Ng 
(1996), and Falconer (1998), and they are also to be applied in this study: cost, 
effectiveness, feasibility, and equity considerations.  The economic ramifications of 
implementing a policy are essential at any level of decision making, and for all decision 
makers, whether individuals, businesses, or governments, because of the opportunity 
costs of implementing such policies.  Implementing an expensive policy means fewer 
resources will be available for other policy initiatives.    Effectiveness is essentially a 
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Table 6.1.  Policy criteria suggested by Patton & Sawicki (1993), Barron & Ng (1996), 






Therefore effectiveness is a vital criterion.  Feasibility, including political viability and 
administrative ease, is key to the success of a policy in practice.  A policy which appears 
effective in theory, but which would be politically damaging to implement, or which 
faces administrative barriers, is unlikely to ever be put into practice.  Finally, equity is an 
ethical criterion which all policymakers strive to meet, and an important policy goal.  Ho 
(2000) suggests that broad policy criteria like equity, which are also goals, should be 
treated as constraints, unlike more specific criteria such as cost, which can be treated as 
maximands.  Therefore the criterion of equity, and also the criterion of legality, will be 
treated as screening criteria in this analysis; any policy package which appears to be 
inequitable or illegal will not be considered for further evaluation. 
 Other criteria to be considered in this analysis include the benefit of increasing 
environmental quality in general; minimally increasing other risks (especially other 
environmental or health risks); capacity to monitor compliance with the policy; 
adaptability and flexibility of the policy; and selectivity, the ability to target specific 
locations or specific products with the policy.  Minimally increasing other risks is 
important as policies cannot be considered in isolation, nor can environmental 
compartments; a policy which reduces the release of PhACs to the environment but 
increases the release of other contaminants is sub-optimal.  A policy which benefits 
environmental quality beyond reducing PhAC release, should receive extra consideration 
for its added benefits.  Environmental quality can be improved directly, for instance by 
mitigating the release of other contaminants to water; or indirectly, by enhancing 
environmental stewardship and awareness, which should lead to a long-term 
improvement in environmental quality.  The capacity to monitor policy compliance and 
effectiveness is important because of the iterative and adaptive nature of the risk 
management process.  Information on the performance of policies is needed so 
adjustments can be made where compliance and effectiveness are insufficient.  Policies 
themselves must also be flexible, so they can be adapted as new information is acquired; 
flexibility is essential given the high degree of uncertainty associated with the issue of 
PhACs in the environment (see Chapter 3).  Finally, it is also advantageous to have 





address particular products, addressing aspects of the PhAC issue such as localized 
contamination, or pharmaceutical-specific concerns. 
 
6.5.  Policy Packages: Feasible Manipulations 
 A wide variety of policy instruments, meeting the criteria of equity and legality, 
and to some degree the other criteria discussed above, are available for the management 
of PhACs in the environment.  Table 6.2 describes the manipulation of these policy 
variables to different degrees (low, medium, and high), according to the methods of May 
(1981).  May (1981) suggests that different policy variables, or instruments, can be 
applied to differing degrees, and that it is by combining the policy instruments, applied at 
different strengths, into policy packages, that the best overall policy approaches emerge. 
The policy variables and the meaning of the degrees of manipulation are discussed below.  
In Table 6.3, the policy variables are combined into several sets of policy strategies, in 
accordance with the methodology of May (1981).  
 The first policy variable is environmental risk assessment regulations.  Such 
regulations are currently the only policy in place internationally that address the 
environmental impacts of PhACs.  The U.S. has existing regulations requiring 
environmental assessments for human pharmaceuticals (FDA, 1998), while the EU has 
draft guidelines for the assessment (CHMP, 2005), and Canada is currently in the process 
of developing environmental assessment regulations (Health Canada, 2002).  As 
discussed in Chapter 5, while most stakeholders are in favour of such regulations, they 
question their effectiveness, given the limited capacity of current risk assessment 
methods to detect the complex effects of PhACs.  Furthermore, there remains much 
debate concerning what the outcome of the environmental assessment should be.  Should 
the environmental assessment regulation merely ensure the development of a database on 
the environmental impacts of PhACs?  Should PhACs be labelled based on their 
environmental risks, to the degree to which these can be determined, as is being 
considered in Sweden (Stockholm läns landsting, 2005)?  Should the prohibition of 
registration, in other words, the banning of pharmaceuticals because of environmental 
concerns, be an option?  These three possibilities are presented as the ‘low, moderate, and 
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industry to voluntarily set 
up returns programs for 
proper drug disposal, and 
to make consumers aware 
of the programs 
Regulations requiring the 
pharmaceutical industry 
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consumers aware of the 
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demand  
Extend patents on ‘green’ 
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WWTPs to better remove 
PhACs without upgrading 
Fund upgrading all 
WWTPs in cities where 
effluent makes up 10% or 
more stream flow 
Fund upgrading WWTPs in 
large cities or areas of high 
PhAC contamination to 
include advanced treatment 




Status quo: special 
treatment for hospital 
wastewater not required 
Fund largest hospitals to 
pre-treat their wastewater 
using secondary treatment 
before release to 
municipal systems 
Fund all hospitals to pre-
treat their wastewater using 
using secondary treatment 




Table 6.2.  Feasible manipulation of policy variables for the management of PhACs in 
the environment to low, moderate, and high degrees, according to the methods of May 






Pharmaceutical returns programs can reduce the entry of pharmaceuticals into the 
environment through proper disposal.  Although disposal is believed to be a minor 
contributor to environmental contamination in comparison with the release of PhACs 
through consumption and excretion (Heberer, Feldmann, Reddersen, Altmann, & 
Zimmerman, 2002), some estimates suggest that up to a third of pharmaceuticals may be 
disposed of rather than used (Greiner & Rönnefahrt, 2003).  Furthermore, pharmaceutical 
returns programs were one of the preferred options of stakeholders in Chapter 5. 
Currently, the Model Standardsof Practice for Canadian Pharmacists state that 
pharmacists should collect medications for proper disposal, and proper disposal of 
medications is being incorporated into provincial professional codes of ethics in most 
Canadian provinces. In European countries and Canadian provinces, the pharmaceutical 
sectors (including manufactuers, pharmacies, etc.), together with governments,  
voluntarily organize returns programs for pharmaceuticals (NAPRA, 2002; SIGRE, 
2002).  Some examples include Nova Scotia’s ‘Dead Drugs’ program and PEI’s ‘Take it 
Back’ programs (Halasi, 2005). Such voluntary systems are the basis of the ‘low’ degree 
of manipulation shown in Table 6.2.  Chapter 4, together with research by Health Canada 
(COMPAS for Health Canada, 2002), suggest, however, that many Canadians continue to 
dispose of their pharmaceuticals improperly, throwing them in the toilet or in the garbage. 
Furthermore, the National Association of Pharmacy Regulatory Agencies (NAPRA) 
believes that increased public awareness through promotion, and more organized and 
convenient returns programs, together with increased funding from stakeholders, are 
needed (Halasi, 2005). Therefore, a stronger approach to the variable of pharmaceutical 
returns may be needed.  In the province of British Columbia, waste management 
regulations require the pharmaceutical industry to organize and advertise for 
pharmaceutical returns programs (Government of British Columbia, 1997, 2004).  Such 
regulations are described under the ‘moderate’ level of manipulation in Table 6.4.  
However, to ensure the public becomes truly aware of the issue of pharmaceuticals in the 
environment and participate actively in returns programs, education and awareness 
campaigns on a larger scale than those required by the B.C. regulations may be needed.  





out large-scale advertising campaigns, comprise the ‘high’ level of manipulation of this 
variable. 
  Education of medical practitioners and patients to reduce pharmaceutical over-use 
also emphasizes awareness as a means of reducing environmental contamination by 
PhACs.  Because most PhACs enter the environment after being consumed, reducing 
unnecessary pharmaceutical consumption is a logical, front-end approach to the problem, 
and was suggested by several stakeholders in Chapter 5.  Furthermore, physicians can be 
discouraged from collecting large quantities of drug samples.   In 2001, physicians were 
asked to return unused and expired medications for incineration and proper disposal to 
Lions Gate hospital in North Vancouver; over a 2-day period, 47 kg of medications were 
contributed by 25 people; worth $20 000 or more wholesale (Halasi, 2005).  Clearly, the 
disposal of physician samples contributes to the loading of PhACs to the environment.  
The education of medical practitioners and patients can range from, at the low end, small-
scale campaigns to make physicians aware that pharmaceuticals enter and may impact the 
environment.  At a moderate level of manipulation, it entails a somewhat larger 
campaign, targeting specific pharmaceuticals of concern.  For example, physicians might 
be asked to reduce their prescription of the highly persistent pharmaceutical, 
carbamazepine (Andreozzi, Raffaele, & Nicklas, 2003; Clara, Strenn, & Kreuzinger, 
2004; Cordy et al., 2004), or of antibiotics commonly found in environmental samples.  
Returns programs for physicians, such as the case discussed above, in Vancouver, would 
be implemented. The high level of manipulation would involve a campaign targeting not 
only medical practitioners but also the public, and would suggest that pharmaceuticals 
such as carbamazepine be used only as a last resort.  Additionally, alternatives to the use 
of physician drug samples would be sought; trial prescription programs, allowing patients 
to pick up small quantities of medications for free from pharmacies, rather than from 
physicians’ collection, could provide such alternatives (Halasi, 2005).   
 The manufacture of environmentally friendly pharmaceuticals, or ‘green’ drugs, 
which degrade quickly, and have little to no effect on non-target organisms, is in theory 
an ideal approach to the management of PhACs in the environment.  If such drugs can be 
manufactured, the environmental issue is dealt with up front, and management strategies 





believes that green pharmaceutical manufacturing is essential and perhaps the most 
important strategy for the management of PhACs in the environment, but his ideas are the 
subject of much controversy among scientists, managers, and members of the 
pharmaceutical industry (see Ch. 5).  Furthermore, the question must be asked as to how 
pharmaceutical manufacturers can be convinced to put research efforts into the 
development of ‘green’ drugs.  Some members of the industry feel that market forces 
alone provide incentive for companies to develop a niche market in the manufacture of 
‘green’ drugs (Ch. 5).  This is the basis of the ‘low’ level of manipulation of the ‘green’ 
pharmaceutical manufacturing variable.  However, further inducements may be needed to 
convince the industry to invest in green manufacturing; such inducements are an 
increasingly common policy instrument in the management of environmental 
contaminants.  One suggestion by an industry stakeholder in Chapter 5 was to provide 
extensions on patents for ‘green’ pharmaceuticals.  This constitutes the moderate level of 
manipulation.  A final option, at the ‘high’ level of manipulation, would be to provide 
financial incentives, such as tax breaks, to companies which manufacture ‘green’ 
pharmaceuticals. 
 Municipal wastewater treatment technology has been the subject of much 
discussion in the academic literature, as a means of reducing the release of PhACs to the 
environment.  Because most PhACs pass through wastewater treatment plants (WWTPs) 
before entering the environment, removal of PhACs by WWTPs has the potential to 
strongly reduce environmental contamination.  Some researchers believe upgrading 
WWTPs is the best way of managing PhACs in the environment (O'Brien & Dietrich, 
2004).  Certainly, scientific research indicates that advanced treatment methods such as 
ozonation and membrane filtration effectively remove PhACs from the water (Heberer et 
al., 2002; Huber, Canonica, Park, & Von Gunten, 2003; Ternes et al., 2003; Zwiener & 
Frimmel, 2000).  But the degree of upgrading can vary.   At a low level, optimization of 
existing WWTPs to better remove PhACs, without upgrading the WWTP technology, is 
an option.  A moderate level of manipulation might involve upgrading all WWTPs in 
cities with where effluent is 10% or more of streamflow to a minimum of secondary 
treatment.  As reported by the Sierra Legal Defense Fund (2004), some large Canadian 





others such as Charlottetown employ only primary treatment.  While much of this 
wastewater is released to oceans, some is released to inland rivers and streams; 15% of 
inland municipalities still do not have secondary wastewater treatment.  Therefore the 
upgrades entailed in the ‘moderate’ level of manipulation could contribute to reducing the 
release of PhACs to the environment.  Finally, a high level of manipulation would entail 
upgrading WWTPs in large municipalities, and in areas where PhAC concentrations in 
surface water are relatively high, to include advanced wastewater treatment methods such 
as ozonation.  Based on Chapter 4, Section 4.5.3, ozonation appears to be more 
financially viable than membrane filtration at this time. 
 Hospital wastewater treatment is a technical variable similar to municipal 
wastewater treatment.  Hospital wastewater may contain certain pharmaceuticals, such as 
antineoplastics (chemotherapy drugs) and antimicrobials, at levels higher than municipal 
wastewater (Al-Ahmad, Daschner, & Kümmerer, 1999; Kümmerer, Steger-Hartmann, & 
Meyer, 1997; Steger-Hartmann, Kümmerer, & Hartmann, 1997).  In some cases the 
concentrations of antibiotics in hospital wastewater have been found to be near the MIC50 
values for pathogenic bacteria; concentrations at which the development of antimicrobial 
resistance may occur (Kümmerer, Al-Ahmad, & Mersch-Sundermann, 2000; Kümmerer 
& Henninger, 2003).  Not only do PhACs enter hospital wastewater by excretion, but 
hospital staff are permitted to dispose of small quantities of non-narcotic, non-neoplastic 
pharmaceuticals via the toilet (Canadian Society of Hospital Pharmacists (CSHP), 1997).  
Currently, in Canada, hospitals are not required to pre-treat wastewater before releasing it 
to municipal systems; the status quo is considered the ‘low’ level of manipulation of this 
variable.  At a moderate level of manipulation, large hospitals only could be required to 
treat wastewater with secondary methods before releasing it to municipal sewage 
collection systems.  And at a high level of manipulation, all hospitals could be required to 
treat their wastewater before releasing it to municipal systems. 
 These variables, manipulated to different degrees, can be combined to form policy 
packages, or alternative policy strategies.  Table 6.3 illustrates the strategies which will 
be considered for analysis.  The first strategy, called ‘minimalism’, involves little effort 
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assessment regulations, some minor efforts at education, and encouragement of voluntary 
risk management action on the part of the pharmaceutical industry.  The next strategy, 
called ‘incrementalism’, involves some active management, through the potential 
labelling of environmentally harmful PhACs, the development of regulations related to 
pharmaceutical returns programs, and upgrades to primary treatment for those 
municipalities without such treatment.  While this does not constitute an overwhelming 
effort to keep PhACs out of natural waters, Hrudey (1996) believes that incrementalism is 
the best way of managing uncertain environmental risks such as the PhAC issue.  
Incrementalism is also among the most adaptive approaches to policy making and 
management (see Ch. 3). The third strategy, called ‘moderation’, involves a moderate 
level of manipulation of all variables;such a moderate approach could potentially reduce 
the release of PhACs to the environment while remaining affordable and feasible.  The 
remaining policy packages involve particular approaches to the management of PhACs in 
the environment.  One such approach is the ‘command and control’ strategy, where 
environmental risk assessment regulations are paramount, and regulations for 
pharmaceutical returns programs are also included. The ‘front-end’ strategy takes a green 
manufacturing approach while trying to minimize the entry of pharmaceuticals into the 
waste stream.  ‘Education and awareness’ focuses on teaching the public and physicians 
about the environmental risks of pharmaceuticals.  The ‘stakeholder effective’ package 
emphasizes those management strategies deemed most effective by stakeholders in 
Chapter 5.  Finally, the ‘local efforts’ package emphasizes management which can occur 
on a local scale; advanced wastewater treatment in cities which need it most, and local 
pharmaceutical returns programs, regulated, however, by a higher level of government. 
 
6.6  Policy Evaluation 
 The policy strategies are evaluated by means of comparison against the criteria 
discussed in section 6.4.  Table 6.4 presents a qualitative scoring of strategies against 
evaluation criteria.  It should be kept in mind that not all criteria are equally important; 
the criteria of effectiveness, feasibility, and cost, are the most vital criteria, whereas the 





Criteria Minimalism Incrementalism Moderation 
Effectiveness 
in: 
1) Reduction of 
PhAC loading 
to environment,  
2) Reduction of 
loading of most 
harmful PhACs 
to environment 
P – Will have little 
effect on release of 
PhACs 
S – Mandatory pharmaceutical 
returns programs and 
secondary WWTPs in all cities 
will reduce PhAC loading 
somewhat, and labelling 
resulting from EA regulations 
will reduce the release of the 
most harmful PhACs.  But 
many PhACs will still be 
released. 
VG – By targeting the issue 
from many angles, a significant 
reduction in PhAC release 
should be achievable, although 
this reduction will be 
incomplete without advanced 
wastewater treatment 
Feasibility E – Easiest strategy 
to implement 
E – Incrementalism 
corresponds closely with what 
stakeholders in Ch. 5 deemed 
most feasible. 
VG – Generally feasible 
although patent extensions for 
drug companies and separate 
wastewater treatment for 
hospitals somewhat less so 
Minimal 
Financial Cost 
E – Least 
expensive  
VG – The main expense is the 
upgrading of WWTPs to 
secondary treatment.  This will 
be expensive but not 
unreasonably so. 
S – Costs of upgrading 
municipal WWTPs and funding 
wastewater treatment in large 
hospitals may be somewhat 
prohibitive 
Minimal 
increase in other 
environmental 
or health risks 
E – Little is being 
done so little effect 
in increasing other 
risks 
VG – Upgrading WWTP 
treatment facilities may 
slightly increase energy use 
and therefore CO2 emissions. 
S – Upgrading municipal 
WWTPs and requiring hospital 
wastewater treatment will 
increase energy use 
Benefit to 
environmental 
quality at large 
P – No direct 
benefits to 
environmental 
quality and little 
awareness/stewards
hip 
VG – Upgrading WWTPs will 
improve river and stream 
quality generally, and required 
pharmaceutical returns 
programs will enhance 
awareness/stewardship 
E – Upgrading WWTPs and 
installing hospital wastewater 
treatment will enhance surface 
water quality, and education of 
physicians and returns 




E – Not locked into 
any long-term 
strategies 
VG – WWTP upgrades are 
somewhat inflexible but 
overall the incremental 
strategy allows for adaptation 
S – Although education-related 
strategies are flexible, 
wastewater treatment related 




P – Voluntary 
strategies difficult 
to monitor 
S – Regulatory control on 
returns programs allows for 
some compliance monitoring, 
as does funding for WWTP 
upgrades.  Labelling of PhACs 
resulting from environmental 
assessments does not result in 
behaviour that can be 
monitored. 
S – Regulated variables and 
funded technological upgrades 
can be monitored but education 
of physicians, labelling, and 
particularly outcomes of patent 
extensions from green drugs are 
hard to monitor 
Selectivity P – No targeting of 
local contamination 
or harmful PhACs 
S – WWTP upgrades are not 
targeted but labelling of 
PhACs targets compounds of 
greatest concern 
LS – This strategy does not 
target any aspect of the PhAC 
problem, or any geographic 
location, although some PhACs 
are targeted 
Table 6.4a.  Evaluation for strategies, ‘minimalism’, ‘incrementalism’, and ‘moderation’.  










Table 6.4b.  Evaluation for strategies, ‘command & control’, ‘front end’, and ‘education 
& awareness’.  E=Excellent, VG=Very Good, S=Satisfactory, LS=Less than Satisfactory, 
P=Poor 
 
Criteria Command & 
Control 
Front End Education & Awareness 
Effectiveness 
in: 
1) Reduction of 
PhAC loading 
to environment,  
2) Reduction of 
loading of most 
harmful PhACs 
to environment 
LS – EA regulations 
may result in banning 
of some harmful PhACs 
but will miss others, 
and returns programs 
will have a minor 
impact 
VG – Should be 
effective in theory but 
in practice, perhaps less 
so 
VG – If consumption and 
improper disposal are reduced, 
could be quite effective.  But 
effectiveness of education 
campaigns always questionable. 
Feasibility S – Ethical 
considerations and 




LS – Stakeholder in Ch. 
5 did not consider 
‘green’ manufacturing 
feasible 
VG – Pharmaceutical industry 




E – Not financially 
expensive 
P – Cost of providing 
incentives large enough 
to influence drug 
companies huge! 
S – Large-scale education 
campaigns are expensive 
Minimal 
increase in other 
environmental 
or health risks 
S – No effects on 
environmental risks but 
banning drugs could 
increase health risks 
E – Should not increase 
other risks 
VG – No increase in 
environmental risks but possible 
health risk if patients refuse to 




quality at large 
S – Some increase in 
environmental 
awareness though 
returns programs and 
labelling 
VG – Benefit in terms 
of environmental 
awareness  




VG – Regulations can 
be amended 
VG – Incentives can be 
modified, as can 
education programs 





E – Command & 
control allows for 
enforcement 
P – Difficult to monitor 
effects of incentive for 
green drugs and of 
education 
LS – Can regulate returns 
programs but effects of 
education hard to monitor 
Selectivity S – Selective for 
PhACs but not for 
location 
S – Would replace most 
harmful PhACs but not 
geographically selective 
S – Targets certain PhACs but 





Criteria Stakeholder Effective Local Efforts 
Effectiveness in: 
1) Reduction of 
PhAC loading to 
environment,  
2) Reduction of 
loading of most 
harmful PhACs to 
environment 
E – This package deemed highly 
effective by stakeholders in Ch. 5 
E – Advanced wastewater treatment 
highly effective 
Feasibility S – High level of technological 
requirements plus large scale 
education campaign may harm 
feasibility 
VG – Generally feasible despite large 
technological investment because targeted 
at certain municipalities 
Minimal Financial 
Cost 
LS – Cost of advanced WWTPs, 
large education campaign, and of 
hospital wastewater treatment 
relatively high 
S – Advanced wastewater treatment 
expensive but not prohibitively so 





LS – Energy intensive advanced 
treatment increases release of CO2.  
Also ozonation generates reaction 
products of unknown effect. 
LS – Energy intensive advanced 
treatment increases release of CO2.  Also 




quality at large 
VG – Better wastewater treatment 
benefits rivers and streams; education 
increases awareness 
VG – Better wastewater treatment 




LS – Heavy investments in 
technology not easy to modify but 
education programs more easily 
modified 
LS – Heavy investments in technology 
not easy to modify but returns programs 




S – Technological component can be 
monitored but education component 
less so 
VG – Technological component easy to 
monitor, regulated returns programs can 
be somewhat monitored 
Selectivity E – Advanced technology 
geographically targeted and 
education targets certain PhACs 
VG – Geographically targeted but not 








Table 6.4c.  Evaluation for strategies, ‘stakeholder effective’ and ‘local efforts’  





Only two of the policy strategies received the lowest possible score, ‘poor’, on one of the 
three main criteria.  The strategy of ‘minimalism’ received this score for effectiveness; as 
the strategy entails little action beyond the status quo, it is not expected to significantly 
reduce the release of PhACs to the environment.  Performing poorly on the criterion of 
effectiveness means that this policy strategy would not meet the objectives outlined in 
Section 6.3.  Therefore this strategy should not be considered for implementation.  The 
strategy, ‘front end’, which relies heavily upon incentives to induce the pharmaceutical 
industry to produce ‘green’ drugs, received a poor score in terms of financial cost.  
Providing financial incentives sufficiently large to influence the pharmaceutical industry 
would be extremely expensive, to the point of being prohibitive. PRMA (Pharmaceutical 
Researchers and Manufacturers of America, 2003) estimate that the research costs to 
bring 1 drug to market over a 10 year period are $700 million  CDN.  Assuming that an 
incentive of at least 10% of the costs of drug development would be needed to influence 
the industry, a 70 million dollar (CDN) investment would be required over 10 years as an 
incentive for the manufacturing of a single ‘green’ drug.  Furthermore, stakeholders were 
not convinced of the feasibility of green manufacturing; while some stated that green 
manufacturing is already occurring, others considered the concept, “naïve” (Ch. 5).  
Although the ‘front end’ strategy scored well in terms of criteria including effectiveness, 
minimal increase in other environmental risks, benefit to environmental quality at large, 
and adaptability, its poor performance in terms of cost and feasibility suggests that this 
strategy should not be implemented at this time.  While green manufacturing has the 
potential, in theory, to effectively reduce the environmental impacts of PhACs, it will 
likely be up to pharmaceutical companies to develop their own niche markets in this area, 
without the help of government incentives or policies.   
 Two strategies received scores of less than satisfactory for one main criterion, and 
satisfactory for another.  ‘Command & Control’, which emphasized environmental 
assessment regulations, including labelling and banning as outcomes, as well as regulated 
pharmaceutical returns programs, was deemed unlikely to be highly effective.  As 
discussed in Ch.2 and Ch. 5, and in the academic literature, risk assessment methodology 
is insufficient for the detection of the subtle, detrimental impacts resulting from the 





of risk assessment (Länge & Dietrich, 2002; O'Brien & Dietrich, 2004; Sanderson et al., 
2004).  Therefore, few substances are likely to be prohibited from entering the market 
due to such regulations.  Furthermore, it is not clear whether such regulations would 
address the large number of substances already on the market, which might also have 
environmental impacts.  Pharmaceutical returns programs, while beneficial, and while 
being ranked highly in terms of effectiveness by stakeholders, can only prevent a fraction 
of PhACs from entering the environment; among the largest estimates is 1/3 of 
pharmaceuticals (Greiner & Rönnefahrt, 2003).  Another important consideration is the 
feasibility of banning pharmaceuticals due to their environmental impacts.  Because most 
pharmaceuticals are needed for the maintenance of patient’s quality of life, banning them 
is arguably unethical; one can argue that doing so violates the patients’ autonomy, 
treating the patient as a means to the end of environmental protection, rather than as an 
end in themselves (Paton, 1958).  This policy has the benefits, however, of being 
relatively inexpensive, adaptable, and enforceable.  Nevertheless, because of the 
problems with effectiveness, feasibility, and ethical issues in particular, this is not one of 
the best policy packages available. 
 The ‘stakeholder effective’ package, designed to be highly effective, scored less 
well in terms of feasibility and financial cost.  The strategy includes a high level of 
manipulation on both municipal wastewater treatment and education of physicians, as 
these were the two strategies considered most effective by stakeholders.  Pharmaceutical 
returns programs and hospital wastewater treatment are manipulated to a moderate 
degree, as they were also considered relatively effective strategies.  Putting large efforts 
into various forms of technological improvement and some large-scale education 
campaigns, however, may harm feasibility, and certainly results in a high cost for this 
strategy.  For example, the Region of Waterloo spends $110 000 per year on education 
campaigns regarding waste management (pers. comm.., Deanna Dakin, Regional 
Municipality of Waterloo); extrapolating this to a national scale, an investment of 
approximately $8 million CDN might be needed for a large-scale education campaign.  In 
terms of advanced wastewater treatment, in Chapter 4, it is estimated that installing and 
operating ozonation would cost slightly less than $10 CDN per resident per year in a mid 





requiring advanced treatment, with the country’s population being approximately 25 
million, a cost of 25 million dollars would be required for the upgrades. This figure does 
not include the extra cost of installing wastewater treatment systems in large hospitals. 
Therefore the total cost of this strategy would be over $35 million CDN.  The cost is 
large although not necessarily prohibitively so, given the benefits; the strategy performs 
well in terms of benefiting the environment at large, by generally improving surface 
water quality and by increasing environmental stewardship and awareness.  The use of 
advanced wastewater treatment in large cities or areas with high PhAC concentrations 
also makes the strategy selective.  However the adaptability is limited, compliance 
monitoring is somewhat difficult for the education campaigns, and the energy used for 
advanced municipal wastewater treatment and hospital wastewater treatment will increase 
the release of CO2 to the atmosphere.  This strategy is not optimal at the present time, but 
it should be kept in mind for the future.  If it becomes increasingly clear, through the 
acquisition of more scientific evidence, that PhACs are harmful to the environment, it 
may be worthwhile investing in expensive and somewhat inflexible strategies to mitigate 
their release. 
 The strategy, ‘education & awareness’, performed well in terms of benefit to 
environmental quality at large, by making people aware of the impact of their actions on 
the environment; it is also extremely flexible, feasible, and should not increase risks to 
the environment or health, unless patients become afraid of taking medications seen as 
bad for the environment.  The strategy could be quite effective in theory, because it aims 
to reduce both consumption of pharmaceuticals and improper disposal, though education.  
However, the success of education campaigns is questionable.  While campaigns 
encouraging people to recycle have been relatively successful, with 70-80% of Ontarians 
participating in blue-box programs by 1991 (Alberni Environmental Coalition, 1991), 
campaigns encouraging people to reduce energy consumption and thereby CO2 
emissions, do not appear to have met with much success in Canada, as greenhouse gas 
emissions have generally increased over the past decade (David Suzuki Foundation, 
2005).  Furthermore, as a stakeholder in Ch. 5 suggested, there is pressure from the 
pharmaceutical industry, and from patients, for physicians to prescribe drugs.  Finally, 





possible to reduce their consumption.  So although returns programs and physician/public 
education were ranked quite highly in terms of effectiveness by stakeholders, it is argued 
that only a moderate level of effectiveness can be expected from this strategy.  
Furthermore, the large-scale education campaigns that would be required to achieve even 
a moderate level of success, would likely be expensive, as discussed with regard to the 
‘stakeholder effective’ strategy.  While the ‘education & awareness’ strategy should not 
be rejected entirely, other policy packages which rely only partially, rather than entirely, 
on education campaigns, may be more effective. 
 The three remaining strategies have in common, at a minimum, a moderate level 
of manipulation of the variables of municipal wastewater treatment and pharmaceutical 
returns programs.  They are, in order of increasing effectiveness, ‘incrementalism’, 
‘moderation’, and ‘local efforts’. However ‘moderation’ and ‘local efforts’ are more 
expensive and less feasible than ‘incrementalism’.  Selecting a preferred strategy among 
these three is difficult, although ‘incrementalism’ and ‘local efforts’ appear slightly better 
than ‘moderation’; if the most important point is effectiveness (as this researcher suggests 
it ideally should be), ‘local efforts’ appears best.  However, if the purpose is simply to 
achieve some small reduction in PhAC loading, with the maintenance of low cost and 
high feasibility being essential (which may be more realistic), ‘incrementalism’ seems 
best.  Looking beyond the criteria of effectiveness, feasibility, and cost, ‘incrementalism’ 
performs well as upgrading WWTPs to secondary treatment improves water quality, 
without consuming the quantities of energy that would be required if hospitals also 
treated their wastewater (‘moderation’), or if advanced wastewater treatment methods 
were used (‘local efforts’).  Furthermore, the ‘incrementalism’ strategy is reasonably 
adaptive, not making overly heavy or immutable commitments.  ‘Local efforts’, however, 
also performs reasonably well on secondary criteria, as it can be monitored, is highly 
geographically targeted, and should also increase stream and river quality.  ‘Moderation’ 
performs only slightly less well.  Based on the qualitative scoring of the strategies, they 
can be ranked in different ways, depending on whether effectiveness, cost and feasibility, 
or secondary criteria, are used to separate strategies which perform similarly well (Table 
6.5.).  It is suggested therefore, that particularly among the top 3 strategies, the choice of 





selected here.  Furthermore, other strategies such as ‘stakeholder effective’, which 
performed only moderately well overall, should be kept in mind for the future, as new 
information is certain to affect the evaluation of the policy packages. 
 
Ranking Effectiveness Cost & Feasibility Secondary Criteria 
1 Local Efforts Incrementalism Incrementalism 










5 Stakeholder Effective Command & Control Command & Control 
6 Command & Control Stakeholder Effective Stakeholder Effective 
7 Front End Minimalism Front End 
8 Minimalism Front End Minimalism 
 
Table 6.5.  Rankings of policy strategies, depending on whether effectiveness, cost and 
feasibility, or secondary criteria are used to distinguish between similarly-performing 
strategies. 
 
6.7.  Jurisdictional issues within Canada 
 This analysis has been conducted without considering which level of government 
might be responsible for implementing the different policy strategies.  In fact, most of the 
strategies suggested would require a mixture of efforts on the part of federal, provincial, 
and local governments.  The federal government is responsible for environmental 
assessment regulations; these will be administered either by Health Canada or 
Environment Canada (Health Canada, 2002).  Regulations regarding pharmaceuticals 
returns programs appear to fall under provincial jurisdiction; British Columbia has 
included pharmaceutical returns programs under its waste management regulations, 
specifically its regulations on recycling (Government of British Columbia, 1997, 2004).  
However, all governments have the ability to influence their citizens’ participation in 





be particularly influential in the education process; for instance, the Region of Waterloo 
distributes a monthly environmental newsletter, which could potentially include 
information on returning unused or expired medications to the pharmacy.  Similarly, 
various levels of government could implement the education of medical practitioners and 
patients to reduce pharmaceutical over-consumption.  It might be most practical, 
however, to conduct such education at a federal or provincial level, through cooperation 
with an association of medical practitioners such as the College of Family Physicians of 
Canada or the Natinal Pharmacy Regulatory Agency (NAPRA).  Any attempts to 
influence pharmaceutical manufacturers to produce green drugs – whether through patent 
extensions, or financial incentives such as tax breaks – would likely have to occur at a 
federal level; provincial and particularly municipal governments would have difficulty 
influencing such large and powerful corporations.  The installation of advanced systems 
in municipal WWTPs, or the upgrading of WWTPs to secondary treatment, would occur 
on a local scale.  However municipal governments are unlikely to have sufficient funds 
for such upgrades; grants from provincial and federal governments would be needed.  
Similar grants would be needed for the installation of wastewater treatment facilities at 
hospitals.  In essence, while local governments have an important role to play with 
respect to education and awareness regarding PhACs in the environment, much of the 
financial and regulatory burden in managing this issue would need to be carried by 
federal and provincial governments for the policy strategies to be implemented. 
 
6.8.  Conclusions 
 The precautionary principle requires that policy strategies be developed to 
manage human pharmaceuticals in the environment.  The overarching goal of these 
policies would be sustainable development, with environmental protection as a sub-goal.  
More specifically, the objectives of such policies would be to minimize the release of 
PhACs in general, as well as particular PhACs of concern, to the environment.  Strategies 
to manage PhACs in the environment must be equitable and legal.  It is important that 
they be effective, feasible, and of minimal cost; furthermore they should have additional 
benefit in terms of generally improving environmental quality, and should not generate 





enforceable.  In this analysis, several policy variables, including risk assessment 
regulations, pharmaceutical returns programs, education of medical practitioners, 
incentives for ‘green’ pharmaceutical manufacturing, municipal wastewater treatment and 
hospital wastewater treatment, were combined to form different policy packages.  Among 
these packages, ‘local action’, ‘incrementalism’, and ‘moderation’ appeared to be the best 
strategies.  ‘Local action’ involves upgrading the WWTPs of large municipalities or those 
with high downstream PhAC concentrations to include advanced treatment, as well as 
some regulations and education related to pharmaceutical returns programs.  
‘Incrementalism’ also involves regulated returns programs, as well as risk assessment 
regulations with environmental labelling of pharmaceuticals as an outcome, and the 
upgrading of WWTPs in cities of 10 000 or more to secondary treatment, where such 
treatment is not already in place.  Finally, ‘moderation’, involved a moderate degree of 
action on all the variables discussed above.  Municipal, provincial, and federal 
governments will need to collaborate in implementing such strategies to mitigate the 
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Ch. 7: Conclusions 
 
7.1  Conclusions 
 After a decade of research consistently indicating the presence of pharmaceuticals 
in natural waters, it is time that management action to reduce their release to the 
environment be considered.  Such management action must be based, firstly, on current 
scientific understanding of the issue.  A review of the literature suggests that human 
PhACs are entering the environment primarily through consumption, followed by 
excretion, entry into the wastewater collection system, and treatment at wastewater 
treatment plants; as many PhACs are not effectively removed during secondary 
treatment, they are subsequently released to surface waters (Heberer, 2002a).  Advanced 
treatment methods such as ozonation, membrane filtration, and activated carbon, can, 
however, remove PhACs more effectively (Adams, Wang, Loftin, & Meyer, 2002; Boyd, 
Reemtsma, Grimm, & Mitra, 2003; Heberer, Feldmann, Reddersen, Altmann, & 
Zimmerman, 2002; Huber, Canonica, Park, & Von Gunten, 2003; Ternes et al., 2003; 
Zwiener & Frimmel, 2000).  Other sources and routes of entry for human PhACs include 
disposal to toilet and landfill (Eckel, Ross, & Isensee, 1993; Greiner & Rönnefahrt, 2003; 
Holm, Rugger, Bjerg, & Christensen, 1995); spreading of sewage sludge on agricultural 
land followed by runoff (Lissemore, Yang, Hao, & Solomon, 2005); industrial release of 
PhACs, particularly in manufacturing wastewater (Balcýoðlu & Ötker, 2003; 
Guardabassi, Petersen, Olsen, & Dalsgaard, 1998); and the washing off of dermally 
applied PhACs during bathing and swimming (Daughton & Ternes, 1999).  Human 
PhACs are frequently detected in surface water; less commonly in groundwater; and only 
a handful of PhACs have been detected in drinking water (Heberer, 2002a, 2002b; 
Ternes, 1998).  Their presence raises concerns about possible impacts on aquatic 
ecosystems and human health.  Field and laboratory evidence of the effects of low 
concentrations of PhACs on aquatic organisms exists; some well-known examples 
include the feminization of fish exposed to 17α-ethinylestradiol (Jobling, Nolan, Tyler, 
Brightly, & Sumpter, 1998; Larsson et al., 1999; Purdom et al., 1994), and the spawning 
of mussels exposed to the antidepressant fluoxetine (Fong, 1998).  Human health risk 





present a risk (Christensen, 1998; Schulman et al., 2002; Webb, Ternes, Gibert, & 
Olejniczak, 2003); however the effects of long-term exposure to mixtures of PhACs, as 
well as effects on sensitive sub-populations, cannot be ruled out (Daughton & Ternes, 
1999).  The possibility of mixture effects, and the complex nature of the mechanisms 
through which pharmaceuticals affect organisms, make the effects of PhACs, particularly 
on non-target species, very difficult to predict, leading to gaps in understanding (Brain et 
al., 2004; Länge & Dietrich, 2002).  However, certain classes of PhACs are believed to 
be of particular concern; these include antimicrobials; synthetic hormones; lipid 
regulators; anti-inflammatories and analgesics; antiepileptics; and selective serotonin 
reuptake inhibitors.  Furthermore, based on data available in the literature, it was possible 
to conduct a rough, back-of-the envelop ranking of pharmaceuticals according to 
expected environmental risk (Table 2.3).  This ranking suggests that the PhACs 
carbamazepine, clofibric acid, ifosfamid, 17α-ethinylestradiol, oxytetracycline, 
ciprofloxacin, and diclofenac, may be of particular concern.  Nevertheless, uncertainty in 
the scientific understanding of PhACs in the environment remains high. 
 Risk management provides an appropriate framework for addressing the issue of 
human PhACs in the environment.  However, problems are encountered at the scientific 
risk assessment stage of risk management, as the methodology to quantitatively assess the 
risks of PhACs, particularly to aquatic organisms, has not been fully developed.  This 
inability to quantitatively assess risk could potentially stall the risk management process; 
however the precautionary principle provides an impetus for risk management to continue 
despite incomplete science, as it states that uncertainty must not be used as a reason for 
postponing risk management and for allowing environmental damage to continue (CEPA, 
1999; Commission of the European Communities, 2000; Government of Canada, 2001; 
Quijano, 2003).  The theory of adaptive planning is also of use in coping with 
uncertainty, as it suggests that environmental policies developed under conditions of 
uncertainty must have characteristics such as flexibility, to allow them to respond to 
evolving scientific understanding (Holling, 1978; Lessard, 1998).  By applying the 
precautionary principle and the theory of adaptive planning to the U.S. EPA risk 





Assessment and Risk Management, 1997a, 1997b), a modified risk management 
framework particularly suited to PhACs in the environment was developed (Ch. 3). 
 Based on this framework, a study of potential PhAC management strategies at a 
local scale, in the Region of Waterloo, was conducted.  Analysis of wastewater indicated 
that PhACs were indeed being released from local WWTPs at concentrations similar to 
those in other urban areas.  The precautionary principle therefore suggests that 
management action is desirable.  Questionnaires administered locally suggested that 
many people dispose of their medications improperly, and that education programs might 
therefore be of help in reducing the release of PhACs to the environment.  Local residents 
were interested in seeing management action taken, but their willingness to pay for such 
management action was limited.  Installing ozonation equipment to remove PhACs from 
wastewater, did, however, fall within the range of what residents were willing to pay.  It 
is therefore recommended that the Region consider both education programs to improve 
proper pharmaceutical disposal and ozonation of wastewater as future means of 
minimizing the release of human PhACs to the local environment. 
 In order to develop management strategies at a broader scale, interviews were 
conducted with stakeholders from the pharmaceutical industry, government and 
academia, in Canada, the U.S. and Europe.  The stakeholders generally felt that PhACs in 
the environment represented both an ecosystem and a human health concern, although 
they thought serious and irreversible impacts on ecosystems were more likely.  
Contamination of groundwater and surface water by PhACs was seen as less of a concern 
than contamination by nutrients, pesticides and metals, but a greater concern than 
contamination by road salt or organic solvents.  Interestingly, North American 
interviewees were more concerned about water contamination by pathogens than by 
pharmaceuticals, but the reverse was the case for Europeans.  The interviewees felt that 
ecotoxicological research into PhACs in the environment was needed to reduce scientific 
uncertainty, which they perceived as high.  In terms of management, they suggested that 
governments are doing little at this time to address PhACs other than research.  While 
they supported research activity, many interviewees also felt management action was 
required.  The interviewees liked the idea of risk assessment regulations; however, they 





wastewater treatment, education of medical professionals, and pharmaceutical returns 
programs coupled with public education, were considered most likely to effectively 
prevent environmental impacts by PhACs.  Of these three, pharmaceutical returns 
programs were seen as most feasible, and were favoured to the greatest degree by 
interviewees from the pharmaceutical industry.  These stakeholder consultations may be 
helpful to governments in developing policies to manage PhACs in the environment. 
 With the purpose of developing policy recommendations for the management of 
human PhACs in Canada, a structured policy analysis was conducted.  Policy packages 
were assembled by considering the policy instruments discussed with stakeholders in Ch. 
5; the instruments were combined into packages using the feasible manipulations 
methods of May (1981).  Policy strategies were evaluated based on the criteria of 
effectiveness, feasibility, minimal financial cost, minimal increase in other environmental 
or health risks, benefit to environmental quality at large, adaptability, potential for 
compliance monitoring and enforcement, and selectivity.  The analysis suggested that the 
optimal policies involved local efforts, or incremental or moderate application of a 
variety of policy instruments.  A combination of returns programs, education, wastewater 
treatment and to a lesser degree, green drug development and environmental assessment 
regulation, was best.  Policy packages focusing excessively on regulation or on incentives 
for the development of green drugs performed less well, because they were, in the case of 
the former, ineffective, and in the case of the latter, overly expensive without necessarily 
being effective.  It is recommended that Canada’s federal government consider a 
combination of strategies to address human PhACs in the environment, rather than 
focusing solely on risk assessment regulations. WWTP upgrades, together with better 
returns programs and education, should become part of the government’s strategy for 
managing PhACs in the environment.   
 In addition to making a practical contribution to the management of PhACs in 
Canada, this study also provides new insight at a more theoretical level.  Pharmaceuticals 
represent one of many uncertain environmental risks that managers and policy makers are 
struggling to address.  The precautionary principle provides a tool for risk management 
under conditions of uncertainty, yet it is unclear how the principle should be applied (Ch. 





the application of the precautionary principle in environmental management.  The steps 
followed in developing management strategies can be condensed into a framework for 
precautionary decision making, shown in Fig. 7.1.  The framework shows that 
precautionary action is needed when there is some evidence of harm, but quantitative risk 
assessment is not possible. Furthermore, it illustrates that precautionary management 
action should only be undertaken if it meets stakeholder needs and several criteria 
including effectiveness and financial affordability.  This framework can provide guidance 
to environmental researchers, managers and policy managers faced with the challenge of 








Figure 7.1.  A decision-making framework for the application of the precautionary 
principle to uncertain environmental risks.
Should precautionary management action be undertaken? 
Is there some scientific evidence suggesting a 
risk to human health or the environment? no 
yes 
Is there sufficient knowledge 
 and data for a thorough,  
quantitative risk assessment? 
no 
yes 
No need for 
precautionary 
management action 
Perform a quantitative  
risk assessment – no need 
for the precautionary 
 principle 
Conduct qualitative risk assessment 
 and stakeholder consultation 
-Do stakeholders, including the public, desire 
 management action? 
-Do management strategies exist which meet the 
 following criteria (see Ch. 6): 
  - effective 
  - feasible 
  - financially affordable 
  - adaptive/flexible 
  - benefit environment 
  - minimally harm environment/human health 
  - increase environmental stewardship 
  - enforceable 
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Appendix A:  Instrumental parameters for analysis of pharmaceuticals in 
wastewater (As reported to the Region of Waterloo by C. Metcalfe and X. Miao, 
2004) 
1.  Neutral Drugs 
Neutral drugs were analyzed by LC-MS/MS using the APCI source. The column 
employed was Genesis C18 (150 × 3 mm, 4µ), with a flow rate of 0.5mL/min. The 
mobile phase consisted of 10mM ammonium acetate aqueous solution (A) and 
acetonitrile (B). The injection volume was 20 µL.  The neutral drugs were separated 
using the following linear gradient elution profile at room temperature: mobile phase B 
was increased from the initial 5% to 20% over 4 min and reached 95% at 12 min; it 
remained at 95% for the next 3 min and then ramped back to 5% within 2 min. Using the 
software Analyst 1.4., multiple reaction monitoring (MRM) with unit resolution on both 
of the first and second analyzer was selected for data acquisition in the positive-ion mode 
and nitrogen was used as curtain, nebulizer, auxiliary and collision gas. The mass 
spectrometric parameters were optimized by continuously infusing the analytes using a 
syringe pump at 20µL/min.  The syringe pump was then teed into the LC flow of 50:50 
10mM ammonium acetate-acetonitrile at 0.5mL/min and determined as follows: curtain 
gas 20 psi, nebulizer gas 70 psi, auxiliary gas 15 psi, corona discharge needle current 2.0 
µA, probe temperature 470°C, interface heater on, CAD gas 5. Collision energy and 
declustering potential for each compound are listed in the table below. The dwell time for 
each MRM transition was set at 200 ms. 
 






Caffeine 195 > 138 7.45 47 25 
Carbamazepine 237 > 194 10.91 40 28 
Cotinine 177 > 80 7.11 40 40 
Cyclophosphamide 261 > 140 9.93 40 28 
Pentoxifylline 279 > 181 9.09 40 24 
Fluoxetine 310 > 148 12.48 15 12 






2.  Acidic Drugs 
 For the acidic drugs, Negative-ion TurboIonSpray source was used. Therefore, a 
Genesis C18 column of 150 × 2.1mm, 4µ was employed at the flow rate of 0.2mL/min 
for the analyses. The mobile phases A and B consisted of 10 mM ammonium acetate 
aqueous solution and 40:60 acetonitrile-methanol, respectively. The linear gradient 
elution was performed to separate the analyzed compounds. The initial condition was 
20% B which was held for 0.5 min. The mobile phase B was then increased to 40% at 1 
min, reached 95% at 9 min and held at this level for 7 min. Next, it was ramped back to 
20% over 2 min. The injection volume was 25 µL and the chromatographic separation 
was conducted at room temperature. By continuously introducing the analytes through a 
syringe pump at 10µL/min, which was then teed into the LC flow consisting of mobile 
phases A and B (50:50) at 0.2mL/min, the following mass spectrometric parameters were 
optimized to achieve reasonable sensitivity for each individual compound operating in 
multiple reaction monitoring (MRM) mode: curtain gas 30 psi, nebulizer gas 30 psi, turbo 
gas 60 psi, ionspray voltage –3000 V, heater gas temperature 350°C, interface heater on, 
CAD gas 5; declustering potential and collision energy were also determined. Nitrogen 
was used for all kinds of gases and a dwell time of 200 ms was selected for each MRM 
transition.  
 






Bezafibrate 360 > 274 11.86 –56 –20 
Clofibric Acid 213 > 127 10.75 –40 –21 
Diclofenac 294 > 250 12.99 –43 –17 
Fenoprofen 241 > 197 12.41 –45 –13 
Gemfibrozil 249 > 121 15.47 –45 –25 
Ibuprofen 205 > 161 13.38 –40 –15 
Indomethacin 356 > 312 13.33 –53 –15 
Ketoprofen 253 > 209 11.34 –43 –15 






Six sulfonamide compounds were analyzed using APCI in the positive-ion mode. The 
separation was conducted on a Genesis C18 column (150 × 3 mm 4 µ) at the flow rate of 
0.5mL/min using a linear gradient elution. The mobile phases A and B were water 
containing 0.1% formic acid and acetonitrile, respectively. The mobile phase B was 
initially held at 3% for 0.5 min, increased to 24% at 1 min, then further increased to 43% 
at 10 min and held at 43% for 2 min. Finally, it reached 95% at 13 min and was held for 3 
min. Afterwards, B was ramped back to 3% at 17 min. The injection volume was 20 µL 
and the chromatographic separation was performed at room temperature. Multiple 
reaction monitoring (MRM) was employed for acquiring mass spectrometric data and two 
pairs of MRM transitions were selected for each compound. By introducing the analytes 
through a syringe pump at 20 µL/min which was combined with a LC flow of the mobile 
phase A and B (50:50) at 0.5mL/min into the mass spectrometer, the optimized operating 
parameters were determined as follows: curtain gas 15 psi, nebulizer gas 60 psi, auxiliary 
gas 15 psi, corona discharge needle current 2 µA, probe temperature 450°C, interface 
heater on, CAD gas 5. Declustering potential and collision energy were also optimized 
for each compound. Nitrogen was used for the gases of all purposes and a dwell time of 
200 ms was set for each MRM transition. 






Sulacetamide 215 > 156 





Sulfapyridine 250 > 156 





Sulfadiazine 251 > 156 





Sulfamethoxazole 254 > 156 





Sulfisoxazole 268 > 156 





Sulfamethazine 279 > 186 












The detection of fluoroquinolones was performed with TurboIonSpray source in the 
positive-ion mode. The chromatography was achieved on a Genesis C18 column (150 × 
2.1 mm, 4 µ) with the following linear gradient elution at room temperature, where the 
mobile phase A was 20 mM ammonium acetate aqueous solution containing 0.1% formic 
acid and the mobile phase B was acetonitrile: the gradient was increased from 12% to 
55% B in 8 min, to 95% in 2 min, then held for 4 min at 95% B and finally ramped back 
to initial 12% B in 2 min. The flow rate was 0.2mL/min and the injection volume was 20 
µL. The mass spectrometer was operated in multiple reaction monitoring (MRM) mode 
and the corresponding parameters were optimized by introducing fluoroquinolones 
through a syringe pump at 10 µL/min which was then combined with a LC flow of 
mobile phases A and B (50:50) at 0.2 mL/min into the mass spectrometer: curtain gas 30 
psi, nebulizer gas 30 psi, turbo gas 60 psi, ionspray voltage 1700 V, heater gas 
temperature 360°C, interface heater on, CAD gas 5. Declustering potential and collision 
energy were also optimized and characteristic of each individual analyte. Nitrogen was 
used as curtain, nebulizer, turbo and collision gas. A dwell time of 200 ms was selected 
for each MRM transition. 
 






Ciprofloxacin 332 > 314 10.44 50 30 
Norfloxacin 320 > 302 10.27 50 25 








Appendix B:  PhAC concentrations in wastewater and blanks, showing standard 
deviations, and detection limits. 
Table 1.  Concentrations of pharmaceutical analytes in wastewater (showing 









































































































































































































(±0.151) NA N.D. N.D. N.D. 

















Sulfonamides       
Sulfacetamide N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
Sulfapyridine 









Sulfadiazine N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
Sulfamethoxazole 
 3.050 (±0.278) 
21.291 










































Fluoroquinolones        
Ciprofloxacin 





































Table 2.  Relative standard deviations for PhAC analyses (%). 





Neutral Drugs      
Caffeine 
 3.1 3.43 5.1 9.27 
Carbamazepine 
 8.3 3 8 22 
Cotinine 
 5 5.77 11 3 
Cyclophosphamide 
 8 2 N.D. N.D. 
Fluoxetine 
 1 21 N.D. N.D. 
Pentoxifylline 
 0.6 1 N.D. N.D. 
Trimethoprim 
 4.4 1.18 4 5 
Acidic Drugs     
Bezafibrate 
 3 4.2 7.41 N.A. 
Clofibric Acid N.D. N.D. N.D. N.A. 
Diclofenac 
 11 17 5.8 N.A. 
Fenoprofen N.D. N.D. N.D. N.A. 
Gemfibrozil 
 0.6 21 8.29 N.A. 
Ibuprofen 
 2 21.1 3.88 N.A. 
Indomethacin 
 0.7 22 17.8 N.A. 
Ketoprofen N.D. N.D. N.D. N.A. 
Naproxen 
 5.5 20.5 0.00 N.A. 
Sulfonamides    
Sulfacetamide N.D. N.D. N.D. N.D. 
Sulfapyridine 
 23 5.8 3 N.D. 
Sulfadiazine N.D. N.D. N.D. N.D. 
Sulfamethoxazole 
 9.11 2.55 1.8 22 
Sulfisoxazole 
 N.D. N.D. N.D. 43 
Sulfamethazine 
 N.D. N.D. N.D. 3 
 
Fluoroquinolones     
Ciprofloxacin 
 11 4.9 0.6 32.7 
Norfloxacin 
 N.D. 7.5 3.0 4.6 
Ofloxacin 





















 Effluent Influent 
Neutral Drugs     
     
Caffeine 1.4 3.5 1.2 6 
Carbamazepine 0.07 0.175 0.05 0.125 
Cotinine 0.4 1 0.6 1.5 
Cyclophosphamide 1 2.5 0.5 1.25 
Dihydroxycarbamazepine 0.6 1.5 0.6 1.5 
Fluoxetine 5 12.5 2 5 
Pentoxifylline 0.8 2 0.5 1.25 
Trimethoprim 0.7 1.75 1 2.5 
 Effluent Influent 
Acidic Drugs     
     
Bezafibrate 0.9 2.25 0.8 2 
Clofibric Acid 0.5 1.25 0.5 1.25 
Diclofenac 2.8 7 2.9 7.25 
Fenoprofen 6 15 3 7.5 
Gemfibrozil 0.3 0.75 0.3 0.75 
Ibuprofen 4 10 2 5 
Indomethacin 15 37.5 10 25 
Ketoprofen 3 7.5 3 7.5 
Naproxen 3 7.5 2 5 
 Effluent Influent 
Sulfonamides     
     
Sulfacetamide 6 15 6 15 
Sulfapyridine 2 5 2 5 
Sulfadiazine 0.8 2 1.5 3.75 
Sulfamethoxazole 0.5 1.25 0.8 2 
Sulfisoxazole 0.5 1.25 0.5 1.25 
Sulfamethazine 0.6 1.5 1 2.5 
 Effluent Influent 
Fluoroquinolones     
     
Ciprofloxacin 2.5 6.25 2.5 6.25 
Norfloxacin 3.3 8.25 3.3 8.25 






Appendix C:   Questionnaire for social surveys in Kitchener and Foxboro 
 
Questionnaire: Pharmaceuticals in the Environment 
 
Please answer the questions by circling the answer where a choice is given, or by filling 
in the blank where there is a blank.  Please circle only one answer unless the question 
asks you to do otherwise. 
 
1.  Often people have medications that are expired or that they do not intend to use, 
which they need to dispose of.  How often do you dispose of unused  or expired 
medication (both prescription and non-prescription drugs)?   
a) daily 
b) weekly 
c)  monthly 
d) yearly 
e) almost never – I almost never have unused or expired medications 
 
2.  If you dispose of unused  or expired medications, which of the following methods 
do you use to dispose of them?  Circle all the methods you use. 
a)  flushing down toilet or sink 
b)  throwing in garbage 
c)  return to the pharmacy 
d)  other ____________ 
 
3.  Before reading this questionnaire, were you aware that you could return your 




4.  How much do you agree or disagree with the following statement: “Taking my 
unused or expired medication to the pharmacy for disposal would be 
inconvenient.”? 





b) agree somewhat 
c) neither agree nor disagree 
d)  disagree somewhat 
e)  strongly disagree 
 
5.  Before reading this questionnaire, were you aware that pollution of rivers and 




6. How much would you be willing to pay per year to improve sewage treatment so 
that river and stream pollution by pharmaceuticals could be reduced? 
a) nothing 
b) less than $10 
c) $10-$24.99 
d) $25-$49.99 
e) $50 or more 
 
7.  Improving sewage treatment methods can reduce many types of river and stream 
pollution (including pollution by pharmaceuticals).  Knowing that improved sewage 
treatment can generally improve the quality of stream and river water, how much 
would you be willing to pay per year to improve sewage treatment? 
a) nothing 
b) less than $10 
c) $10-$24.99 
d) $25-$49.99 
e) $50 or more 
 
8.  How much do you agree or disagree with the following statement:  “We should 
only spend money on environmental problems that affect human health, not on 





a) strongly agree 
b) agree somewhat 
c) neither agree nor disagree 
d)  disagree somewhat 
e)  strongly disagree 
 
9. How much do you agree or disagree with the following statement: ”We should try 
to prevent all water pollution, even if we have no evidence that a pollutant will harm 
human or ecosystem health.” 
a) strongly agree 
b) agree somewhat 
c) neither agree nor disagree 
d)  disagree somewhat 
e)  strongly disagree 
 
10.  How much do you agree or disagree with the following statement: “If an 
environmental problem doesn’t affect my health or my property, I don’t care about 
it.” 
a) strongly agree 
b) agree somewhat 
c) neither agree nor disagree 
d) disagree somewhat 
e)  strongly disagree 
 
11.  If one of the medications you take were bad for the environment, would you be 
willing to switch to a more environmentally friendly medication? 
a) definitely 
b) probably 
c) not sure 
d) probably not 






12.  How would you rank the following 5 items in terms of how important they are 
to you?  Rank the items from 1 to 5, with 1 being the most important and 5 the least 
important. 
____  Human Health 
____  Education 
____  The Environment 
____  Jobs 
____  Transportation (Roads, public transit, etc.) 
 
13.  To understand which pharmaceuticals could enter the environment, it is 
important for us to know which types of pharmaceuticals (medications) you take 
frequently.  Which prescription drugs have you taken over the past year, and how 
often do you take them?  Please circle the ones you have taken and write in how 
often you have taken them. 
      drug      how often? 
a) cholesterol medication ______________________________ 
b) pain medication  ______________________________ 
c) chemotherapy  ______________________________ 
d) heart medication     ______________________________ 
e) antibiotics   ______________________________ 
f) hormones   ______________________________ 
g) other   ______________________________ 
 
 
14.  Which non-prescription drugs (ex: aspirin, ibuprofen) do you take, and how 
often do you take them?  Please circle the ones you have taken over the past year, 
and write in how often you have taken them. 
      drug      how often? 
a) ASA (Aspirin)   ______________________________ 





c) Ibuprofen    ______________________________ 
d) Herbal medications     ______________________________ 
e) Cough & cold medications  ______________________________ 
f) Anti-histamines   ______________________________ 
g) Other    ______________________________ 
 
15.   In order to compare your responses with those of people from both similar and 
different backgrounds, we need to ask a few standard questions.  Could you tell us 




d) over 60 
 
16.  Are you male or female?  M  F 
 
17.  What is the highest level of education you have completed? 
 a)  public/elementary school 
 b)  some high school 
 c) graduated high school 
 d)  some vocational/college 
 e)  graduated vocational/college 
 f)  some university 
 g)  graduated university 
 h)  post-graduate degree 
 








Appendix D:  Photos from Kitchener and Foxboro WWTPs 
 
1.  Solids removal, Kitchener 
 






















































































Appendix E: Interviews – Scientific/Management Experts 
 
1) By whom are you employed? 
a) a university 
b) government 
c) private company/industry 
d) NGO 
e) other _________ 
 
2.  What is your field of specialty (ex: toxicology, hydrogeology)? 
 
 
3.  Where do you live? 
a) Canada 




4.  Do you see the contamination of surface water and groundwater by 
pharmaceuticals as: 
a) a human health concern only 
b)  a concern for aquatic ecosystems only 
c)  both a human health concern and a concern for aquatic ecosystems 
d)  neither a human health concern nor a concern for aquatic ecosystems 
e) other ____________________________________ 
 





5.  How important or unimportant do you think it is for your country’s government 
to take action to reduce the release of pharmaceuticals to the environment? 
a) very important 
b) somewhat important 
c) neither important nor unimportant 
d) somewhat unimportant 
e) very unimportant 
 










6.  a) Is your country’s government currently taking action to reduce the release of 










b)  Is your government conducting research on pharmaceuticals in the 










7.  a)  Do you support the use of the Precautionary Principle in environmental 
decision-making? (Precautionary Principle as defined in the Rio Declaration: Where 
there are threats of serious or irreversible damage, lack of full scientific certainty 
shall not be used as a reason for postponing cost-effective measures to prevent 






b)  What, in your view, does the Precautionary Principle mean for pharmaceuticals 

















8.  Which policies or management techniques would you like to see used to reduce 











9.  How, in your opinion, does surface and groundwater contamination by 









10.  Please rank the following surface and groundwater contaminants in order of 
greatest concern/need for action in your country.  Rank the issue that you believe 
needs the most attention/action as 1, and the issue that you believe needs the least 
attention/action as 7. 
 
___ road salt 
___ pharmaceuticals  
___ metals  
___ pathogens 
___ pesticides 
___ organic solvents  
___ nutrients (nitrate, phosphate) 
 


























12.  On a scale of 1 to 5, how much scientific uncertainty is associated with the 
effects of pharmaceuticals on aquatic ecosystems, with 1 representing no 









13.  How likely do you think it is that pharmaceuticals in surface water and 
groundwater will cause serious or irreversible damage to aquatic ecosystems? 
a) very likely 
b) somewhat likely 
c) neither likely nor unlikely 
d) somewhat unlikely 
e) very unlikely 
 
 
14.  How likely do you think it is that pharmaceuticals in surface water and 
groundwater will cause serious or irreversible damage to human health? 
a) very likely 
b) somewhat likely 
c) neither likely nor unlikely 
d) somewhat unlikely 






15.  What is your view of the following management strategies? 
 
a)  Require all wastewater treatment plants in your country to use secondary 


























g)  Best management practices in agriculture:  Improved controls on spreading of 




h)  Pharmaceutical returns programs: Organization of returns programs and 

















k)  Optimization of existing wastewater treatment plants to better remove 
pharmaceuticals (without upgrading technology) 
 
 
l)  Other? 
 
 
16.  For these same management techniques, please assign a score on a scale of 1 to 
10 in terms of effectiveness at preventing environmental impacts from 
pharmaceuticals, and in terms of feasibility of implementation: 
 
a)  Require all wastewater treatment plants in your country to use secondary 










































g)  Best management practices in agriculture:  Improved controls on spreading of 






h)  Pharmaceutical returns programs: Organizatin of returns programs and 


















k)  Optimization of existing wastewater treatment plants to better remove 

















17.  Do you have any further comments you would like to make on the topic of 



















Appendix F: Interviews – Pharmaceutical Industry 
 
1.  Where do you live? 
a) Canada 
b) the United States 
c) the European Union 
d) other _____________ 
 
 
2.  Do you see the contamination of surface water and groundwater by 
pharmaceuticals as: 
a) a human health concern only 
b)  a concern for aquatic ecosystems only 
c)  both a human health concern and a concern for aquatic ecosystems 
d)  neither a human health concern nor a concern for aquatic ecosystems 
e) other ____________________________________ 
 





3.  How important or unimportant do you think it is for your government to take 
action to reduce the release of pharmaceuticals to the environment? 
a) very important 
b) somewhat important 
c) neither important nor unimportant 
d) somewhat unimportant 
e) very unimportant 
 






4.  a) Is your country’s government currently taking action to reduce the release of 














5.  What, in your view, does the Precautionary Principle mean for pharmaceuticals 
in the environment? (Precautionary Principle as defined in the Rio Declaration: 
Where there are threats of serious or irreversible damage, lack of full scientific 
certainty shall not be used as a reason for postponing cost-effective measures to 









6.  How likely do you think it is that pharmaceuticals in surface water and 
groundwater will cause serious or irreversible damage to aquatic ecosystems? 
a) very likely 
b) somewhat likely 
c) neither likely nor unlikely 
d) somewhat unlikely 
e) very unlikely 
 
 
7.  How likely do you think it is that pharmaceuticals in surface water and 
groundwater will cause serious or irreversible damage to human health? 
a) very likely 
b) somewhat likely 
c) neither likely nor unlikely 
d) somewhat unlikely 






8.  Several countries have developed, or are in the process of developing, 
environmental assessment regulations for human and veterinary pharmaceuticals. 
a) As a representative of the pharmaceutical industry, do you feel it is a good idea to 













c)  What do you believe the end products of environmental assessments for 
pharmaceuticals should be?  For example, should the purpose simply be to generate 
information for a database?  Or should management action such as labelling or 






9.  Several other ways of managing pharmaceuticals in the environment have been 
suggested by researchers.  One of these is to have pharmaceutical returns programs, 
whereby customers would return their unused medications to the pharmacy or 
another location for disposal.  
 a) In your opinion, would your organization likely be willing to contribute to the 
development of a drug returns program, or to an education program, to encourage 








b) Pharmaceuticals are also used in agriculture.  Would your organization likely be 
willing to contribute to a program by which farmers could return their unused 








10.  Another way of minimizing environmental contamination by pharmaceuticals 
would be to improve sewage treatment.  Research conducted as part of my study 
suggests that some members of the public feel the pharmaceutical industry should 
contribute to any upgrading of sewage treatment plants to improve the removal of 
pharmaceuticals.  Do you think your organization would be willing to contribute 
financially to the upgrading of sewage treatment plants, to prevent pharmaceuticals 









11.  Some people have suggested that the pharmaceutical industry should try to 
manufacture more ‘green’ drugs.  These environmentally friendly drugs would be 
more biodegradable and less harmful to aquatic organisms like fish.  How feasible 
do you think it would be to develop ‘green’ drugs… 









c)  How likely do you think the pharmaceutical industry is to try to develop ‘green’ 





d)  Given incentives from government, how likely do you think the pharmaceutical 




e)  What sort of incentives would the pharmaceutical industry require to increase its 




12.  As a representative of a pharmaceutical company, what is your opinion on the 
following potential management strategies to reduce the release of pharmaceuticals 
to the environment?  Please give each management strategy a score out of 10 based 
on (in your opinion) how much the pharmaceutical industry would like to see the 
management strategy implemented, with 10 meaning the pharmaceutical industry 
would definitely support its implementation, and 1 meaning the pharmaceutical 
industry would definitely not support its implementation.  Please also give your 
opinion of the management strategy verbally. 
 
a)  Require all wastewater treatment plants in your country to use secondary 




Score out of 10: 
 








Score out of 10: 
 





Score out of 10: 
 




Score out of 10: 
 




Score out of 10: 
 





Score out of 10: 
 
g)  Best management practices in agriculture:  Improved voluntary controls on 




Score out of 10: 
 
h)  Pharmaceutical returns programs: Develop returns programs & educate people 




Score out of 10: 
 








Score out of 10: 
 





Score out of 10: 
 





Score out of 10: 
 




Score out of 10: 
 
13.  Do you have any other comments you would like to add on the topic of 














          
 
 
 
